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 In the treatment of HIV/AIDS, protease inhibitors (PIs) and nucleoside/nucleotide analogue reverse 
transcriptase inhibitors (NRTIs) are the major components of highly active antiretroviral therapy 
(HAART).  The side effects of these drugs include various metabolic disorders including insulin 
resistance, dyslipidaemia and lipodystrophy. The precise mechanistic basis of these remains largely 
unknown. In this study we aimed to understand the molecular basis of these metabolic effects by 
analysing the effects on lipoprotein lipase (LPL) activity, insulin signaling and the cellular metabolic 
profile. It was previously shown by this group that indinavir inhibits insulin signaling at a proximal 
level. The study was extended to a wider range of ARVs and in particular, the effects of sodium 
salicylate (NaSal) and berberine chloride (BBR) were analysed to determine if they could reverse the 
effects of the drugs on insulin signalling. In addition, Chinese hamster ovary cells transfected with the 
human insulin receptor (CHO-IR) were used for the first time to study the effects of NRTIs on the 
insulin signaling pathways. The high level of expression of insulin receptor facilitated sensitive 
detection of any alteration in the phosphorylation of signaling proteins as compared to 3T3-L1 
adipocytes.  
Three PIs, indinavir, nelfinavir and ritonavir were used in this study. Indinavir and nelfinavir treatment 
significantly reduced the insulin-stimulated phosphorylation of the IRβ, IRS-1, Akt and MAPK in 
CHO-IR cells. However phosphorylation of GSK-3α\β was not affected by the PIs. Ritonavir also 
decreased (not statistically significant) the phosphorylation of IR-β and IRS-1 but its inhibitory effect 
xxiii 
 
on MAPK was the same as by the other PIs. NRTI’s did not inhibit insulin-stimulated tyrosine 
phosphorylation of IRβ and IRS-1 but reduced phosphorylation at MAPK and Akt. .  
In order to understand the role of NFκ-B pathway in blocking insulin-stimulated tyrosine 
phosphorylation, IKK-16, a selective inhibitor of IkB kinase (IKK) was used but no significant 
involvement of this pathway was found in blocking tyrosine phosphorylation at IRS-1. Similarly, 
NaSal and BBR were also used to reverse the effects induced by PIs and NRTIs in CHO-IR cells but no 
significant change was observed on  Akt and MAPK. NaSal and BBR reduced (but not significantly) 
the effects of PIs (indinavir and nelfinavir) on IR-β and IRS-1. These findings suggest that PIs induce 
insulin resistance by affecting multiple steps in the signaling pathway. At the proximal end of the 
insulin signalling pathway, protease inhibitors affect IR-β and IRS-1 while at the distal end they affect 
phosphorylation of Akt and MAPK.   
CHO-IR cells were also used to measure LPL activity using a colorimetric method employing pNPB as 
substrate. The most commonly used ARVs were tested. These included four PIs and six NRTIs .The 
results showed that NRTIs stavudine and emtricitabine significantly inhibited the LPL activity from the 
CHO-IR cells. PIs indinavir and nelfinavir were also found to decrease LPL activity extracellularly 
when added to the assay reaction in vitro. Similarly nelfinavir and atazanavir sulfate inhibited the 
activity of the LPL from the CHO-IR cells after 16 hour treatment. This suggested that these drugs may 
interfere with the enzyme activity intracellularly either at the level of its synthesis or its transportation 
from cytoplasm to the cell surface. These finding suggests that protease inhibitors may play a role in 
inhibiting lipoprotein lipase activity in vivo, and may thereby induce metabolic disorders in HIV-
positive patients being treated with protease inhibitors. 
Metabolomic analysis was performed on the supernatant of cells treated with PIs and NRTIs, with and 
without insulin stimulation. Many significant alterations and trends in amino acids and organic acids 
levels in CHO-IR cells supernatants (treated with PIs)  were recorded using 
1
H-NMR. For example, PIs 
xxiv 
 
decreased the synthesis of threonine, phenylalanine, lysine, arginine, isoleucine butyrate, glutamate, 
histidine and 2-oxo-isovalerate. Furthermore overproduction of lactate and ketones were observed in 
the nelfinavir treated cells. This may be a consequence of the secondary effects of insulin resistance 
induced by the PIs. Similarly NRTIs (stavudine and tenofovir) treatment also induced changes in the 
levels of many amino acids and organic acids .NRTIs decreased the synthesis of acetate, acetoacetate, 
histidine, methionine, phenylalanine and tryptophan while significant increase in the acetone was 
observed in stavudine-treated cells. 
Taken together, the results of this study suggest that PIs and NRTIs, inhibits LPL activity and 
synthesis, affects insulin signalling pathways at different levels and alters the synthesis of different 








CHAPTER I: GENERAL INTRODUCTION 
 
1.1 Acquired Immune Deficiency Syndrome  
The Acquired Immune Deficiency Syndrome (AIDS) a slow progressive degenerative disease which 
affects the immune system of the host and the infection is caused by the Human Immunodeficiency 
Virus (HIV). AIDS and HIV were first discovered in 1981 by the United States Center for Disease 
Control and Prevention ("Pneumocystis pneumonia--Los Angeles," 1981; Report, 1981b). Following 
the discovery of AIDS and its causative agent it has had huge impact demographically especially in low 
income and resource poor countries. It has also affected social and economic conditions of the high 
epidemic areas. The World Health Organization (WHO) has confirmed 25 million HIV-related deaths 
in 60 million people infected with the virus. In 2011,the WHO reported approximately 34 million 
people were  living with HIV/AIDS  and 2.5 million new cases in 2011  (UNAIDS, 2011). 
 As a result of HIV/AIDS being a leading cause of death worldwide, it has become one of the biggest 
care challenges today in terms of the prolonged treatment regimen and prevention. As a result of being 
an infectious disease with a number of complications both from the disease and from treatment, it is a 
disease that is difficult to treat. Vast numbers of untreated HIV positive individuals progress to the 
development of clinical AIDS in 7-8 years (Anuurad, Bremer, & Berglund, 2010).  There are two 
distinct types of HIV based on serotypes, type I (HIV-I) and type 2 (HIV-II). However the majority of 






The prevalence of HIV infection is highest in Sub-Saharan Africa which accounts for approximately 
67% of HIV infections worldwide (WHO., 2009).  
The HIV prevalence rate in South Africa was approximately 10.6% higher than the any other country  
(Shisana, 2009),  with 5.38 million people reported to be living with HIV and AIDS. Among adults, 
16.6% of the total population is estimated to be HIV positive. Approximately 316,900 adults (age 15 
years or older) were newly infected in 2011, while 63,600 children (age 0-14 years) were estimated to 
be infected with HIV. In the same year 257,910 South Africans were estimated to have died of AIDS, 
accounting for approximately 43.6% of total deaths in South Africa (Africa, 2011)  
 
 
Figure1.1: HIV AIDS Data and Statistics – People living with HIV AIDS world map in 2008. 




1.2 Human Immunodeficiency Virus  
The Human Immunodeficiency Virus is a retrovirus that primarily targets the host immune system and 
makes it weaker and incompetent. HIV-1 has been classified as a member of the lentivirus subfamily of 
retroviruses, based on its morphology, genomic and pathogenic features. HIV-I has a complex structure 
compared to other viral families such as oncoretroviruses (Weiss, 1993) (Figure 1.2). 
 
1.2.1 HIV Morphology           
 
The HIV virion has a spherical morphology (100-120nm) and is covered by a lipid bilayer called an 
envelope which is a derivative of the host cell membrane. It also has the glycoprotein 120 (gp120) 
within the outer lipid layer. It is attached to the viral envelope by glycoprotein 41 (gp41) (Freed & 
Martin, 1995; Sierra, Kupfer, & Kaiser, 2005; Turner & Summers, 1999). Under the envelope of HIV 
there are two layers of protein shells, the outer layer is composed of MA protein called the matrix and 
inner layer composed CA protein called the capsid. The inner part of the HIV contains two copies of 
viral genomic material known as the viral core that is surrounded by the capsid (Fig1.2). The viral core 
contains two copies of RNA with the reverse transcriptase (RT), integrase and protease enzymes 







1.2.2 Life cycle of HIV   
The life cycle of HIV begins upon entry of virus to host cell. It mainly enters through host CD4 T 
lymphocyte cells and macrophages via glycoprotein adsorption to the interacting host cell. Adsorption 
causes the merging of the cell membrane of the host cell and the viral envelope facilitating the release 
of viral capsid into host cell. 
HIV replication comprises a series of steps that starts with the attachment of the viral envelope proteins 
to the specific CD4 receptor of the targeted host cell. For the entry into the CD4 T lymphocyte, HIV 




requires co-receptors called CXCR4 and CCR5 along with CD4 receptors (Berger, Murphy, & Farber, 
1999; Carrington, Dean, Martin, & O'Brien, 1999; Schols, 2004). 
In the subsequent step to the attachment of HIV to the co-receptors there is a conformational change in 
the envelope proteins which ultimately results in the fusion of the viral envelope and the host cell 
membrane. Fusion results in the generation of an opening and the contents of the capsid transfer to the 
cells through this opening. Subsequently in the cytoplasm the single stranded RNA of the virus is 
converted in to double stranded-complementary DNA with the help of the reverse transcriptase. (Gotte, 
Li, & Wainberg, 1999). After the completion of reverse transcription, viral genome and associated 
proteins enter the nucleus after passing through nuclear membrane and integrate with the host DNA ( 
chromosomal DNA ) with the help of enzyme HIV integrase  (Craigie, Fujiwara, & Bushman, 1990; 
Katz, Merkel, Kulkosky, Leis, & Skalka, 1990). 
After the incorporation of viral genome, expression of the viral genes generates precursor strands of 
viral polyproteins (Gag (p55) and Gag-Pol (p160)). These polyproteins are processed by a protease 
(aspartyl endopeptidase) which cleaves the polyprotein strands and new HIV virions are produced 
(Debouck, 1995). In the final steps of the life cycle, the assembly of the new virus particles take place 
at the surface of cells. The viral RNA and proteins combine and new viral particles leave the host cells 
by budding off (B. K. Chen, Gandhi, & Baltimore, 1996; Simon et al., 1997). During the course of 
budding the virion also uses the outer layer of the host cell to form a viral envelope. These virions are 
able to grow and become mature virions that infect other healthy human host cells within 1.5 days 




Figure 1.3: HIV life cycle.(Turner & Summers, 1999). 
1.2.3 HIV infection and treatment 
Initially HIV infection is followed by an asymptomatic period which does not require any antiviral 
therapy immediately. In the asymptomatic period the host immune system halts the progression of HIV 
infection but over the period of time rapid replication of virus weakens the immune system and this 
leads to AIDS. At this stage, proper treatment is required to manage the disease progression and 
associated metabolic challenges (USAID Health Policy Initiative, 2009). 
Since maternal antibodies are present in newborn blood, the status of HIV-infected children cannot be 
determined until they reach 18 months. Therefore, WHO recommends cotrimoxazole to be provided to 
all children born to HIV positive mothers until their status is known. For HIV-positive children, 
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cotrimoxazole should be prescribed for up to five years. After the age of 5 years, cotrimoxazole should 
be continued if the infection has progressed to stage III  (USAID Health Policy Initiative, 2009). 
 
1.3 Highly active antiretroviral therapy  
Highly active antiretroviral therapy (HAART)  improves the life expectancy and prognosis of HIV 
patients, by  reducing viral load along with parallel remedies to increase life span of patients by 
minimizing opportunistic infections and increase CD4+ T-cell count, thus enabling the host immune 
system to counter active viral replication (Hammer et al., 1997; Piacenti, 2006).  
Table 1.1: Estimated number of adults receiving ART and percentage of children receiving ART 
and cotrimoxazole in South Africa  
 
 Adults (15+ years)  Children  
Estimated number 
receiving ART*  
Estimated number 
receiving ART  
Estimated % receiving 
cotrimoxazole  
2010 1 058 399  105 123  38,0 %  
*Source: Health Information Epidemiology Evaluation and Research, Department of Health (November 
2010 / Report) (Africa, 2011). 
 
Currently HAART is the only treatment which became available for HIV/AIDS in 1995 (Arvind et al., 
2008). HAART had a positive health impact with successful outcomes for HIV-infected individuals as 
the number of HIV cases started to fall (Powderly, 2004). Despite new control efforts, 5.8 million cases 
were reported along with 2.3 million AIDS-related deaths (WHO., 2009). 
HAART is a treatment regime that usually combines multiple antiviral drugs to maximize its 
effectiveness. These antiviral drugs are derived from five broad classes aiming to target different parts 
of virus and thus attenuate rapid replication. These are: 1) Entry inhibitors which inhibit entry of virus; 
2) reverse transcriptase inhibitors to inhibit  core enzyme for viral replication; 3)            nucleoside or 
nucleotide reverse transcriptase inhibitors (NRTIs) and  non-nucleotide  based reverse transcriptase 
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inhibitors (NNRTIs), to inhibit integration of viral RNA in host genome; 4) integrase inhibitors, and 5) 
protease inhibitors (Hammer et al., 2008). 
Although HAART has improved life span effectively, it comes with many adverse effects as the 
combination of antiviral drugs affects the metabolism leading to a number of metabolic disorders 
(Table 1.2). 
 HIV is an RNA-based virus which are known to carry mutations during replication due to lack of proof 
reading activity by RNA polymerase (Flint, 2004). HAART requires an optimal combination of drugs 
with better human tolerance and has also been considered effective in reducing the risk of viral 
mutations (Hammer et al., 2008).  
 
Figure 1.4: Changes in survival of people infected with HIV. Figure adapted with permission from 
(Lohse et al., 2007). 
While approximately twenty five antiretroviral drugs have been approved for clinical use in the 
treatment of AIDS, the search for novel drugs and their subsequent development is continuously in 
progress (De Clercq, 2009; Hughes, Robinson, Tseng, & MacArthur, 2009). 
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HAART was implemented in clinical practice in 1995.However continuous efforts from the past two 
decades to improve HIV treatment via our understanding of infection at the molecular level has helped 
in advancement of treatment options. In the present era, because of these efforts HIV epidemic has 
transformed into a manageable complex infection (Chene et al., 2003; Egger et al., 2002; Opravil et al., 
2002). 
A brief description of the FDA approved drug classes that are currently in use for the treatment of HIV 
are presented in Table 1.2. 
Table 1.2 FDA-approved antiretroviral drugs . 
NRTIs NNRTIs PIs FI 


























































 1.3.1 Nucleoside/nucleotide analogue reverse transcriptase inhibitors  
The nucleoside/nucleotide reverse transcriptase inhibitor (NRTIs) was the first drug class approved for 
the treatment of HIV infection. Although NRTIs were less effective against HIV than non-nucleoside 
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reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), they had a central role in 
antiretroviral treatment and remain part of the current standard of care. NRTIs are equally effective 
against HIV-I and HIV-II (Cox, Aperia, Albert, & Wahren, 1994).  
NRTIs are competitive inhibitors of reverse transcriptase (RT) enzyme substrate. NRTIs bear high 
structural similarity with DNA nucleoside bases. NRTIs block the activity of RT by competing against 
natural substrate and incorporate into viral DNA and act as chain terminators (Mitsuya & Broder, 
1986).  Phosphorylation at active 5’ end  is required in the cell for its activity (W. Y. Gao, Agbaria, 
Driscoll, & Mitsuya, 1994). Tenofovir is the only NRTI that requires phosphorylation by cellular 
enzyme to form a diphosphate which is necessary for its antiviral activity.  
 
1.3.2 Non-nucleoside analogue reverse transcriptase inhibitors 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) were introduced in 1996. Nevirapine was the 
first FDA-approved NNRTI. NNRTIs exhibit potent activity against HIV-I and are preferred in the 
treatment regimens (Table1.2) (Shen et al., 2008).   
NNRTIs bind with HIV-RT in a non-competitive fashion (Grob et al., 1992; Merluzzi et al., 1990). All 
NNRTIs bind at the p66 subunit, a hydrophobic pocket that is distinct from the substrate site and block 
DNA polymerase by conformational changes that result in the disruption of the catalytic site of 
enzyme. NNRTIs do require phosphorylation and subsequent incorporation into viral DNA for their 
optimum anti-viral activity (Witvrouw et al., 2004).  
 
1.3.3 Protease inhibitors  
HIV PIs were first introduced in 1995 and are an integral part of the HIV treatment regimen (AIDSinfo, 
2011). A total of 8 compounds have been approved so far (Table 1.2). 
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HIV-I protease is a complex enzyme. Protease inhibitors specifically target the HIV protease enzyme 
resulting in the release of dysfunctional viral particles into the cell devoid of infectious activity (Navia 









1.3.4 Fusion Inhibitor  
Enfuvirtide is the only FDA-approved fusion inhibitor (FI), which is a 36 amino acid peptide and 
homologous to the heptad-repeat 2(HR2). After binding to the heptad-repeat 1(HR1) motif, it inhibits 
the formation of the six helix bundle that is required for fusion (Lalezari et al., 2003). Heptade-repeat 
(HR) 1 and 2 are the two different motifs of gp 41 that unite to form a six helix bundle hairpin 
structure. This hairpin structure then pulls the membrane of the virus and cell closer and result in 
membrane fusion (Lalezari et al., 2003; Lazzarin et al., 2003). 
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1.4 Cellular and biochemical alterations induced by highly active antiretroviral therapy 
Since HAART has been successful in decreasing morbidity and mortality rates significantly (Paik & 
Kotler, 2011), the Southern African HIV Clinician’s Society recommends maximally suppressive ART 
regimen to obtain effective outcomes for anti-HIV treatment and to avoid resistance problem (Meintjes 
G, Conradie F, Osih R, & D., 2012). Non-suppressive regimens e.g., mono/dual NRTI therapy have a 
role in the prevention of mother-to-child transmission (PMTCT), but these  treatment regimens are 
strongly discouraged ((SAHCS), 2008).  
In southern Africa, to reduce pill burden and to provide improved treatment compliance, different 
fixed-dose drug combinations have been recommended. Ritonavir is usually used in combination with 





























*All protease inhibitors (PIs) may be associated with cardiac conduction abnormalities (especially PR prolongation). This seldom results in clinically significant effects, 
but caution should be taken when co-prescribing other drugs that cause delayed cardiac conduction, such as acrolides.  
NRTI = nucleoside reverse transcriptase inhibitor; NtRTI = nucleotide reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = 




Common or severe adverse drug reactions 
Zidovudine (AZT) NRTI 
Bone marrow suppression, gastro-intestinal (GI) upset, headache, myopathy, hyperlactataemia /steatohepatitis (medium 
potential), lipoatrophy 
Didanosine (ddI) NRTI 
Peripheral neuropathy, pancreatitis, nausea, diarrhoea  
hyperlactataemia/steatohepatitis (high potential 
Lamivudine (3TC) NRTI Anaemia (pure red cell aplasia) (rare), hyperlactataemia/steatohepatitis (very low potential) 
Stavudine (D4T) NRTI 
Peripheral neuropathy, lipoatrophy, hyper lactataemia/steatohepatitis (high potential), pancreatitis, HIV associated 
neuromuscular weakness syndrome (HANWS) (rare), dyslipidaemia 
Abacavir (ABC) NRTI Hypersensitivity reaction, hyperlactataemia/steatohepatitis (very low potential) 
Tenofovir (TDF) NRTI 
Renal failure, tubular wasting syndrome, reduced bone mineral density, hyperlactataemia/steatohepatitis (very low 
potential) 
Emtricitabine (FTC) NRTI Palmar hyperpigmentation, hyperlactataemia/ steatohepatitis (very low potential) 
Nevirapine (NVP) NNRTI Rash, hepatitis 
Efavirenz (EFV) NNRTI 
Central nervous system symptoms (vivid dreams, problems with concentration, confusion, mood disturbance, psychosis), 
rash, hepatitis, gynaecomastia 





Kidney stones, unconjugated hyperbilirubinaemia (visible jaundice in minority of patients), GI disturbances, hair loss, 
hyperglycaemia, headache, dyslipidaemia 
Atazanavir (ATV) PI 





GI upset, dyslipidaemia, hepatitis 
Darunavir (DRV) PI GI upset, rash, dyslipidaemia, hepatitis Contains sulphonamide moiety (use with caution in patients with sulpha allergy) 
Saquinavir 
(SQV) (hard gel 
formulation, rarely used 
PI 
GI disturbance (mild), hepatitis, hyperglycaemia, dyslipidaemia 
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A number of side effects have been reported with HAART. These include occurrence of high levels of 
cholesterol, triglycerides and total serum low-density lipoprotein (LDL). This has been reported in 
approximately 70% of HIV-infected patients in association with the lipodystrophy syndrome. 8-10 % 
of HIV infected patients have insulin resistance with elevated levels of C-peptide and insulin leading to 
type II diabetes mellitus (Carr, Samaras, Burton, et al., 1998; Grinspoon & Carr, 2005; Wand et al., 
2007), (see section 1.4.1 for detail).  
These biochemical effects increase the increase risk of developing cardiovascular and metabolic 
disorders in HIV-infected individuals (Friis-Moller, Weber, et al., 2003). Previous studies showed that 
the protease inhibitors, NRTIs, and NNRTIs play a major role in inducing these metabolic disorders in 
HAART-treated patients. However, not much is known about the mechanisms of these   adverse effects  





Fig 1.6: A scheme for the development of HIV/Protease inhibitor-associated lipodystrophy and 
associated adverse effects. (Anuurad et al., 2010). 
11β-HSD1, 11β-hydroxysteroid dehydrogenase type 1; FFA, free fatty acids;HIV, human 
immunodeficiency virus; PI, protease inhibitor; ROS, reactive oxygen species.TG, triglyceride) (11β-





1.4.1 Insulin resistance  
In 1996, when PIs were first used to treat HIV infected individuals, the very first metabolic alteration 
or abnormality observed  was insulin resistance (Carr, Samaras, Burton, et al., 1998; Carr, Samaras, 
Chisholm, & Cooper, 1998). An understanding of the molecular mechanism of this induced insulin 
resistance presents a challenge towards making antiviral drugs safer for use in HIV patients. It is 
absolutely critical to understand the molecular pathway to improve the quality of life of patients and 
minimize the associated metabolic abnormalities (Hruz, 2011). 
 A number of models have been used to explore ARVs and to understand how they induce insulin 
resistance and other associated cellular and biochemical alterations. These have included human and 
animal studies. Cellular models have been used to provide useful insight about ARVs and associated 
metabolic alterations. It has been reported that PIs can block glucose uptake by cells and association of 
NRTIs with mitochondrial toxicity is well described (Hertel, Struthers, Horj, & Hruz, 2004; Mallal, 
John, Moore, James, & McKinnon, 2000). Therefore detailed evaluation of cellular compartments and 
mechanisms will enable us to learn about involvement of various organelles e.g. endoplasmic reticulum 
which may play a role in the metabolic disturbances. Oxidative stress in the endoplasmic reticulum is 
linked to inducing insulin resistance. Furthermore, alteration in adipokine secretion and alterations in 
lipid metabolism may also play a part (Hruz, 2011).   
Short or long term exposure to PIs causes insulin resistance. Clinical studies have shown induction of 
insulin resistance even after a single therapeutic dose of certain PIs in healthy volunteers (Lee GA, 
2004; Noor et al., 2001; Noor et al., 2002). The acute response to PIs is inhibition of peripheral glucose 
uptake (G. A. Lee et al., 2006; Noor, Flint, Maa, & Parker, 2006; Noor et al., 2004). Similarly 
prolonged or chronic treatment has an effect on hepatic glucose metabolism (Haugaard et al., 2005; G. 




Lee, 2005; Noor et al., 2006; Noor et al., 2004; van der Valk et al., 2001). In addition HIV-I infection 
leads to a reduction of insulin sensitivity via activity of the protein (Vpr). Vpr is a HIV- I accessory 
protein which is reported to increase sensitivity to glucocorticoids by up regulating glucocorticoid-
responsive promoters in vitro (Kino et al., 2002). Vpr also causes the reduction of peroxisome-
proliferator-activated receptor-γ (PPAR-γ) activity and obstructs the suppressive effects of downstream 
insulin-regulated transcription factors, which results in tissue-selective insulin resistance (Kino et al., 
2005; Shrivastav, 2000). Therefore it is clear that both viral infection and PI associated changes during 
the course of treatment with PIs on a short term or long term basis alters cellular mechanism and this 
may directly or indirectly lead to insulin resistance. 
 
1.4.1.1 Insulin receptor and post-receptor signaling 
Insulin signalling begins with binding of ligand to its receptor, resulting in activation of the intrinsic 
tyrosine kinase moiety which is an integral part of insulin receptor (IR). The IR has two extracellular 
and two trans-membrane subunits called alpha (α1 and α2) and beta (β1 and β2) subunits respectively. 
Two alpha subunits and beta subunits form a heterotetrameric complex linked by disulphide bonds. 
The tyrosine residues that are phosphorylated are present in the β subunit of IR. Upon binding of 
insulin to the extracellular α subunit  a conformational change is transmitted through the membrane to 
the intracellular tyrosine kinase C terminal domain of the β subunit and thus auto-phosphorylation of 
tyrosine residues occurs in β subunit (Pessin & Saltiel, 2000; Van Obberghen et al., 2001). Auto 
phosphorylation activates the catalytic activity of the tyrosine kinase of IR towards other substrates. 
The phosphotyrosine-binding (PTB) domains of the insulin receptor substrate family (IRS) interact 
with the juxtamembrane phosphorylation sites and facilitate interaction and phosphorylation of IRS 




the target cells for insulin, including hepatocytes, myocytes and adipocytes (Brunetti, Manfioletti, 
Chiefari, Goldfine, & Foti, 2001).  
The subsequent phosphorylation of important tyrosine residues on IRS proteins lead to binding of the 
Src homology 2 (SH2) domains of the p85 regulatory subunit of phosphatidylinositol PI 3-kinase. The 
catalytic subunit of PI 3-kinase, p110 on activation, then phosphorylates phosphatidylinositol (4, 5) 
bisphosphate (PIP2) forming phosphatidylinositol (3, 4, 5) triphosphate (PIP3). PIP3 in the next step 
activates the phosphoinositide–dependent kinase-1 (PDK1). PDK1 phosphorylate serine/threonine 
kinase Akt (also known as PKB). PIP3 also interacts directly with the PH domain of the Akt to recruit 
Akt to the plasma membrane.  The activation of PKB/Akt is required for the steps leading to glucose 
transport, which involves the migration of glucose transporter 4 (GLUT4) from the cytoplasm to the 
cell membrane, in order to facilitate the uptake of extracellular glucose. Akt activation also leads to 
phosphorylation of glycogen synthase kinase 3 (GSK3) in cytoplasm. GSK-3 was initially identified as 
a glycogen regulating enzyme in response to insulin (Welsh, Wilson, & Proud, 1996). GSK-3 is a 
serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase and is an 
important downstream member of the PI3K/Akt cell survival pathway. Its activity is inhibited by Akt-
mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β (Srivastava & Pandey, 1998).  
 
Figure1.7: Insulin signaling pathway showing binding of insulin with the IR leading to activation 




Insulin also causes mitogenic cellular response in the adipocyte through MAP kinases ERK1/2 
pathway. ERK1/2 phosphorylates and regulates a large number of substrates including transcription 
factors such as Elk-1 and c-Fos (Cheng, Tseng, & White, 2010; Plotnikov, Zehorai, Procaccia, & 
Seger, 2011).ERK1/2 also increase the  mRNA translation in response to insulin through the 
phosphorylation and inactivation of the TSC1/2 complex (Ma, Chen, Erdjument-Bromage, Tempst, & 
Pandolfi, 2005) and through phosphorylation of raptor in mTORC1(Carriere et al., 2011; Langlais, Yi, 
& Mandarino, 2011) . Besides it , in response to stimulation with growth factors, also phosphorylation 
of S6 was shown to be regulated by the ERK1/2 pathway acting in parallel to mTORC1 regulation of 
S6 (Roux et al., 2007).So translation of  S6 is regulated both by the PI3K/PKB/mTORC1 and the 
ERK1/2 pathway. 
1.4.1.2 Mechanismsof insulin resistance induced by ARVs at cellular level 
As a result of the alteration in metabolism and cellular pathways associated with HIV infection and 
treatment regimen using anti-retroviral therapy (ART), huge attention has been devoted to the link 
between insulin resistance and changes in cellular pathway due to antiviral drugs. These drug 
dependent cellular and metabolic changes affect glucose uptake and eventually contributes to the 
development of insulin resistance (Hruz, 2011). Insulin resistance is considered to be the primary 
metabolic complication of type 2 diabetes, (Meyer, Levin, Grimmsmann, Beck-Nielsen, & Klein, 2002; 
Nolan, Freidenberg, Henry, Reichart, & Olefsky, 1994; Savage, Petersen, & Shulman, 2005).  
Insulin resistance is a significant clinical challenge in the treatment of HIV patients as they prolong 
exposure of patients to various combinations of drugs has contributed to the side effects seen. These are 
influenced by factors such as genetic predisposition, age, environmental factors and various disease 
related factors (Butt et al., 2009).  
Glucose homeostasis is one of the main metabolic targets affected by ART. The organs and tissues 




HIV infection. However the cross communication between these tissues also regulates the insulin 
sensitivity. In order to gain a better understanding of glucose homeostasis and metabolic syndrome  in 
terms of using ART, we can take advantage of findings of the effects of  ART in HIV negative patients  
and vice versa (Hruz, 2011). 
 
1.4.1.3 Protease inhibitors effect on glucose transport  
The association of PI-based therapy with hyperglycaemia and insulin resistance, in HIV-infected 
patients, has been reported numerous times (G. Behrens et al., 1999; Dube, Johnson, Currier, & 
Leedom, 1997; Walli et al., 1998). Cultured 3T3-L1 adipocytes have widely been used to analyse the 
effects on glucose transport and have proved useful in the investigation of insulin signalling, glucose 
transport and insulin resistance caused by anti-retroviral therapy. 
 
1.4.1.3.1 Inhibition of GLUT4  
The binding of insulin to the insulin receptor of the adipocyte eventually results into the translocation 
of GLUT 4. Similarly fatty acids (FA) metabolized by the adipocyte are mainly produced by the action 
of LPL on the triglyceride (TG) transporting lipoproteins (chylomicrons and VLDL (very low density 
lipoproteins)) (Figure 1.8) (Large, Peroni, Letexier, Ray, & Beylot, 2004). Studies have shown that 
antiviral drugs such as PIs affect glucose uptake or transport. The mechanism by which PIs block 
glucose uptake has been reported to be via direct inhibition of GLUT4 i.e. glucose transporter (Isoform 
4) (Murata, Hruz, & Mueckler, 2000). PIs have been shown to block insulin-stimulated glucose uptake 
in 3T3-L1 adipocytes via inhibition of the insulin-mediated GLUT4 translocation (Hertel et al., 2004; 
Noor et al., 2006). Interestingly, therapeutically relevant drug concentrations of PIs cause reversible 
inhibition of the glucose uptake while acute drug exposure has no effects on insulin signalling 




uptake will result in decreased synthesis of TG (Figure 1.8) (Parker et al., 2005). The decreased TG 
production in the adipocytes will result in decreased cell size and lipoatrophy. Similarly, proteasome 
inhibitions by PIs results in the deposition of unfolded proteins and induce ER stress (Parker et al., 
2005; Ron & Walter, 2007). 
 
Figure 1.8: Protease inhibitors inhibit adipocyte glucose uptake. 
1.4.1.3.2 Role of core peptidomimetic structure in insulin resistance  
Detailed structural analysis of  the first generation of PIs has revealed the presence of phenylalanine-
like core structures surrounded by hydrophobic moieties called peptidomimetic which establishes direct 
interaction with GLUT4 to inhibit the glucose uptake (Hertel et al., 2004). Furthermore, this 
peptidomimetic class of PIs are more potent inhibitors on GLUT4 translocation. PIs, having 




such “tipranavir”. Tipranavir  showed no inhibition of GLUT4 activity explaining the involvement of 
peptidomimetic structure in the mechanism of inhibition (Hruz & Yan, 2006). This is one aspect of the 
inhibition of glucose uptake by PIs. However it is interesting that atazanavir  (ATV)  which has a 
peptidomimetic core does  not act the same way and shows no effect when used in therapeutic 
concentration refuting the idea that peptidomimetic core is required  for exerting such an effect in vitro 
or in vivo (Noor et al., 2004; Yan & Hruz, 2005).  
Earlier structural analysis of PIs also revealed the hydrophobic interaction around phenylalanine –like 
structure and presence of an additional pyridine ring in ATV can have steric interference or hindrance 
and it may prevent the binding to GLUT4. However, this is one of the hypotheses based on 
hydrophobicity but further studies are required to learn the structural differences and mode of actions 
among PIs (Hertel et al., 2004).  
 
Figure 1.9: Shared structural features of the HIV protease inhibitors. Squares represent the core 








1.4.1.3.3 Effect of protease inhibitors on proximal end of inulin signalling 
 
The previous studies described have attributed the major mechanism of insulin resistance due to the 
inhibition of glucose uptake by PIs suggesting that the major effect is at the distal end of signaling, via 
GLUT 4 (Ben-Romano et al., 2003). However, this mechanism may vary amongst PIs when used for 
long periods of time and PIs may also affect the proximal steps in insulin signalling.  
For example a previous study showed that saquinavir inhibited insulin receptor substrate-1 (IRS-1) 
phosphorylation in cultured adipocytes after 48 hours exposure. However, this only occurred at 
relatively high toxic drug concentrations (Algenstaedt et al., 2003). Exposure of 3T3-L1 adipocytes to 
nelfinavir for 18 hours led to inhibition of phosphorylation of Akt without affecting activation of PI3 
kinase (Ben-Romano et al., 2004). 
Oxidative stress is one of the possible underlying causes for these effects (Ben-Romano et al., 2006). 
Prolonged exposure (3 weeks) to indinavir has been associated with activation of the suppressor of 
cytokine signaling-1 (SOCS-1) signalling cascade, as well as increased levels of the sterol response 
element binding protein-1 (SREBP-1) and the inflammatory cytokine tumour necrosis factor-α (TNF-α) 
in diabetes-prone rats (Carper et al., 2008).  
1.4.1.4 Effect of ARVs on Cellular organelles and cytokines and mechanism of insulin resistance   
(a) Mitochondrial dysfunction 
Human and animal studies have shown that insulin resistance occurs independently of HIV infection 
(Hruz, Murata, Qiu, & Mueckler, 2002; Hruz & Yan, 2006; Noor et al., 2006). In these studies, the 
results have shown that most of the PIs cause abrupt peripheral insulin resistance which correlates with 
the ability of PIs to block GLUT4 translocation in vitro.  
The dysregulation in glucose levels amongst HIV-infected patients receiving thymidine NRTIs 
suggests a strong association between insulin sensitivity and lipodystrophic changes (Shlay et al., 




However, this occurs without the alteration in body fat composition as compared to patients receiving 
NRTI-sparing regimens (Blumer et al., 2008). In another study the association between NRTIs use and 
insulin resistance was validated, HIV-negative human volunteers receiving stavudine for 4 weeks had 
decreased mitochondrial function and increased insulin resistance (Fleischman et al., 2007). The exact 
molecular mechanisms involved in inducing insulin resistance have yet to be established. There is 
mounting evidence suggesting the involvement of mitochondrial dysfunction mediating the insulin 
resistance in non-HIV patients with type 2 diabetes (Kelley, He, Menshikova, & Ritov, 2002). 
Thymidine containing NTRIs (zidovudine and stavudine) are associated with severe mitochondrial 
toxicity and lipoatrophy. (McComsey & Walker, 2004). The precise mechanisms underlying 
mitochondrial toxicity are still unclear. Mitochondrial DNA depletion is a consequence of inhibition of 
DNA polymerase γ by NRTIs, is one possible mechanism, however other factors may contribute 
(Feeney & Mallon, 2010). 
(b) Endoplasmic reticulum stress 
Lipoprotein production is regulated by intracellular lipid sensors (Horton, Goldstein, & Brown, 2002) 
known SREBPs (Riddle, Kuhel, Woollett, Fichtenbaum, & Hui, 2001). The SREBPs sensor   
regulatory mechanism works when intracellular lipid levels decreases. It activates the sensor followed 
by transportation from endoplasmic reticulum (ER) to the nucleus. In the  nucleus the sensor up-
regulates the genes involved in synthesis and transport of cholesterol, triglyceride and fatty acid 
synthesis. Once the genes are activated the sensor itself undergoes degradation by the proteasomes 
(Hirano, Yoshida, Shimizu, & Sato, 2001). 
PIs influence activation of the intracellular lipid sensor. In hepatocytes indinavir  and ritonavir activate 
SREBP-1 and SREBP-2 (Riddle et al., 2001; Williams, Rao, Natarajan, Pandak, & Hylemon, 2004) or 
in some cases these PIs are linked to SREBP migration into the nucleus (Facilitated by lamins A and 




et al., 2001; Coffinier et al., 2007). Excessive accumulation of cholesterol in the ER membranes occurs 
as a result of the activation of SREBP, resulting in the alteration of intracellular homeostasis. SREBP is 
also involved in stress sensing, regulation of cell growth, differentiation and apoptosis. This 
mechanism of SREBP activation and involvement in intracellular activities is described as the unfolded 
protein response (UPR) (Xu, Bailly-Maitre, & Reed, 2005; K. Zhang & Kaufman, 2004).  
In order to restore cellular homeostasis due to higher levels of misfolded or unfolded proteins in ER, 
cellular signalling pathways are activated to regulate translation, attenuation of unfolded proteins, up-
regulation of ER chaperones and the degradation of unfolded proteins. However, during the restoration 
of cellular homeostasis cells can undergo apoptosis. 
ER stress is said to induce unfolded protein response. This has helped in the understanding of its 
association with inflammation and insulin resistance in the associated metabolic syndrome  not 
associated with HIV infection (Hotamisligil, 2010). A few in vitro studies have indicated that 
proteasome inhibition by some PIs can result in ER stress and the unfolded protein response in 
adipocytes (Parker et al., 2005). Excess calorie intake and lack of physical activity can lead to obesity. 
Obesity-related ER stress can further exacerbate visceral adiposity.  
Endoplasmic reticulum stress related activation of c-Jun N-terminal kinase (JNK) or IKK either 
directly or via increased generation of reactive oxygen species (ROS), induce serine phosphorylation of 
IRS-1. NRTI-induced mitochondrial dysfunction can also induce ROS production, which further 
enhances the inhibitory effects on insulin signaling pathways, but similar to PI-mediated toxicities, 
mitochondrial dysfunction varies depending on the class of the drug (Maagaard & Kvale, 2009).  
(c) Inflammatory cytokines   
There is strong association of inflammation with adipose tissues and it was investigated in non HIV-
infected patients (Cawthorn & Sethi, 2008). Inflammatory cytokines are secreted by macrophages 




resistance in HIV positive patients. TNF-α and IL-6 are among the inflammatory cytokines that 
mediate insulin resistance (Brown, Tassiopoulos, Bosch, Shikuma, & McComsey, 2010). 
The mechanism of induction of insulin resistance via TNF- α is channelled via activation of mitogen 
activated protein kinase (MAPK) which leads to the inhibition of interferon kappa B kinase (IKK) 
which eventually phosphorylates serine residues of IRS-1. Protein tyrosine phosphorylase b (PTP1b) 
plays role in an inactivation of insulin receptor and IRS-1 via tyrosine dephosphorylation. TNF-α 
influences the activation of PTP1b, which can dephosphorylate and deactivate insulin receptors and 
IRS proteins (Tilg & Moschen, 2008). Accumulation of fatty acids in skeletal muscles due to elevated 
hepatic triglyceride is yet another indirect route to insulin resistance mediated by TNF-α (Qin, 
Anderson, & Adeli, 2008). 
1.4.1.5 Effect of ARVs on skeletal muscle and mechanism of insulin resistance  
Skeletal muscle is responsible for the majority of peripheral glucose uptake upon insulin activation. 
Insulin activation brings about the translocation of GLUT4 from intracellular storage vesicles to the 
plasma membrane. Since the insulin signalling pathways are the same in adipocytes and myocytes, it is 
not surprising that PIs also play a role in the inhibition of glucose uptake in these tissues and can 
directly cause a decrease in glucose disposal in muscle. 
On the basis of the gold standard test used to measure glucose uptake in peripheral blood (clamp 
studies), it was concluded the impaired skeletal muscle glucose uptake is associated with HAART in 
HIV infected patients (G. M. Behrens et al., 2002; DeFronzo, Tobin, & Andres, 1979).  
Other cellular mechanisms may be involved in contributing towards impaired skeletal muscle insulin 
sensitivity. Long term exposure of ARVs to patients, can lead to ectopic skeletal muscle accumulation 
which can be associated with adipose tissue lipolysis. This compromises adipocyte storage capacity 




Another study has indicated the involvement of PIs in abnormal fatty acid oxidation in cultured C2C12 
myotubes (Richmond et al., 2010). 
The effects of abnormal fat partitioning in skeletal muscles among uninfected patients has provided 
new insights among those infected with HIV (Unger, Clark, Scherer, & Orci, 2010). Many lipid 
derivatives have been identified as being involved in insulin resistance via the activation of protein 
kinase θ, JNK and IKK, which cause phosphorylation at serine 307 residue of IRS-1 resulting in IRS-1 
inactivation (Z. Gao et al., 2004). A Few studies have recently demonstrated that an excess in 
diaglycerol can cause IRS-1 inactivation (Samuel, Petersen, & Shulman, 2010). Similarly, another 
study characterized the insulin signalling pathway in muscle harvested from lipodystrophic HIV-
infected patients under hyperinsulinaemic clamp conditions. The results showed dysregulation of the 
insulin signaling pathway downstream of IRS, at the level of Akt phosphorylation (Haugaard et al., 
2005). An in vivo study investigated the extent to which nelfinavir impaired Akt phosphorylation using 
cultured adipocytes. Similar findings were observed in insulin signalling pathways in skeletal muscle 
exposed to PIs (Ben-Romano et al., 2004). 
 
1.4.2 Effect of ARVs on fat redistribution in HIV infected patients  
It is not clear if lipodystrophy is induced due to a single mechanism. It has been proposed that multiple 
different disorders in HIV-infected patients contribute to the development of lipodystrophy. 
Furthermore, it is considered that the mechanism of peripheral lipoatrophy is different from the 
mechanism associated with central lipohypertrophy  (Mulligan et al., 2006). Similarly in the early stage 
of PI treatment, the associated accumulation of trunk fat (buffalo hump) indicates that visceral fat is 
relatively more resistant to the side effects of PIs and NRTIs but the  impact of hyperlipidaemia is same 




A study of HIV patients with lipoatrophy, having been treated for more than three months with ARVs 
(PIs and NRTIs) showed increased glucose uptake in subcutaneous fat. This was not seen in patients 
treated similarly, but without the evidence of fat wasting (Hadigan et al., 2006). It has been 
hypothesized that the counteractive action of PIs causes the inhibition of GLUT4. However, no up-
regulation of GLUT1 expression was observed to account for the slow increase in glucose uptake 
(Hadigan et al., 2006). NRTIs also play an important role in the development of lipoatrophy. However, 
only a link between PIs and the wasting of white adipose tissue has been established in human (Dube et 
al., 2005; Heath et al., 2002) and animal models (Prot et al., 2006).  
Visceral fat is functionally and metabolically different from subcutaneous fat (DiGirolamo, Newby, & 
Lovejoy, 1992; Katzmarzyk, Perusse, & Bouchard, 1999). Irrespective of the cause, the 
pathophysiologic signals that stimulate alterations in the body fat distribution in HIV, affect cellular 
metabolism and at the same time inhibit normal storage and increase the accumulation of ectopic 
visceral fat (Unger, 2003).  
The clinical picture depends on the amount of body fat at baseline and total energy balance 
(lipoatrophic or lipohypertrophic). Patients with higher total body fat and positive energy balance, after 
the exposure of the ARVs result in further increases in trunk, visceral, breast, and dorsocervical fat 
accumulation. However those with lower total body fat and neutral or negative energy balance, present 
with decrease in fat from arms , face and missing ectopic fat deposition (He, Engelson, & Kotler, 
2005). Interestingly the final picture irrespective of the initial level of adipose tissue, consistently 
results in central adiposity (Bacchetti et al., 2005). 
This hypothesis seems consistent with many group studies, that peripheral lipodystrophy and central 
adiposity results from separate and independent metabolic pathways (Bacchetti et al., 2005; Wand H, 
2005). The role of the drugs in this scenario appears pivotal because some body fat changes may 




appears that these aforementioned findings support independent mechanisms and an individual role of 
each drug in affecting metabolic pathways involved in lipid formation and distribution. 
The molecular and genetic basis for non-HIV lipodystrophy syndromes has helped efforts to explain 
the metabolic variations that occur in ARV-treated HIV infected individuals (Garg & Misra, 2004; 
Simha & Garg, 2006). It is believed that abnormal storage of triglycerides as fat results in irregular 
lipid deposition amongst the insulin targeted tissues (such as liver and skeletal muscles) and this 
eventually leads to impaired insulin signaling (Samuel et al., 2010).  
As described earlier, visceral and subcutaneous fat deposits, are metabolically and functionally 
different from each other (Wajchenberg, 2000) and these differences must be considered while 
analysing insulin resistance in HIV-infected patients. Visceral adipose tissue (VAT) appears to be 
closely linked with insulin resistance (Wajchenberg, 2000) and varies in nature through the effects of 
glucose level regulation. However in HIV-infected patients, omental-mesenteric fat is more closely 
associated with insulin resistance rather than VAT (He, Engelson, Albu, Heymsfield, & Kotler, 2003). 
The molecular basis of the metabolic differences between fat depots is still not well understood. 
Factors such as regional blood flow and cellular composition of different tissues (adipocytes, 
fibroblasts, endothelial cells, macrophages), and relative metabolic activity may explain these 
metabolic differences (Hruz, 2011). 
1.4.2.1 Adipose tissue  
Adipose tissue is the largest endocrine organ and source of energy, and hence plays an important role 
in the maintenance of normal glucose levels in the body (Galic, Oakhill, & Steinberg, 2010). Any 
dysregulation in the body fat and adipocyte function is directly related to the non-HIV metabolic 
syndrome (Bruce & Byrne, 2009). The development of lipodystrophy in HIV-infected patients 
(increased visceral adiposity and peripheral lipoatrophy) has been directly associated with the use of 




Misra, & Garg, 2002).The link between lipid and insulin resistance has previously been described. 
Association between free fatty acids and blockage of insulin stimulated glucose uptake in muscle 
through inhibition of pyruvate dehydrogenase was studied previously (Randle, 1963). Many in vivo and 
in vitro experiments elucidated that lipid-induced insulin resistance occurred via impaired insulin 
signalling pathways and through decreased glucose uptake rather than by a decreased glycolytic 
pathway (Dresner et al., 1999; Griffin et al., 1999). 
Recent studies have shown that HIV PIs affect adipocyte differentiation (Dowell, Flexner, 
Kwiterovich, & Lane, 2000; R. J. Kim, Wilson, Wabitsch, Lazar, & Steppan, 2006; Lenhard et al., 
2000; B. Zhang et al., 1999). Moreover, other researchers have revealed that PIs alter the expression 
and location of SREBP-1, which affects the expression of adipogenic factors (Bastard et al., 2002; 
Caron et al., 2001). 
Metalloproteinase ZMPSTE24 is essential for lamin A synthesis. Abnormality in ZMPSTE24 has been 
linked to hereditary lipodystrophy (Agarwal, Fryns, Auchus, & Garg, 2003). Some PIs such as 
indinavir and nelfinavir target ZMPSTE24 directly in adipocytes (Caron et al., 2003; Coffinier et al., 
2007; Goulbourne & Vaux, 2010).  
 
(a) Role of Adipocytokines  
The role of adipose tissue goes further than what was initially understood as being only for energy 
storage, in that its role includes being involved in maintaining the level of glucose in the body by 
secreting adipocytokines such as adiponectin, leptin, and resistin (Waki & Tontonoz, 2007). The need 
to further understand the role of HAART and its effects on adipocytokine levels were realized when 
altered levels of adipocytokines were observed among HAART treated HIV-infected patients 




Abnormal secretion of leptin, adiponectin and resistin by adipocytes can result in insulin resistance. 
This hypothesis is supported by the fact that an increase in insulin sensitivity was observed following 
leptin administration to patients suffering with severe hereditary lipodystrophy (Oral & Chan, 2010). 
Leptin administration has also been shown to improve lipid profiles and insulin sensitivity among 
leptin deficient lipodystrophic HIV-infected subjects (Mulligan et al., 2009). 
Adipokines (adiponectin and leptin) have direct effects on muscle insulin sensitivity (Rabe, Lehrke, 
Parhofer, & Broedl, 2008). Studies conducted in HIV-negative human volunteers have highlighted the 
possible importance of PI-induced changes in adipokine levels. Single doses of lopinavir in healthy 
human volunteers reduced insulin sensitivity (measured by hyperinsulinaemic euglycaemic clamps) 
without affecting adiponectin levels (G. A. Lee et al., 2006). However, after 4 weeks of lopinavir 
treatment, no insulin resistance was noticed but adiponectin levels were elevated suggesting that 
compensatory changes may have been provoked (G. A. Lee et al., 2004).  
Adiponectin is secreted in large quantities, and can elicit fatty acid oxidation .It also enhance insulin-
dependent reduction in gluconeogenesis in liver (Berg, Combs, Du, Brownlee, & Scherer, 2001). A 
study has shown that decreased adiponectin concentrations is linked to insulin resistance and impaired 
glucose homeostasis in ARV treated HIV-infected patients with lipoatrophy and metabolic disorders 
(Vigouroux et al., 2003) or HIV seronegative patients (Weyer et al., 2001). 
The causes appear to be multifaceted and affect both, adipocyte mass and function. It remains unclear 
whether HAART plays a primary role in affecting insulin signalling and glucose transport in 
adipocytes or whether it directly affects the adipokine secretion. 3T3-F442A adipocytes treated with 
nelfinavir, ritonavir and saquinavir all demonstrated decreased adiponectin secretion (Jones, Janneh, 
Back, & Pirmohamed, 2005). Similarly, in another study cultured human adipocytes exposed to various 
PIs have shown that a change in adipokine expression levels is associated with the production of 




infected subjects also suggests an association with stavudine and zidovudine (NRTIs) with decreased 
adiponectin and SREBP1c (Jones, Qazi, et al., 2005). 
 
1.4.3 Dyslipidaemia  
It is well established fact now that HAART is associated with abnormal levels of lipids in body. HIV 
infected individuals are most susceptible to metabolic syndrome and about 20-30% have low levels of 
HDL cholesterol. Furthermore, approximately 10-30% and 20-40% HIV infected patients have 
elevated cholesterol and triglycerides in blood respectively (Grinspoon & Carr, 2005). Abnormal 
redistribution of fats is a consequence of HAART and is either characterized by fat deposition in 
localized areas mainly under the skin called lipohypertrophy or localized loss of fat tissue and the 
condition is known as lipoatrophy. This abnormal fat redistribution (mixed lipodystrophy) is one of the 
main effects linked with HAART (Grinspoon & Carr, 2005; Lugassy, Farmer, & Nelson, 2010; Nagy 
et al., 2003). However, the highest prevalence of lipid abnormalities occurs among those with visible 
lipodystrophy (Grinspoon & Carr, 2005). 
 
1.4.3.1 Protease inhibitors and nucleoside reverse ttranscriptase inhibitors associated 
dyslipidaemia  
There is high percentage of nearly 10-85% patients affected by dyslipidaemia as a result of NRTIs and 
PIs. Such a high incidence of dyslipidaemia due to HAART depends on length of exposure to drug. 
Time is the important factor in terms of HAART associated risk factors such as lipodystrophy. It is also 
worth noticing that  about 35% of the patients on HAART  develop lipodystrophy in association with 




also an elevation in the levels of total cholesterol and low density lipoproteins at the commencement of 
HAART, suggesting a return to pre-seroconversion levels (Riddler et al., 2003).  
Abnormalities associated with HAART are not limited to adult patients but have been evident in young 
patients and children. Length of exposure to these drugs has similar effects/ consequences in younger 
patients and in children as discussed in adult patients (Aldrovandi et al., 2009; Carter et al., 2006; 
Vigano et al., 2003). HIV-infected children and adolescent experiencing lipodystrophy can range from 
5% (Carter et al., 2006)  to 85% (Vigano et al., 2003) of the cases. 
A recent study suggests that the effects of treatment among naïve HIV-infected patients demonstrate 
that a pattern in fat redistribution can occur during the course of a two-year treatment. From the first 
few months up to a year, there is an increase in the peripheral fat, however after such time there 
appears to be a gradual decline. On the other hand central fat accumulation occurs in a steady manner 
during the six month of therapy (Calmy et al., 2008; Dube et al., 2007; Mallon et al., 2003). 
Clinical findings indicate that during the two years of treatment hypercholesterolaemia develops early 
(after 4 months) while hypertriglyceridaemia and hyperinsulinaemia usually develop later (Mallon et 
al., 2003). The percentages of therapy induced hyperglycaemia, hypercholesterolaemia, 
hypertriglyceridaemia and lipodystrophy were; 5%, 25%, 20% and 15% respectively during the 5 years 
of receiving HAART (Tsiodras, Mantzoros, Hammer, & Samore, 2000).  
HIV infection related abnormalities in lipid and lipoproteins levels were observed among both patients 
with or without AIDS. Before the era of HAART, HIV-infection was linked with acute phase response 
and inflammatory mediators such as interferon-α (Grunfeld et al., 1991) or TNFα. These responses 
were thought to promote dyslipidaemia (Feingold et al., 1993).  
In the early phases of HIV infection, levels in both low-density lipoprotein cholesterol (LDL-C) and 




of the disease to AIDS, triglycerides become significantly higher and LDL particles become less dense 
(Feingold et al., 1993).  
 
1.4.3.2 Possible mechanisms for protease inhibitors -associated dyslipidaemia 
Several mechanisms which link PIs to dyslipidaemia have been suggested include inhibition of 
SREBP-1, breakdown of Apo lipoprotein -B (Liang et al., 2001)   increase in production of  very low-
density lipoproteins (VLDLs) (Purnell et al., 2000) and a resultant  reduction in the lipoprotein lipase 
activity (Ranganathan & Kern, 2002) and changes in distribution of lipid stores (Reeds et al., 2003).  
The effect of PIs on serum lipid levels appear to be independent from  HIV infection itself  but not all 
PIs are involved in causing dyslipidaemia in HIV-negative and positive subjects (Jemsek et al., 2006; 
Noor et al., 2001).Similarly lipid associated abnormalities also seen in treatment regimen without PIs 
(Dube et al., 2003; van Leth et al., 2004). 
1.5 Objective 
 
1.5.1 Background of study  
This work continued on work done previously with   the 3T3 LI Adipocyte (the most commonly used 
cellular model for insulin resistance) treated with PIs. This previous work was conducted in University 
of Cape Town as part of another PhD thesis and has been published in the Journal of Cellular 
Biochemistry (2013). 
Protease inhibitors and NRTIs, are the major components of HAART, and cause various metabolic 
disorders in HIV patients (section 1.4). The primary side-effects induced by these drugs are insulin 
resistance and lipodystrophy. The understanding of the insulin resistance and lipodystrophy induced by 




mechanisms of insulin resistance and lipodystrophy because most studies have been performed using 
different models and thus providing different conclusions.  
 
 
1.5.2 Aims of study 
The objectives were therefore:  
1. To analyse the effects of PIs and NRTIs on the insulin signalling pathway of Chinese hamster 
ovarian cells transfected with high levels of human insulin receptor (CHO-IR). The study will 
focus on the proximal steps in the cascade as well as some of the more distal steps and 
regulatory pathways such as nuclear factor k B (NFκB).  
2. To determine the potency of therapeutic compounds sodium salicylate and berberine chloride to 
reverse the effects induced by PIs and NRTIs. 
3. To evaluate the effect of PIs and NRTIs on metabolic pathways in CHO-IR cells by analysing 
metabolites in the cell culture medium, particularly amino acids and organic acids.  
4.  To analyse and compare the effects of PIs and NRTIs on lipoprotein lipase activity, an 
important step in the insulin-activated anabolic functions. This will be achieved by establishing 










2.1 Materials  
2.1.1 Antibodies 
Actin goat polyclonal IgG (SC1615)  Santa Cruz Biotechnology, CA, USA 
Goat anti-mouse horseradish peroxidase-
conjugated (HRP) (31430) 
Pierce, IL, USA 
Goat anti-rabbit HRP (SC2004) Santa Cruz Biotechnology, CA, USA 
IR β-subunit rabbit polyclonal IgG (SC711) Santa Cruz Biotechnology, CA, USA 
Mouse anti-goat HRP (#31400)  Pierce, IL, USA 
Mouse monoclonal IgG of PY20 (610000) BD Transduction Laboratories, NJ, USA  
P-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
Mouse mAb #9106 
Cell signaling Technology 
 
p44/42 MAPK (Erk1/2) Rabbit mAb #9102  Cell signaling Technology 
P-Akt rabbit(Ser 473)(9271) Cell signaling Technology 
Akt  anti-rabbit  (#9272) Cell signaling Technology 
P-GSK-3alpha/beta(ser21/9)(#9331)  Cell signaling Technology 
 
 
2.1.2 Cell line  
 
CHO-IR cells Dr. Gus Gustafson, University of Maryland, 








2.1.3 Chemicals/Reagents  
Acetic acid (2789) Merck, South Africa  
Acetonitrile (1525162) BDH laboratory supplies UK  
Acrylamide/bis (A3449) Sigma, MO, USA 
Antibiotic/antimycotic solution (17-745E) Lonza, MA, USA 
Ammonium per sulphate (APS) (A3678) Sigma, MO, USA 
Bromophenol blue (B5525)   Sigma, MO, USA 
Bicinchoninic acid solution(B9643) Sigma, MO, USA 
Bovine serum albumin (BSA) (A3059)  Sigma, MO, USA 
Copper (II) Sulphate solution C2284 Sigma, MO, USA 
LumiGlo Chemiluminescent substrate system  
(54-60-00) 
KPL, Maryland, USA 
Dulbecco’s modified Eagle’s medium  
(DMEM) (D5671)   
Sigma, MO, USA 
Dimethyl sulphoxide (DMSO) (802912-500) Merck, South Africa 
Ethanol(2233540LP)  Merck, South Africa  
Fetal calf serum (FCS) (DE14-801FI) Lonza, MA, USA  
G418-sulphate (11811-064) Gibco, CA, USA  
Gentamicin (G1272)   Sigma, MO, USA  
Glycerol (LC2676520)  Merck, South Africa 
Glycine (2676600EM)  Merck, South Africa 
Ham’s F12 medium (12-615F)   Lonza, MA, USA  
Heparin sodium-fresenius 1000 i.u/ml Bodene, Port Elizabeth, South Africa  
4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) (IM) 
Lonza, MA, USA 
 
Hydrogen per oxide H2O2 (3063820LP) Merck, South Africa 
Insulin Human (12643) Sigma, MO, USA  
Isopropanol (5075040LC)  Merck, South Africa 
L-glutamine (17-605E)   Lonza, MA, USA  
Lipoprotein lipase (LPL) from  
Pseudomonas sp. (62336)   




Methanol (4164080LC) Merck, South Africa 
Phosphate buffered saline (PBS) (4417) Sigma, MO, USA 
Phosphatase inhibitors for cell culture 
(04906837001) 
Roche, Basel, Switzerland 
Protease inhibitors Merck, Darmstadt, Germany and NIH, MD, 
USA 
Ponceau S (p3504) Sigma, MO, USA  
 
Precision plus protein dual colour standard  
(marker) (161-0374)    
Bio-Rad, CA, USA  
 
Protease inhibitors for cell culture 
(04693124001) 
Roche, Basel, Switzerland  
Skimmed milk powder (92964) Marvel, London, UK  
Sodium dodecyl sulphate (SDS) (3017542)  BDH laboratory supplies UK  
Sodium chloride (5822320EM) Merck, South Africa 
Sodium phosphate, monobasic, anhydrous 
(6346) 
Merck, South Africa 
Sodium salicylate (S2679) Sigma, MO, USA  
N, N, N’, N’,-tetra-methyl-ethylenediamine  
(TEMED) (1.10732.100)    
Merck, South Africa 
Tris base(1.08382.500)  Merck, South Africa 
Triton x-100 (UN3082)     Sigma, MO, USA 
3-Trimethylsilypropionic acid (TSP)(180335) Sigma, MO, USA 
Trypsin-ethylenediaminetetraacetic acid  
(trypsin-EDTA) (17-161E)   
Lonza, MA, USA 
Tween 20 (63158)   Honeywell Riedel-de haen USA  
2-mercaptoethanol (4161200)  Merck, South Africa 
p-nitrophenyl butyrate (pNPB)(N9876)  Sigma, MO, USA  
       
  
2.1.4 Consumables  
6 well plate   Corning, NY, USA 31.1 
6-well plate (140675) Techno Plastic Products, Switzerland 
15 ml centrifuge tubes Corning, NY, USA 31 
25 cm
2




50 ml centrifuge tube  BD Biosciences, USA 
75 cm
2
 flask (156499) Corning, NY, USA 31 
Cryotube Corning, NY, USA 31 
Disposable cuvette Lasec, Cape Town, South Africa 
Eppendorf tubes and tip QSP, CA, USA  
Filter paper (3030-861)  Whatman, Kent, UK  
Nitrocellulose membrane (RPN303P)  
Hybond ECL     
Amersham Biosciences, NJ, USA 
Syringe   Pall, NY, USA  
Syringe filter (0.2μm) Pall, NY, USA  
      
2.1.5 Instruments, software and web server  
 
ChemiImager Alliance 2.7   UVI tech limited UK 
Cary 60 spectrophotometer Agilent Technologies, CA, USA  
BIO-RAD Turbo transfer  Bio-Rad, CA, USA  
H
1
-NMR Bruker Advance III spectrometer Bruker Biospin, Karlsruhe, Germany 
AMIX program, version 3.9  Bruker Biospin, Rheinstetten, Germany 
Graph Pad Prism GraphPad Software, CA, USA  









2.2 Methods  
 
This study was designed to investigate the molecular basis of insulin resistance induced by protease 
inhibitors and NRTIs in vitro, using a cell culture system. The study of insulin signaling was performed 
using CHO-IR cells (Ahmed & Pillay, 2001) . Advantages such as short doubling time and easy 
handling make CHO-IR cell line a useful cell culture model for the study of insulin signaling and make 
the planning of experiments relatively straightforward. CHO-IR cells have been transfected with high 
levels of human insulin receptor at a level of approximately 1 x 10
6
 receptors / cell.  High protein 
expression in these cells allows sensitive detection of changes in signalling proteins involved in the 
insulin receptor signalling pathway.  
The cells were serum-starved and then stimulated with insulin, both in the presence and absence of 
protease inhibitors; nelfinavir, indinavir, ritonavir and nucleoside reverse transcriptase inhibitors, 
tenofovir and stavudine. The level of insulin stimulation was compared with that of the basal 
unstimulated cells (the control). The cell lysates were then subjected to immunoblotting with the 
appropriate antibodies. The CHO-IR cells were also pre-treated with therapeutic compounds sodium 
salicylate and berberine chloride, prior to treatment with PIs and NRTIs. The results were analysed 
using Alliance 2.7 imaging system (ChemiImager).  
In addition, the cell culture supernatants of CHO-IR cells treated with PIs and NRTIs were used to 
assay for lipoprotein lipase activity and for metabolomic analysis.  
 
2.2.1 Preparation of culture medium and maintenance of cell lines  
The CHO-IR cells were cultured in Ham’s F12 mixture culture medium in 75 cm
2 
flasks, and incubated 
at 37 °C in a 5 % CO2 incubator. The medium was supplemented with 10 % FCS, 2 mM L-glutamine, 1 




gentamicin and 400 μg/ml G418-sulphate solution. Ham’s F12 medium was used as a base medium for 
the CHO-IR cells as the cells require L-proline, which is supplied by the medium. FCS has a high level 
of insulin growth factor (IGF) to stimulate the growth of cells. L-glutamine is an essential amino acid 
for supporting the growth of cells, and is an alternative energy source for rapidly dividing cells and 
cells that use glucose inefficiently. Antibiotic / antimycotic solution is effective against the most 
common forms of cell culture contamination, including gram-positive and gram-negative bacteria, 
yeast and fungi. Gentamicin was used to prevent contamination of the mycoplasma in the cell culture 
medium. As mentioned earlier in this chapter, CHO-IR cells are transfected cells with insulin receptor. 
The transfected insulin receptor is on a plasmid that contains the G418 resistance gene. G418 is an 
antibiotic to ensure that only transfected cells are present in a flask while any cells that lose the plasmid 
will die.  
Within 3-4 days, after the cells had reached semi-confluence in a 75cm
2
 flask, they were split for 
subculture in the following way: the culture medium was discarded and the cells were rinsed, first with 
10 ml of sterile phosphate buffered saline (PBS) followed by the addition of 2ml 1x trypsin-
ethylenedinitrilotetraacetic acid (Trypsin-EDTA) to coat the surface. The excess was removed 
immediately and the flask was incubated at 37 °C for 2 min to allow the cells to become de-attached 
from the flask. The trypsin reaction was terminated using 5 ml of culture medium, and 1 ml of the 
culture medium was then transferred for every new 75mm
2
 flask containing 20 ml of fresh culture 
medium.  
Stocks of frozen CHO-IR cells were routinely prepared for storage in -80 ultra-freezers and then in 
liquid nitrogen. The freezing medium for CHO-IR cells was prepared using 20 % dimethyl sulfoxide 
(DMSO) in FCS solution. Following trypsinization and suspension in culture medium, the cells were 
mixed in a cryotube, with a volume ratio of 1:1 to freezing medium. The tubes were then placed in an 




container to freeze the cells gradually. Isopropanol facilitated the temperature in the container to drop 
at a rate of about 1°C per minute.  
Cells were thawed by placing the cryotubes in 37 °C in an incubator for approximately 2 min, or until 
thawed. The cells/freezing medium solution was then added to 5 ml of the culture medium (i.e. Ham’s 
F12 mixture culture medium) in a 25 cm
2
 flask, and resuspended. The culture medium was changed 
after 12 h, grown as above, and split into a 75 cm
2
 flask when the cells were in a state of semi-
confluence. 
 
2.2.2 Serum starvation procedure  
1 x 10
5
 cells/ml of CHO-IR cells were plated into 6-well plates until they were in a state of semi-
confluence. CHO-IR cells were serum-starved for 16 h in a serum-free medium (2 mM L-glutamine, 1 
% of 100 x antibiotic/antimycotic and 0.1 % gentamicin in DMEM). The cells were incubated at 37 ºC, 
with 10 % CO2.  
The cells were stimulated with 10 ng/ml (1.7 nM) insulin for 5 min before aspirating the serum-free 
medium. The serum-free medium from the CHO-IR cells were stored at -80 ºC until subsequent 
analysis.  
 
2.2.3 Preparation of cell lysates  
After serum-starvation for 16 h, followed by insulin stimulation for 5 min, the serum-free medium was 
discarded. The 6-well plates were put on ice. Subsequently, 200 μl lysis buffer (consisting of 50 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5, 1 % phenoxylpolyethoxyethanol 
(Tritron X 100), 10 % glycerol, 50 mM sodium chloride (NaCl), protease inhibitor and phosphatase 




inhibitor tablets had been previously added to the lysis buffer (1 tablet each/10ml of lysis buffer) to 
protect proteins of the cells against dephosphorylation. Specifically, protease inhibitor inhibits a broad 
spectrum of serine, cysteine, metalloproteases and calpains, while phosphatase inhibitor inhibits a 
broad spectrum of phosphatases such as acid, alkaline, serine/threonine and tyrosine protein 
phosphatase.  
The cells were scraped with a scraper and transferred into a micro-centrifuge tube. Tubes were then 
centrifuged at 4 °C and 10 000 rpm for 10 min. 120 μl of the supernatant were mixed with 30 μl of 5 x 
Laemmli buffer (25 nM Tris, pH 6.8, 2 % SDS, 0.002 % bromophenol blue, 10 % glycerol and 5 % 2-
mercaptoethanol) prior to boiling at 100 ºC for 5 min, and brief spinning to settle all the evaporation 
from the lid of the micro-centrifuge tube. The cell lysate was stored at -20 °C prior to use, or at -80 °C 
for extended maintenance.  
 
2.2.4 Measurement of protein concentration  
A bicinchoninic acid (BCA) assay was used to measure the concentration of protein in the cell lysate. 
The principle of assay relies on the formation of a Cu
2+
-protein complex under alkaline conditions, 




. The amount of reduction is proportional to the protein 





. BCA forms a purple-blue complex with Cu
1+
 in alkaline environments, thus 
providing a basis to monitor the reduction of alkaline Cu
2+
 by proteins at absorbance maximum 562 
nm.   (BSA) was used as a protein standard. 
Protein detection reagent was prepared by adding 1 mL of copper sulphate pent hydrate 4% Solution 
to 49 mL of the bicinchoninic Acid Solution. 1 mg of bovine serum albumin (BSA) was used to 
generate the standard curve by diluting to 0.8mg, 0.6mg, 0.4mg and 0.2 mg. Twenty five microliters of 






The absorbance of the mixture in the 96 wells plate was measured at 562 nm, with the reagent as a 
blank. 
2.2.5 Stock  preparation of drugs and therapeutic compounds 
All drugs and compounds were made in different stock concentrations in dimethyl sulphoxide (DMSO) 
except nelfinavir which was prepared in ethanol as described in Table 2.1. The drugs 0.5 M sodium 
salicylate and 2.6 mM berberine chloride (BBR) were prepared fresh on the day of experiment in 1 M 
Tris, pH 7.4 and DMSO respectively(Yuan et al., 2001). CHO-IR cells were pre-treated with sodium 
salicylate (5 mM) and berberine chloride (27µM) at 37 ºC for 1 h prior to treatment with ARVs for 16 
h. Selective inhibitor of IκB kinase (IKK)  IKK-16 (4mM) was prepared in H2O.  Cell lysates were 
prepared as described in section 2.2.3.  
Table 2.1 ARVs stock concentrations and solvent 
 
 
Drug  Class Stock 
Concentration 
Solvent  Drug 
concentration  
References  
Indinavir  PI 5mM DMSO 100 µM (Murata et al., 2002) 
Nelfinavir PI 5mM 100 % 
Ethanol 
30 µM (Ben-Romano et al., 
2004) 




PI 5mM DMSO 20 µM (Minami et al., 2011) 
Lamivudine NRTI 10mM DMSO 10 µM (Heald et al., 1996) 
Stavudine NRTI 10mM DMSO 5 µM (Dudley et al., 1992) 
Zidovudine( 
AZT) 
NRTI 10mM DMSO 10 µM (Minami et al., 2011) 
Emtricitabine NRTI 10mM DMSO 20 µM (Minami et al., 2011) 
Efavirenz NRTI 10mM DMSO 20 µM (Minami et al., 2011) 






2.2.6 Statistical analysis  
 
Statistical comparisons were made using Student’s t-test or factorial-ANOVA using Microsoft Excel 




CHAPTER 3: ANALYSIS OF THE INSULIN SIGNALING PATHWAYS 
FOLLOWING EXPOSURE TO ANTIRETROVIRAL DRUGS 
 
3.1 Introduction  
The advancement in HIV treatment has increased the life span of  HIV-infected individuals yet the 
treatment regime i.e. HAART comes with a package of side effects which affects major organs causing 
cardiovascular disease (Friis-Moller, Sabin, et al., 2003), chronic kidney disease (Wyatt et al., 2007)  
and neurocognitive impairment(Suarez et al., 2001).  Although safer ARVs aiming to minimize 
antiretroviral toxicities have been developed, these still lead to   metabolic complications resulting in 
insulin resistance. Insulin resistance is one of the first metabolic side-effects with high incidence 
observed following the implementation of HAART. 
There are a number of potential mechanisms whereby antiretroviral drugs can induce insulin resistance. 
This can occur by direct effects on the insulin signaling cascade in the cell or indirectly by interfering 
with lipid metabolism or with the actions of adipocytokines (Hruz, 2011). Insulin resistance observed 
in HIV-associated lipodystrophy is classical example of inducing insulin resistance by affecting the 
lipid metabolism. There are a lot of common effects exhibited by the different antiretroviral drugs in 
their tendency to induce insulin resistance and in vivo this makes it more difficult to attribute the 
insulin resistance to a particular antiretroviral. HIV-infected patients are generally more susceptible to 
the consequences of antiretroviral-induced insulin resistance and diabetes mellitus. Optimum treatment 
plans for treating the insulin resistance during HIV therapy have not been established as yet (Feeney & 
Mallon, 2011).  
Initially it was believed that only PIs are responsible for most of the metabolic complications described 
in the previous chapter. In 1999, Brinkman reported for the first time that  certain NRTIs (Thymidine 




involvement in the inhibition of DNA polymerase-g which plays an important role in the mitochondrial 
replication (Brinkman, Smeitink, Romijn, & Reiss, 1999; Lewis, Day, & Copeland, 2003). Up to 15-20 
% patients treated with NRTIs develop several types of mitochondrial toxicities leading to 
lipodystrophy in adipose tissue, insulin resistance in skeletal muscles and lactic acidosis in liver and 
neuropathy in nerves. This tends to depend on the specificity of NRTIs and the nature of the tissue 
(Gerschenson & Brinkman, 2004; Lewis et al., 2003). Two recent studies further clarified the 
involvement of different NRTIs (stavudine, zidovudine, lamivudine) in insulin resistance and 
mitochondrial dysfunction (Fleischman et al., 2007; van Vonderen et al., 2010).  
 
Fig.3.1 Potential causes of insulin resistance in HAART-treated HIV-infected patients. HAART = 
highly active antiretroviral therapy. NRTIs = nucleoside reverse transcriptase inhibitors. PIs = protease inhibitors. HCV = 




In this study we sought to evaluate the role of protease inhibitors and NRTIs in insulin resistance by 
examining the effects on insulin signaling pathways.  We used the following PIs (nelfinavir indinavir, 
ritonavir) and NRTIs (tenofovir and stavudine) in the study. CHO-IR cells were treated with various 




3.1.1 Sodium salicylate, berberine chloride and IKK-16 Treatment 
Berberine chloride is contained in a Chinese traditional medicinal compound used for the treatment of 
type 2 diabetes mellitus, lowering cholesterol and treating diarrhoea (Kong et al., 2004; Lau, Yao, 
Chen, Ko, & Huang, 2001; C. E. Taylor & Greenough, 1989).  
Studies to evaluate the mechanistic basis of berberine to decrease glucose showed that berberine 
stimulates glucose transport through a mechanism different from insulin in 3T3-L1 adipocytes (Zhou et 
al., 2007). Berberine activated AMP- activated protein kinase (AMPK) and induced glycolysis in L6, 
C2C12, and 3T3-L1 cell lines (Yin, Gao, Liu, Liu, & Ye, 2008)]. Two separate studies indicated that 
berberine also activated extracellular signal-regulated kinase (ERK) (Zhou et al., 2007) and c-jun N-
terminal kinase, ( JNK) (S. Lee et al., 2007) in HepG2 cells. On the basis of these studies, could 
hypothesized that berberine acts on several different pathways to moderate insulin sensitivity. 
Another potential hypoglycemic compound is Sodium salicylate. The molecular mechanism by which 
sodium salicylate reduces blood glucose levels is through IKKβ in the NFκB pathway (Yuan et al., 
2001). The hypoglyacemic properties of salicylates have been known for many decades. The 
compound has been reported to reduce glucose levels in fasting state of diabetic patients (Yuan et al., 
2001). After it was shown that  IKKβ was involved in insulin resistance  and that salicylates were 
found to be strong hypoglycaemic candidates (Fleischman, Shoelson, Bernier, & Goldfine, 2008; 
Koska et al., 2009), even though they had been superseded by other oral hypoglycaemic compounds 
such as metformin (Yuan et al., 2001). With this mind, it would be appropriate to test the role of the 
NFκB pathway using salicylates or alternative IKKB inhibitors. In this study, we used IKK-16 
(selective inhibitor of the IκB kinase (IKK)) to evaluate the involvement of the NFκB pathway in the 
effects of the antiretroviral drugs on the insulin signalling pathway.   
As discussed previously, the precise mechanism by which protease inhibitors induce insulin resistance 




mechanisms by which protease inhibitors induce insulin resistance in CHO-IR cells by the analysis of 
signalling proteins in the insulin signalling pathway.  
 
3.2 Methods  
3.2.1 Preparation of acrylamide gels for sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE)  
The SDS-polyacrylamide gels (dimensions 8 cm x 7.3 cm x 1.5mm) were prepared in batches of 12 in 
a multi gel casting chamber (Bio-Rad) according to the standard protocol. The stacking gel (upper) was 
a 4 %  (0.126 M Tris, pH 6.8, 4 % acrylamide/bis , 0.1 % SDS, 0.05 % ammonium persulphate (APS) 
and 0.1 % N, N, N’, N’,-tetramethylethylenediamine (TEMED)) and the resolving gel (lower) was a 
7.5 % (0.375 M Tris, pH 8.8, 7.5 % acrylamide/bis , 0.1 % SDS, 0.05 % APS and 0.05 % TEMED) 
each (Figure 3.2). The stacking gel also contained the 10-wells for sample loading.  
 
3.2.2 Electrophoresis  
The protein samples (25 μl) and a molecular weight marker (Precision Plus Protein Dual Colour 
Standard, Bio-Rad) (5 μl) were loaded into the wells of the gel. The four gels were assembled with the 
electrode assembly and then placed in the tetra cell mini buffer dam (Bio-Rad) filled with running 
buffer (0.025 M Tris, 0.192 M glycine and 0.1 % SDS). Electrophoresis was performed at 150 V and 






Figure 3.2: SDS-polyacrylamide gel electrophoresis procedure.  
 
3.2.3 Protein transfer  
Nitrocellulose membrane and thick filter paper were soaked for 15 min in transfer buffer (0.025 M 
Tris, 0.192 M glycine and 20 % methanol). Following electrophoresis, the acrylamide gels were placed 
for 10 min in transfer buffer to equilibrate. The protein transfer sandwich was assembled with the 
nitrocellulose membrane and gel in the middle and thick filter papers on either side as shown in Figure 
3.3, and placed in tray of the Bio-Rad turbo Transfer. The transfer procedure was performed at 0.25 A 















Figure 3.3: Transfer sandwich. 
 
3.2.4 Immunoblotting  
The membrane was stained (by rinsing) with ponceau (0.1 % Ponceau S in 5 % acetic acid) to verify 
the successful and uniform transfer of proteins to the membrane. The membrane was de-stained with 
deionized water and incubated in a blocking solution (5 % BSA or 5 % skimmed milk solution  in Tris-
buffered saline (0.05 M Tris, 0.150 M NaCl, pH 7.4)) + 0.1% Tween 20 (TBST) for 1 h at room 




incubated with a specific primary antibody   (Table 3.1) for 1 h, and washed with 20 ml TBST for 15 
min, 4 times.  
The membrane was then incubated with a horseradish peroxidase (HRP)-labelled secondary antibody 
(Table 3.1) to detect the primary antibody bound to the protein of interest. It was washed three times 
10min each with TBST and then once rinsed with deionized water (20 ml). The membrane was then 
soaked in chemiluminescent reagent (LumiGlo) (600µl) for 1 min, and excess reagent was drained 
























Mouse anti-PY20(1 mg/ml) 1 in 2000 3 % BSA 
Goat anti-mouse 
(1 mg/ml) 
1 in 5000 3 % BSA 
IR β-subunit rabbit 
polyclonal IgG (200 μg/ml) 
1 in 1000 5 % NFDM 
Goat anti-rabbit (400 
μg/ml) 
1 in 1000 5 % NFDM 
Actin goat polyclonal IgG 
(200 μg/ml) 
1 in 1000 5 % NFDM 
Mouse anti- goat 
(1 mg/ml) 
1 in 1000 5 % NFDM 
P-p44/42 MAPK (Erk1/2) 1 in 1000 5 % BSA 
Goat anti-mouse 
(1 mg/ml) 
1 in 5000 5 % BSA 
P-Akt rabbit(Ser 473) 1 in 1000 5 % BSA 
Goat anti-rabbit (400 
μg/ml) 
1 in 1000 5 % BSA 
P-GSK-3alpha/beta 1 in 1000 5% BSA 
Goat anti-rabbit (400 
μg/ml) 
1 in 1000 5% BSA 
Akt  anti-rabbit  1 in 1000 5% NFDM 
Goat anti-rabbit (400 
μg/ml) 
1 in 1000 5% NFDM 
p44/42 MAPK (Erk1/2) 1 in 1000 5 % NFDM 
Goat anti-rabbit (400 
μg/ml) 
1 in 1000 5 % NFDM 
PY20 = phosphotyrosine, IR = insulin receptor, MAPK=Mitogen-activated protein (MAP) kinases, PKB(Akt)= protein kinase B, GSK-3=Glycogen 
synthase kinase-3 





3.2.5 Re-probing of membrane  
The membrane was incubated with hydrogen peroxide solution for 30 min at 37 ºC, and 5 min at room 
temperature for stripping to block the HRP signals (Sennepin et al., 2009). In the next step membrane 
was put in blocking solution once more and then re-probed with a different primary antibody (Table 
3.1) as indicated in Section 3.2.4.  
 
3.2.6 Quantification of chemiluminescence  
The membrane was analysed using a real-time imager, ChemiImager (Fluorchem 5500 Programme, 















3.3 Results  
3.3.1 Effects of the HIV protease inhibitors and nucleoside reverse transcriptase inhibitors on 
insulin-stimulated phosphorylation.  
In the first stage of the study, cells were exposed to PIs (indinavir ,nelfinavir and  ritonavir ) and an 
NRTI (tenofovir), prior to insulin stimulation to examine the effects on the insulin receptor - β (IR- β) 
subunit tyrosine phosphorylation, IRS-1 tyrosine phosphorylation and downstream activation of 
proteins such as protein kinase B (Akt or PKB), MAPK and GSK-3 in CHO-IR cells. The cells were 
pre-treated with PIs and NRTIs for 16 h followed by insulin stimulation (10 ng/ml) (1.7 nM) for 5 min. 
3.3.2 Effects of protease inhibitors 
 
3.3.2.1 Effects of i                             β,                               -1 
phosphorylation and activation of Akt, Map Kinase and GSK-3   (Figure 3.4.)  
Indinavir was used in two concentrations (25 and 50 µM).Indinavir at 50 M significantly inhibited the 
tyrosine phosphorylation at IR-β (p=.0048) and IRS-1(p=.0037) (Figure 3.4(a)) while phosphorylation 
of MAPK was inhibited by both concentrations (p=.0021) (Figure 3.4(b). The phosphorylation of Akt 
was mildly (not significantly) reduced while GSK3 was not affected by either concentration of 
indinavir (Figure 3.4(c) and (d)). The phosphorylation of Akt was significantly reduced in the later 










(a )                                                                                                             (b) 
    
(c)                                                                                                 (d) 
     
Figure 3.4: Effects of indinavir on insulin-stimulated phosphorylation in CHO-IR cells. CHO-IR 
cells were treated with different concentrations of indinavir for 16 h followed by (10ng/ml) insulin stimulation. 
The cells were then lysed and the lysates subjected to immunoblotting with antibodies against: (a) 
phosphotyrosine PY20 antibody (b) Phospho-p44/42 MAPK (Erk1/2) (c) phospho-Akt (d) Phsopho-GSK-3α/β. 
The blots were then stripped and reprobed with anti-IR β-subunit (a) p44/42 MAPK (Erk1/2)(b)  total Akt (c) 
and actin (d) respectively (lower panel). Bound antibodies were visualised by chemiluminescence. 
Chemiluminescence was quantified by CemiImaging system. The band intensity of the proteins from one 
experiment was normalised to the band intensity of total protein. Data are shown as mean ± S.E.M. (n=2). pIR 
(PY20) = tyrosine phosphorylation of IR, tIRβ = total insulin receptor β-subunit,p-IRS-1 =phosphorylation of 
Insulin receptor substrate ,P-MAPK = Phospho-p44/42 Mitogen-activated protein kinase, t-MAPK= Total 
Mitogen-activated protein kinase, p- Akt = phosphorylation of protein kinase B,t-Akt = Total protein kinase B, 
P-GSK3= phospho-Glycogen synthase kinase-3 alpha/beta.*p < 0.05, using one way ANOVA.“*” statistically 
significant change in phosphorylation after insulin stimulation as copmared to basel level.“#” statistically 




3.3.2.2 Effects of n  f                           β,                               -1 
phosphorylation and activation of Akt, MAPK and GSK-3   (Figure 3.5)  
For comparison with indinavir , nelfinavir was used in two concentration (30µM and 60µM).Both low 
and high concentrations of nelfinavir significantly inhibited the insulin-stimulated tyrosine 
phosphorylation of the insulin receptor β-subunit (IR- β) (p=.0027), IRS-1(p=.0019), MAPK 
(p=.001)and Akt (p=.00129) by greater than 50%, (Figure 3.5 (a), (b) and (c) respectively). Nelfinavir 
did not cause change in the serine phosphorylation of GSK-3 (figure 3.4(d)) detected by the phospho 
specific antibody which detects phosphorylation of GSK-3alpha/beta (ser21/9). The expression levels 
of total insulin receptor β-subunit, total Akt, total MAPK and actin were unchanged (Figure 3.5 (a) , (b) 




















( a )                                                                              (b)  
                                                                                                                     
(c )                                                                                                             (d)   
             
Figure 3.5: Effects of nelfinavir on insulin-stimulated phosphorylation in CHO-IR cells. CHO-IR 
cells were treated with different concentrations of nelfinavir for 16 h followed by (10ng/ml) insulin stimulation. 
The cells were then lysed and the lysates subjected to immunoblotting with antibodies against: (a) 
phosphotyrosine PY20 antibody (b) Phospho-p44/42 MAPK (Erk1/2) (c) phosphor-Akt (d) Phospho-GSK-3α/β. 
The blots were then stripped and reprobed with anti-IR β-subunit (a) p44/42 MAPK (Erk1/2)(b)  total Akt (c) 
and actin (d) respectively (lower panel). Bound antibodies were visualised by chemiluminescence. 
Chemiluminescence was quantified by ChemiImaging system. The band intensity of the proteins from one 
experiment was normalised to the band intensity of total protein.Data are shown as mean ± S.E.M. (n=2).  pIR 
(PY20) = tyrosine phosphorylation of IR, tIRβ = total insulin receptor β-subunit,p-IRS-1 =phosphorylation of 
Insulin receptor substrate ,P-MAPK = Phospho-p44/42 Mitogen-activated protein kinase, t-MAPK= Total 
Mitogen-activated protein kinase, p- Akt = phosphorylation of protein kinase B,t-Akt = Total protein kinase B, 
P-GSK3= phospho-Glycogen synthase kinase-3 alpha/beta.*p < 0.05, using one way ANOVA.“*” statistically 
significant change in phosphorylation after insulin stimulation as copmared to basel level.“#” statistically 







3.3.2.3 Effects of ritonavir (Figure. 3.6)  
 Ritonavir was the third protease inhibitor investigated at two concentrations.  The effects of ritonavir 
on the insulin signaling pathway were less profound. In particular, there was minimal change in insulin 
receptor and IRS phosphorylation (Figure 3.6 (a)). However, ritonavir affected the phosphorylation of 
MAPK at both concentrations. Insulin-stimulated Akt and GSK-3 phosphorylation were   unaffected by 






















( a )                                                                                                                    (b) 
     
( c )                                                                                                        ( d )  
  
Figure 3.6: Effects of ritonavir on insulin-stimulated phosphorylation in CHO-IR cells. CHO-IR 
cells were treated with different concentrations of ritonavir for 16 h followed by (10ng/ml) insulin 
stimulation. The cells were then lysed and the lysates subjected to immunoblotting with antibodies 
against: (a) phosphotyrosine PY20 antibody (b) Phospho-p44/42 MAPK (Erk1/2) (c) phosphor-Akt (d) 
Phsopho-GSK-3α/β. The blots were then stripped and reprobed with anti-IR β-subunit (a) p44/42 
MAPK (Erk1/2)(b)  total Akt (c) and actin (d) respectively (lower panel). Bound antibodies were 
visualised by chemiluminescence. Chemiluminescence was quantified by CemiImaging system. The 
band intensity of the proteins from one experiment was normalised to the band intensity of total 
protein. pIR (PY20) = tyrosine phosphorylation of IR, tIRβ = total insulin receptor β-subunit,p-IRS-1 
=phosphorylation of Insulin receptor substrate ,P-MAPK = Phospho-p44/42 Mitogen-activated protein 
kinase, t-MAPK= Total Mitogen-activated protein kinase, p- Akt = phosphorylation of protein kinase 





3.3.3 Effects of NRTIs on insulin signalling pathways 
3.3.3.1 Effects of the tenofovir on insulin receptor signaling pathway 
Tenofovir did not affect on the proximal part of the insulin signaling pathway e.g. insulin receptor-β 
sub unit and IRS-1(Figure 3.6(a)) .Similarly no significant decrease in phosphorylation of Akt and 
GSK-3 with tenofovir (Figure 3.7(c) and (d)) was observed. However, like protease inhibitors, 

















( a )                                                                                      (b) 
   
  (C )                                                                                                          (d)  
  
Figure 3.7: Effects of Tenofovir on insulin-stimulated signaling pathways in CHO-IR cells. CHO-
IR cells were treated with different concentrations of tenofovir for 16 h followed by (10ng/ml) insulin 
stimulation. The cells were then lysed and the lysates subjected to immunoblotting with antibodies 
against: (a) phosphotyrosine PY20 antibody (b) Phospho-p44/42 MAPK (Erk1/2) (c) phosphor-Akt (d) 
Phsopho-GSK-3α/β. The blots were then stripped and reprobed with anti-IR β-subunit (a) p44/42 
MAPK (Erk1/2)(b)  total Akt (c) and actin (d) respectively (lower panel). Bound antibodies were 
visualised by chemiluminescence. Chemiluminescence was quantified by the ChemiImaging system. 
The band intensity of the proteins from one experiment was normalised to the band intensity of total 
protein. p-IR (PY20) = tyrosine phosphorylation of IR, tIRβ = total insulin receptor β-subunit,p-IRS-1 
=phosphorylation of Insulin receptor substrate ,P-MAPK = Phospho-p44/42 Mitogen-activated protein 
kinase, t-MAPK= Total Mitogen-activated protein kinase, p- Akt = phosphorylation of protein kinase 




3.3.4 Effect of protease inhibitors after pre-treatment of CHO-IR cells with sodium salicylate, 
berberine chloride and IKK-16 
In order to evaluate the potential role of the NFκB pathway in the effects of protease inhibitors and 
NRTIs (tenofovir) cells were pre-treated with IKK-16 or sodium salicylate (NaSal). In addition 
berberine chloride (BBR) also tested as a potential therapeutic compound to determine if it would alter 
the insulin-desensitizing effects of ARVs. 
3.3.4.1 Effects on indinavir  
 CHO-IR cells were treated with NaSal (5mM), BBR (2.7mM) and IKK-16 (2µM) for 1 h before the 
addition of indinavir.  
In the presence of indinavir phosphorylation of insulin receptor β-subunit (IR-β p=.0087) substrate 
(IRS-1 p= .0002) and downstream proteins (Akt p=.008 and MAPK p=.0001) except GSK-3 were 
significantly reduced (Figure 3.8 (a), (b), (C) and (d)). In BBR pre-treated CHO-IR cells, a slightly 
increased (but not statistically significant) phosphorylation at IR-β and Akt was observed (Figure 3.8 
(a) and (c)). BBR did not alter the effect of indinavir to inhibit MAPK (Figure 3.8(b)). GSK-3 




( a )                                                                                                        ( b ) 
  
(c)                                                                                                               (d) 
   
Figure 3.8: Effects of BBR on the insulin signaling pathways in CHO-IR cells (Indinavir). CHO-
IR cells were pre-treated with berberine chloride (2.7 mM) for 1 h prior to treatment with indinavir (50 
μM) for 16 h. The cells were stimulated with insulin for 5min. The cells were then lysed and the lysates 
subjected to immunoblotting with antibodies against: (a) IR-βand IRS-1with anti-phosphotyrosine 
PY20 antibody (b) Phospho-p44/42 MAPK (Erk1/2) (c) phospho-Akt and (d) Phospho-GSK-3α/β 
(upper panels). The blots were  reprobed with anti t-IR-β (a) ,p44/42 MAPK (Erk1/2)(b)  total Akt (c) 
and actin (d) respectively (lower panel) . Bound antibodies were visualised by chemiluminescence and 
quantified by ChemiImager. The band intensity of the proteins from 2 independent experiments was 
normalised to the band intensity of total IR. Data are shown as the mean ± S.E.M. (n=2). p-IR (PY20) 
= tyrosine phosphorylation of IR, tIRβ = total insulin receptor β-subunit,p-IRS-1 =phosphorylation of 
Insulin receptor substrate ,P-MAPK = Phospho-p44/42 Mitogen-activated protein kinase, t-MAPK= 
Total Mitogen-activated protein kinase, p- Akt = phosphorylation of protein kinase B,t-Akt = Total 
protein kinase B, P-GSK3= phospho-Glycogen synthase kinase-3 alpha/beta. *p< 0.05, using one way 
ANOVA.“*” statistically significant change in phosphorylation after insulin stimulation as copmared to 
basel level.“#” statistically significant change in the phosphorylation after drug treatment as compared 




In NaSal-treated CHO-IR cells  phosphorylation of  IR-β in the presence of indinavir was slightly 
increased (Figure 3.9 (a)) but NaSal also did not reverse the effects of indinavir on IRS-1, MAPK  and 





























( a )                                                                                        ( b) 
   
( C )                                                                                                             ( d ) 
    
Figure 3.9: Effects of sodium salicylate on CHO-IR cells treated with indinavir. CHO-IR cells 
were pre-treated with sodium salicylate (5 mM) for 1 h prior to treatment with indinavir (50 μM) for 16 
h. The cells were stimulated with insulin for 5min. The cells were then lysed and the lysates subjected 
to immunoblotting with antibodies against: (a) IR-βand IRS-1with anti-phosphotyrosine PY20 
antibody (b) Phospho-p44/42 MAPK (Erk1/2) (c) phospho-Akt and (d) Phospho-GSK-3α/β (upper 
panels). The blots were reprobed with anti t-IR-β (a) ,p44/42 MAPK (Erk1/2)(b)  total Akt (c) and actin 
(d) respectively (lower panel) . Bound antibodies were visualised by chemiluminescence and quantified 
by ChemiImager. The band intensity of the proteins from 2 independent experiments was normalised to 
the band intensity of total IR. Data are shown as the mean ± S.E.M. (n=2). p-IR (PY20) = tyrosine 
phosphorylation of IR, tIRβ = total insulin receptor β-subunit,p-IRS-1 =phosphorylation of Insulin 
receptor substrate ,P-MAPK = Phospho-p44/42 Mitogen-activated protein kinase, t-MAPK= Total 
Mitogen-activated protein kinase, p- Akt = phosphorylation of protein kinase B,t-Akt = Total protein 
kinase B, P-GSK3= phospho-Glycogen synthase kinase-3 alpha/beta. *p< 0.05, using one way 
ANOVA. “*”statistically significant change in phosphorylation after insulin stimulation as copmared to 
basel level.“#” statistically significant change in the phosphorylation after drug treatment as compared 




3.3.4.2 Effects of IKK-16 on cells pretreated with indinavir 
In cells pre-treated with IKK-16 there was not  no significant change in the phosphorylation of   insulin 
























( a )                                                                                                              ( b ) 
  
( c )                                                                                                       ( d )        
   
Figure 3.10: Effects of IKK-16 on the insulin signaling pathway of CHO-IR cells pre-treated with 
indinavir. CHO-IR cells were pre-treated with IKK-16 (2 µM) for 1 h prior to treatment with indinavir 
(50 μM) for 16 h. The cells were stimulated with insulin for 5min. The cells were then lysed and the 
lysates subjected to immunoblotting with antibodies against: (a) IR-βand IRS-1with anti-
phosphotyrosine PY20 antibody (b) Phospho-p44/42 MAPK (Erk1/2) (c) phospho-Akt and (d) 
Phospho-GSK-3α/β (upper panels). The blots were reprobed with anti t-IR-β (a) ,p44/42 MAPK 
(Erk1/2)(b)  total Akt (c) and actin (d) respectively (lower panel) . Bound antibodies were visualized by 
chemiluminescence and quantified by ChemiImager. The band intensity of the proteins from 2 
independent experiments was normalised to the band intensity of total IR. Data are shown as the mean 
± S.E.M. (n=2). p-IR (PY20) = tyrosine phosphorylation of IR, tIRβ = total insulin receptor β-
subunit,p-IRS-1 =phosphorylation of Insulin receptor substrate ,P-MAPK = Phospho-p44/42 Mitogen-
activated protein kinase, t-MAPK= Total Mitogen-activated protein kinase, p- Akt = phosphorylation 
of protein kinase B,t-Akt = Total protein kinase B, P-GSK3= phospho-Glycogen synthase kinase-3 
alpha/beta. *p< 0.05, using one way ANOVA.“*” statistically significant change in phosphorylation 
after insulin stimulation as copmared to basel level.“#” statistically significant change in the 





3.3.4.3Effects of sodium salicylate, BBR and IKK-16 on nelfinavir   
Following the same lines as the experiments with indinavir, the effects of NaSal (5mM), BBR (2.7mM) 
and IKK-16 (5µM) were evaluated on nelfinavir. The CHO-IR cells were treated similarly for one hour 
before then treating the cells with nelfinavir. Nelfinavir significantly blocked the phosphorylation of 
IRS-1(p=.0053), Akt (p=.009) and MAPK (p=.0021) (Figure 3.11(a) (c) and (d)) even in the BBR 



















( a )                                                                                                               ( b ) 
    
(c )                                                                                                             (d)  
    
Figure 3.11: Effects of BBR on the insulin signaling pathway of CHO-IR cells treated with 
nelfinavir. CHO-IR cells were pre-treated with berberine chloride (2.7 mM) for 1 h prior to treatment 
with nelfinavir (30 μM) for 16 h. The cells were stimulated with insulin for 5min. The cells were then 
lysed and the lysates subjected to immunoblotting with antibodies against: (a) IR-βand IRS-1with anti-
phosphotyrosine PY20 antibody (b) Phospho-p44/42 MAPK (Erk1/2) (c) phospho-Akt and (d) 
Phsopho-GSK-3α/β (upper panels). The blots were reprobed with anti t-IR-β (a) ,p44/42 MAPK 
(Erk1/2)(b)  total Akt (c) and actin (d) respectively (lower panel) . Bound antibodies were visualized by 
chemiluminescence and quantified by ChemiImager. The band intensity of the proteins from 2 
independent experiments was normalized to the band intensity of total IR. Data are shown as the mean 
± S.E.M. (n=2). p-IR (PY20) = tyrosine phosphorylation of IR, tIRβ = total insulin receptor β-
subunit,p-IRS-1 =phosphorylation of Insulin receptor substrate ,P-MAPK = Phospho-p44/42 Mitogen-
activated protein kinase, t-MAPK= Total Mitogen-activated protein kinase, p- Akt = phosphorylation 
of protein kinase B,t-Akt = Total protein kinase B, P-GSK3= phospho-Glycogen synthase kinase-3 
alpha/beta. *p< 0.05, using one way ANOVA.“*” statistically significant change in phosphorylation 
after insulin stimulation as copmared to basel level.“#” statistically significant change in the 





Sodium salicylate slightly increased phosphorylation of the IR-β and IRS-1 in the presence of 
nelfinavir (Figure 3.12 (a)) but did not affect the phosphorylation of MAPK and Akt (Figure 3.12 (c) 

























 ( a )                                                                               ( b ) 
        
( c )                                                                                                             ( d )   
    
Figure 3.12: Effects of sodium salicylate on the insulin signalling pathway of CHO-IR cells 
treated with nelfinavir. CHO-IR cells were pre-treated with sodium salicylate (5 mM) for 1 h prior to 
treatment with nelfinavir (30 μM) for 16 h. The cells were stimulated with insulin for 5min. The cells 
were then lysed and the lysates subjected to immunoblotting with antibodies against: (a) IR-βand IRS-
1with anti-phosphotyrosine PY20 antibody (b) Phospho-p44/42 MAPK (Erk1/2) (c) phospho-Akt and 
(d) Phospho-GSK-3α/β (upper panels). The blots were then reprobed with anti t-IR-β (a) ,p44/42 
MAPK (Erk1/2)(b)  total Akt (c) and actin (d) respectively (lower panel) . Bound antibodies were 
visualized by chemiluminescence and quantified by ChemiImager. The band intensity of the proteins 
from 2 independent experiments was normalised to the band intensity of total IR. Data are shown as the 
mean ± S.E.M. (n=2). p-IR (PY20) = tyrosine phosphorylation of IR, tIRβ = total insulin receptor β-
subunit,p-IRS-1 =phosphorylation of Insulin receptor substrate ,P-MAPK = Phospho-p44/42 Mitogen-
activated protein kinase, t-MAPK= Total Mitogen-activated protein kinase, p- Akt = phosphorylation 
of protein kinase B,t-Akt = Total protein kinase B, P-GSK3= phospho-Glycogen synthase kinase-3 
alpha/beta. *p< 0.05, using one way ANOVA.“*” statistically significant change in phosphorylation 
after insulin stimulation as copmared to basel level.“#” statistically significant change in the 




5µM of IKK-16 was used to pre-treat cells  .This may have been  toxic to cells and affected the total 
quantities of t-IRβ, actin, t-MAPK and t-Akt (lower panels) (Figure 3.13 (a), (b), (c) and (d) 
respectively (lower panels). But this toxic effect was apparently reduced in the presence of the 
nelfinavir (Figure 3.13). There was no significant change in the dephosphorylation induced in 


























(a)                                                                                                      ( b)  
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Figure 3.13: Effects of IKK-16on the insulin signaling pathway of CHO-IR cells treated with 
nelfinavir. CHO-IR cells were pre-treated with IKK-16 (5 µM) for 1 h prior to treatment with 
nelfinavir (50 μM) for 16 h. The cells were stimulated with insulin for 5min. The cells were then lysed 
and the lysates subjected to immunoblotting with antibodies against: (a) IR-βand IRS-1with anti-
phosphotyrosine PY20 antibody (b) Actin (c) Phospho-p44/42 MAPK (Erk1/2) and (d) phospho-Akt 
(upper panels). The blots were then reprobed with anti t-IR-β (a), p44/42 MAPK (Erk1/2) (c) and total 
Akt (d) respectively (lower panel) . Bound antibodies were visualised by chemiluminescence and 
quantified by ChemiImager. The band intensity of the proteins from 2 independent experiments was 
normalised to the band intensity of total IR. Data are shown as the mean ± S.E.M. (n=2). p-IR (PY20) 
= tyrosine phosphorylation of IR, tIRβ = total insulin receptor β-subunit,p-IRS-1 =phosphorylation of 
Insulin receptor substrate ,P-MAPK = Phospho-p44/42 Mitogen-activated protein kinase, t-MAPK= 
Total Mitogen-activated protein kinase, p- Akt = phosphorylation of protein kinase B,t-Akt = Total 
protein kinase B, *p< 0.05, using one way ANOVA.“*” statistically significant change in 
phosphorylation after insulin stimulation as copmared to basel level.“#” statistically significant change 




3.3.5 Effect of berberine chloride on cells treated with NRTIs. 
3.3.5.1 Effects of tenofovir  
For the first time in this study, CHO-IR cells were used to examine the molecular effects of NRTIs 
(Tenofovir and Stavudine) on the insulin signaling pathway. The cells were treated with NRTIs for 16 
h followed by insulin stimulation (10 ng/ml) (1.7 nM) for 5 min. In order to evaluate the effects of the 
NaSal and BBR on the NRTIs, the cells were pre-treated with (5 mM) NaSal and (2.7 mM) BBR for 
one hour before the drug treatment for 16 h. 
Tenofovir showed no effect on the insulin-stimulated phosphorylation at IR-β and IRS-1 as shown in 
(Figure 3.14(a)). However tenofovir decreased the phosphorylation at MAPK and Akt (Figure 3.14(b) 
and (c)).In the same experiment, the effect of NaSal was also evaluated. NaSal caused a small increase 
in Akt phosphorylation in the tenofovir-treated cells (Figure 3.14(c)) but Nasal did not increase the 
phosphorylation of MAPK in tenofovir treated CHO-IR cells (Figure 3.14(b)). In further experiments 
BBR chloride was evaluated (Figure 3.15 (a) and (b)). BBR treatment did not alter phosphorylation of 
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Figure 3.14: Effects of sodium salicylate on the insulin signaling pathway of CHO-IR cells treated 
with tenofovir. CHO-IR cells were pre-treated with sodium salicylate (5 mM) for 1 h prior to 
treatment with tenofovir (5 μM) for 16 h. The cells were stimulated with insulin for 5min. The cells 
were then lysed and the lysates subjected to immunoblotting with antibodies against: (a) IR-βand IRS-
1with anti-phosphotyrosine PY20 antibody (b) Phospho-p44/42 MAPK (Erk1/2) and (c) phospho-Akt 
(upper panels). The blots were reprobed with anti t-IR-β (a), p44/42 MAPK (Erk1/2) (b) and total Akt 
(c) respectively (lower panel). Bound antibodies were visualized by chemiluminescence  and quantified 
by ChemiImager. The band intensity of the phosphorylated proteins was normalized to the band 
intensity of total proteins.  p-IR (PY20) = tyrosine phosphorylation of IR, tIRβ = total insulin receptor 
β-subunit,p-IRS-1 =phosphorylation of Insulin receptor substrate ,P-MAPK = Phospho-p44/42 
Mitogen-activated protein kinase, t-MAPK= Total Mitogen-activated protein kinase, p- Akt = 
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Figure 3.15: Effects of BBR on the insulin signaling pathway of CHO-IR cells treated with 
tenofovir. CHO-IR cells were pre-treated with berberine chloride (2.7mM) for 1 h prior to treatment 
with tenofovir (5 μM) for 16 h. The cells were stimulated with insulin for 5min. The cells were then 
lysed and the lysates subjected to immunoblotting with antibodies against: (a) Phospho-p44/42 MAPK 
(Erk1/2) and (b) phospho-Akt (upper panels). The blots were reprobed with  p44/42 MAPK (Erk1/2) 
(a) and total Akt (b) respectively (lower panel) . Bound antibodies were visualized by 
chemiluminescence and quantified by ChemiImager. The band intensity of the phosphorylated proteins 
was normalized to the band intensity of total proteins. p-MAPK = Phospho-p44/42 Mitogen-activated 
protein kinase, t-MAPK= Total Mitogen-activated protein kinase, p- Akt = phosphorylation of protein 
kinase B,t-Akt = Total protein kinase B. 
3.3.5.2 Effects of stavudine  
In further experiemnts, stavudine treatment had  no effect on the proximal end of insulin signaling 
pathway as observed by the phosphorylation of IR-β and IRS-1of CHO-IR cells (Figure 3.16 (a)) .Also 
no change was observed in the total quatities of the insulin receptor-β as shown in the same Figure 
3.16(a). Stavudine caused a significant decrease in  the phosphorylation of MAPK and Akt (Figure 
3.16 (b ) and (c)) .BBR treatment did not alter protein phosphorylation in cells treated with stavudine in  
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Figure 3.16: Effects of BBR on the insulin signaling pathway of CHO-IR cells treated with 
stavudine. CHO-IR cells were pre-treated with berberine chloride (2.7 mM) for 1 h prior to treatment 
with stavudine (5 μM) for 16 h. The cells were stimulated with insulin for 5min. The cells were then 
lysed and the lysates subjected to immunoblotting with antibodies against: (a) IR-βand IRS-1with anti-
phosphotyrosine PY20 antibody (b) Phospho-p44/42 MAPK (Erk1/2) and (c) phospho-Akt (upper 
panels). The blots were reprobed with anti t-IR-β (a), p44/42 MAPK (Erk1/2) (b) and total Akt (c) 
respectively (lower panel) . Bound antibodies were visualized by chemiluminescence and quantified by 
ChemiImager. The band intensity of the phosphorylated proteins was normalized to the band intensity 
of total proteins.  p-IR (PY20) = tyrosine phosphorylation of IR, tIRβ = total insulin receptor β-
subunit,p-IRS-1 =phosphorylation of Insulin receptor substrate ,P-MAPK = Phospho-p44/42 Mitogen-
activated protein kinase, t-MAPK= Total Mitogen-activated protein kinase, p- Akt = phosphorylation 




Table 3.2:Summary of the effects of ARVs on  phosphorylation of different  insulin signalling  proteins with and without  Berberine chloride 
and sodium salicylate.
 Protease inhibitors NRTIs 
 Indinavir Nelfinavir Ritonavir Tenofovir Stavudine 
IR-β ↓ ↓ ↓ NC NC 
IRS-1 ↓ ↓ slight↓  NC NC 
p-AKt                  *↓ ↓ slight↓ Slight ↓ ↓ 
p-MAPK ↓ ↓ ↓ ↓ ↓ 
P-GSK-3α/β No significant change  Slight decrease  NC NC NC 
 Effects of BBR  BBR 
IR-β Slight ↑ NC    
IRS-1 NC NC    
p-AKt Slight ↑ NC  NC slight↑ 
p-MAPK NC NC  NC NC 
P-GSK-3α/β NC NC    
 Sodium Salicylate  Sodium Salicylate 
IR-β Slight↑ Slight ↑    
IRS-1 Slight↑ NC    
p-AKt NC NC  slight↑  
p-MAPK NC NC  NC  
P-GSK-3α/β      
 IKK-16    
2µ 5µM 
IR-β NC Toxic to cells(NC)    
IRS-1 NC NC    
p-AKt NC NC    
p-MAPK NC NC    
P-GSK-3α/β NC     
NC =No change 
  ↑ = Increased in phosphorylation 
  ↓ = inhibition of phosphorylation 
*↓= Decrease in the phosphorylation with new drug vial 




3.4 Discussion  
The insulin resistance that arises in HIV infected individuals is largely due to the use of PI-based ARV 
therapy (Ismail et al., 2009), but a few studies have also shown the involvement of NRTIs in insulin 
resistance without detailing its molecular basis (Fleischman et al., 2007; van Vonderen et al., 2010). 
Similarly,  a number of  studies using PIs (indinavir, nelfinavir and saquinavir) have mainly described 
downstream events in the insulin signalling pathway (Ben-Romano et al., 2003; Murata et al., 2002; 
Noor et al., 2002; Ranganathan & Kern, 2002; Y. Yang et al., 2006). However, the precise molecular 
mechanisms leading to insulin resistance have not been completely explored. 
In this study, CHO cells transfected with a high number of insulin receptors was used to analyse 
various effects of protease inhibitors and NRTIs on insulin receptor β-subunit tyrosine kinase 
activation and subsequent phosphorylation. For the first time, NRTIs were also used to investigate their 
role in inducing insulin resistance at the cellular level. In this study, not only was the proximal part of 
the insulin signalling studied but also downstream signalling events were also evaluated including 
phosphorylation of Akt, MAPK and GSK-3α/β. The high expression of insulin receptors facilitates the 
detection of downstream insulin-dependent signaling events such that any potential inhibitory effects 
will be prominent.  
The results obtained in this study reveal that CHO-IR cells treated with nelfinavir (30µM) and 
indinavir (50 μM) for 16 h, followed by insulin stimulation, showed inhibition of tyrosine 
phosphorylation of the insulin receptor β-subunit, IRS-1 and Akt but there was no significant inhibition 
observed with ritonavir at the level of IRS-1. This inhibition of phosphorylation by PIs occurs in the 
proximal and distal parts of insulin signalling after insulin stimulation. Whereas in the case of NRTIs, 
both tenofovir (5 µM) and stavudine (5 µM) showed no effect on the proximal part of the insulin 
signaling pathway at  the level of phosphorylation of IR-β sub unit and IRS-1. The total expression of 




cellular toxicity caused by protease inhibitors and NRTIs on CHO-IR cells and no significant decrease 
in expression was observed in insulin receptor-β subunit , Akt, MAPK and actin. Initially old vial of 
indinavir was used which showed only mild decrease in the phosphorylation at Akt but later on new 
vial received from NIH-USA (national institute of health) which showed significant decrease in the 
phosphorylation in Akt levels after treatment. 
Insulin (10 ng/ml, equivalent to1.7 nM) was used in this study to determine the effects of protease 
inhibitors and NRTIs on the signalling pathway. In previous studies, in cultured cells, 10 nM or higher 
concentrations of insulin (supra physiological concentrations) were used to analyse IR signalling 
pathways (Li, Barrett, Wang, Chai, & Liu, 2005; Murata et al., 2000).  In this study we used a 
submaximal concentration of 10ng/ml (1.7nM) of insulin, because the effects of PIs and NRTIs may 
only be apparent at low insulin concentrations (1.7 nM). The maximal activation of the insulin receptor 
tyrosine phosphorylation was observed at 100ng/ml (17 nM).  Owing to the overexpression of the 
insulin receptor and a high level insulin receptor phosphorylation, inhibitory effects of protease 
inhibitor and NRTIs may be masked if pharmacological concentrations of insulin are used.  
Fetal calf serum used to in the growth medium  contains small molecules like amino acids, sugars, 
lipids, and hormones which are essential for the maintenance and growth of cultured cells(Even, 
Sandusky, & Barnard, 2006; Shah, 1999) . Trypsin treatment is also known for having insulin like 
effects in rat adipocytes(Tamura, Fujita-Yamaguchi, & Larner, 1983). Both these factors are 
considered to be responsible in CHO cells to cause basal level phosphorylation insulin receptors in the 
absence of insulin. Protease inhibitors also showed a small decrease in this basal level phosphorylation 
in the absence of insulin as shown in fig 3.12 and 3.13.But this impact is not apparent in all blots.   
In some cases the decrease in phosphorylation of IR-β and IRS-1 may not be rate limiting steps in 




(Y. B. Kim, Nikoulina, Ciaraldi, Henry, & Kahn, 1999; Leng, Karlsson, & Zierath, 2004). So in the 
post-receptor steps of insulin signaling, phosphorylation at Akt, MAPK and GSK-3α/β were also 
analysed. The phosphorylation results indicated that protease inhibitors and NRTIs significantly 
affected phosphorylation of MAPK at both high and low concentrations. Similarly phosphorylation of   
Akt was inhibited by the protease inhibitors. GSK-3α/β phosphorylation step was not significantly 
affected by either protease inhibitors or NRTIs and was not different from the control. In a prior study 
using 3T3 L1 adipocyte cells treated with nelfinavir (30 µM) for 18 h,  decreased phosphorylation of 
the Akt and GSK-3α/β protein (Kachko et al., 2009) were observed. The effect of protease inhibitors 
may differ for different cellular proteins owing to differences in cell lines (Ben-Romano et al., 2003; 
Noor et al., 2006). 
Impairment during the early steps of insulin signalling (phosphorylation at IR-β and IRS-1) is most 
often the proposed mechanism responsible for insulin resistance however insulin resistance induced 
without affecting the insulin receptor activation was observed with ceramide (Summers, Garza, Zhou, 
& Birnbaum, 1998; C. N. Wang, O'Brien, & Brindley, 1998), oxidative stress (Rudich et al., 1998), and 
GH (Takano et al., 2001) suggested that downstream signalling step(s)  of  insulin receptor can be 
functionally affected and rate limiting. Furthermore, decreased insulin-stimulated PKB/Akt 
phosphorylation was also reported in adipocytes, with or without impairment of the proximal insulin 
signalling pathway (Danielsson et al., 2005; Tirosh, Potashnik, Bashan, & Rudich, 1999). Bearing in 
mind that NRTI were used for the first time to evaluate the distal steps of insulin signalling, our results 
showed that tenofovir significantly decreased the phosphorylation of MAPK and slightly affected the 
phosphorylation of Akt. Stavudine was also shown for the first time to inhibit the phosphorylation of 
Akt and MAPK pathway without affecting the initial steps in insulin signalling. Activation of PKB/Akt 
is a critical step for most of insulin’s key functions (Lawlor & Alessi, 2001). Numerous molecular 




normal activation of PI 3-kinase in vitro. Such mechanisms would include  increased activity of protein 
phosphatase 2A (PP2A; a major PKB/Akt phosphatase) (Cazzolli, Carpenter, Biden, & Schmitz-
Peiffer, 2001), impaired sub cellular localization of PI 3-kinase and/or PKB/Akt (Ogihara et al., 2004; 
Tirosh et al., 1999), defective PIP3 synthesis with normal kinase activity (C. Yang, Watson, 
Elmendorf, Sacks, & Pessin, 2000), protein kinase C-ξ (PKC)  triggered phosphorylation at PH domain 
of PKB/Akt (Powell, Hajduch, Kular, & Hundal, 2003; Weyrich et al., 2007) and complex formation 
between PKB/Akt and Drosophila Tribbles homologue protein 3 (TRB3) (Du, Herzig, Kulkarni, & 
Montminy, 2003). 
Mitogen-activated protein kinases are a widely conserved family of serine/ threonine protein kinases 
involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The 
p44/42 MAPK (ERK1/2) signaling pathway is activated in response to a wide range of extracellular 
stimuli including mitogens, growth factors, and cytokines (Baccarini, 2005; Meloche & Pouyssegur, 
2007; Roux & Blenis, 2004). MEK1 (MAPK kinase 1) is the  primary regulatory MAPK kinase in this 
pathway (Rubinfeld & Seger, 2005). MEK1 activate p44 and p42 through phosphorylation of 
activation loop residues Thr202/Tyr204. The protein, p44/42 are negatively regulated by a family of 
dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (Owens & Keyse, 2007), 
along with MEK inhibitors such as U0126 and PD98059. 
A recently-discovered novel regulatory mechanism affecting insulin sensitivity was described to affect 
the extracellular signal-regulated kinase/MAP kinase signaling pathway (ERK/MAPK) during an 
insulin response by  controlling the expression of the insulin-like receptor (inr) gene in Drosophila (W. 
Zhang, Thompson, Hietakangas, & Cohen, 2011). This transcriptional regulation is mediated through 
the Ets-1 (a transcription factor regulated by the MAPK/ERK pathway) (O'Neill, Rebay, Tjian, & 




Berberine is used as an anti-hyperglycaemic agent by many physicians in China and has been known to 
reduce body weight and improve glucose metabolism in animal models of metabolic syndrome (Y. S. 
Lee et al., 2006). Many studies describe its multiple affects at different levels in the cells to increase 
glucose uptake by positive impact on the activation of AMP-activated protein kinase-(AMPK) p38 
MAPK-GLUT4, JNK  PPARα pathways (Yin et al., 2008; Q. Zhang et al., 2011),  insulin receptor 
expression (H. Zhang et al., 2010) and ERK1/2 (Cui et al., 2009) in different cell lines.  
For the first time, in this study, berberine was used to minimize the inhibitory effects of ARVs on 
insulin sensitivity in CHO-IR cells. However, there was no significant change observed with berberine. 
One reason could be that CHO-IR cells are transfected with a high number of insulin receptors and 
therefore the augmented effect of berberine was not discernible under these conditions.  
Sodium salicylate and aspirin are known to decrease blood glucose levels in diabetic patients via 
inhibition of NFκB and its upstream activator IKKβ (Yuan et al., 2001). In this study, sodium salicylate 
was used in the context of cells treated with protease inhibitors. In CHO-IR cells treated with protease 
inhibitors, our findings revealed that salicylate did not inhibit the effects of protease inhibitor on insulin 
receptor tyrosine phosphorylation. The inhibition of NFκB pathway and IKKβ in pre-treated with 
sodium salicylate showed a slight increase in insulin-stimulated tyrosine phosphorylation of insulin 
receptor β-subunit and tyrosine phosphorylation of IRS-1 in cells. In order to evaluate and confirm the 
results of sodium salicylate and the role of NFκB pathway in insulin resistance induced by protease 
inhibitors, IKK-16 a selective inhibitor of IKKβ was used. In the IKK-16 treated cells no significant 
change was observed in the inhibition of phosphorylation at IRS-1 and IR-β induced by PIs. These 
results were consistent with the results obtained with sodium salicylate. On the basis of these results 
further investigations are required to evaluate whether other mechanisms are involved in insulin 





The PIs indinavir, nelfinavir, ritonavir inhibited insulin-stimulated tyrosine phosphorylation of the 
insulin receptor β-subunit, IRS-1 Akt and MAPK in CHO-IR cells. Similarly NRTIs tenofovir and 
stavudine also inhibited the downstream parts of insulin signaling such as Akt and MAPK without 
affecting the phosphorylation of IR-β subunit and IRS-1.The role of NFκB pathway was also evaluated 
in this study by using the sodium salicylate and IKK-16 but inhibition of NFκB pathways did not alter 
the impact of protease inhibitors and NRTIs on the insulin stimulated phosphorylation. Therapeutic 
compound Berberine chloride also failed to reverse the effects of ARV at different levels of its 
signaling pathway.  
 We conclude that protease inhibitors inhibit phosphorylation at both proximal (IR-β and IRS-1) and 
distal ends (Akt and MAPK) of insulin signaling pathways while NRTIs only affect the downstream 
signaling proteins (Akt and MAPK) of insulin signaling pathway without any effect on proximal steps. 





















CHAPTER 4: THE EFFECT OF NUCLEOSIDE/NUCLEOTIDE REVERSE 
TRANSCRIPTASE INHIBITORS AND PROTEASE INHIBITORS ON 
LIPOPROTEIN LIPASE 
 
4.1 Introduction   
Lipoprotein lipase (LPL) is a central enzyme in lipid metabolism and transport. It is produced in 
numerous cell types but skeletal muscle and the parenchyma of adipose tissue are the major sites of 
synthesis and physiological actions. 
 
4.1.1 The synthesis, processing and regulation of lipoprotein lipase  
The physiological location of LPL-mediated hydrolysis of lipoproteins is at the capillary endothelial 
cell but functional LPL is first synthesized by the parenchymal cells and then translocated to its site of 
action (Braun & Severson, 1992; Camps et al., 1991; Camps, Reina, Llobera, Vilaro, & Olivecrona, 
1990). The mature LPL enzyme is glycosylated with approximately 12% of carbohydrates and is 
comprised of  two complex oligosaccharide chains, and in few species two complexes and one high 
mannose chain (Doolittle, Ben-Zeev, Elovson, Martin, & Kirchgessner, 1990; Masuno et al., 1991; 
Semb & Olivecrona, 1989; Vannier & Ailhaud, 1989). Catalytically active LPL is a homodimer that 
forms in the endoplasmic reticulum and it has been proposed that these chains are formed by the 
trimming of glucose residues via glucosidase in the endoplasmic reticulum. It has been shown by 
several lines of experimental evidence that N-linked glycosylation and dimerization of LPL are vital 
for its catalytic activity (Braun & Severson, 1992). 
The synthesis and release of the LPL is regulated at multiple levels by multiple factors as described in 
Figure 4.1.There are four main levels of regulation depending upon the location of LPL synthesis in 
different tissues. These are at the transcriptional, posttranscriptional, translational and post-translational 




on LPL synthesis enables tissues to maintain a balance in lipid metabolism and  furthermore it also 





4.1.2 Role of lipoprotein lipase in lipid and lipoprotein metabolism 
Triacylglycerol (TAG) is transported and secreted from the intestine and liver in the form of 
chylomicrons and VLDL respectively. Both classes of lipoproteins enter the circulation in the form of 
large multi-molecular lipoprotein particles in order to distribute TAG to tissues and other organs. 
TAG-rich lipoprotein particles are too large to cross the capillary endothelium in most tissues.  LPL is 
found attached via highly charged, membrane bound chains of heparin sulphaate-proteoglycans 
(HSPG) to the luminal surface of the capillary endothelial cells  and this is the location of the LPL 
activity where TAG on lipoproteins are easily accessible (Braun & Severson, 1992; Cryer, 1981; 
Figure 4.1: Levels of LPL regulation in different tissues and factors (hormonal 
nutritional and regulatory proteins) which affect its synthesis, translocation, 
glycosylation and secretion. RAP, receptor-associated protein; APOA5, Apo lipoprotein A5; 
LMF1, lipase maturation factor 1; Angptls, angiopoietin like; GPIHBP1, 
glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1; WAT, 





Enerback & Gimble, 1993; Mead, Cryer, & Ramji, 1999; Mead & Ramji, 2002; C. S. Wang, Hartsuck, 
& McConathy, 1992). 
LPL plays an important role in lipid metabolism and transport. It catalyses the hydrolysis of TAG 
attached to circulating chylomicrons and VLDL. The resulting reaction produces non-esterified fatty 
acids (NEFA) and 2-monoacylglycerol for tissue utilization (Braun & Severson, 1992; Cryer, 1981; 
Enerback & Gimble, 1993; C. S. Wang et al., 1992). NEFAs in white adipose tissue are re-esterified 
for energy storage as TAG (Cryer, 1981). Additionally, fatty acids are oxidized to provide an energy 
source in the heart and to regulate thermogenesis in  brown adipose tissue (Cryer, 1981).  
 
4.1.3 Role of insulin, heparin and glucose in lipoprotein lipase regulation 
As discussed above the regulation of LPL synthesis is very important for normal homeostasis of lipid 
metabolism and insulin is the primary regulator of LPL synthesis in adipocytes and the translocation 
from there to the luminal domain of the endothelial cells. Generally insulin increases LPL activity but 
synthesis of LPL  involves  many steps including  LPL gene transcription, mRNA processing, transport 
and translation, posttranslational modification (glycosylation) “activation” or “inactivation”, and finally 
secretion (Olivecrona, Chernick, Bengtsson-Olivecrona, Garrison, & Scow, 1987; Raynolds et al., 
1990; Vannier, Amri, Etienne, Negrel, & Ailhaud, 1985). Insulin affects  different steps of LPL 
synthesis in adipocytes such as during the process of differentiation  by enhancing gene transcription 
(Semenkovich, Wims, Noe, Etienne, & Chan, 1989) while in fully differentiated adipocytes it regulates 
LPL synthesis by increasing mRNA levels and enzyme activity by both posttranscriptional and post-
translational modifications of LPL (Albalat et al., 2007; Albalat, Sanchez-Gurmaches, Gutierrez, & 




LPL release from cells is increased by both insulin and heparin in a dose and time-dependent manner. 
The mechanisms by which insulin and heparin release LPL from the cells are not exactly known. Some 
researchers have observed that heparin acts as a secretagogue thereby suggesting that the released LPL 
is at first present in intracellular secretory vesicles, which fuse with the plasma membrane upon 
stimulation with heparin. Other data indicate that there is a heparin-binding site on the LPL dimer, 
which binds to the heparin sulphate-proteoglycan extracellular matrix. Heparin treatment of cells shifts 
the plasma membrane-bound LPL by competition with the HSP, resulting in the release of LPL into the 
cell culture medium (Bengtsson, Olivecrona, Hook, Riesenfeld, & Lindahl, 1980; Cisar, Hoogewerf, 
Cupp, Rapport, & Bensadoun, 1989; Rojas, Enerback, & Bengtsson-Olivecrona, 1990).  
Intracellular glucose levels also accelerate LPL synthesis in adipocytes and its boosting effect on LPL 
is mainly associated with glycosylation of LPL which is very important for the normal LPL enzymatic 
activity and its release. Glucose also enhances the effects of insulin to increase LPL synthesis but there 
is no evidence that glucose affects the transcriptional level (mRNA) of LPL synthesis as observed with 
insulin (Kern, Mandic, & Eckel, 1987; Ong & Kern, 1989). Different studies associate insulin 
resistance with decreased LPL activity, hypertriglyceridaemia, elevated cholesterol and 
chylomicronaemia (Bijvoet et al., 1996; Brunzell, 1995) 
4.1.4 Pathophysiology of lipoprotein lipase 
4.1.4.1 Role of lipoprotein lipase in atherosclerosis 
Increased LPL activity can result in either pro or anti-atherogenic effects, depending on the cellular 
location of LPL synthesis. LPL secreted by the parenchymal cells of adipose tissue in the vascular 
endothelium and muscle tissue (major sources) provides a protective role, whilst LPL secreted by 
monocyte-derived macrophages has pathophysiological effects that promote foam cell formation and, 





4.1.4.2 Role of lipoprotein lipase in insulin resistance  
A recent study in insulin resistant offspring of type 2 diabetes parents revealed a link between insulin 
resistance and decreased mitochondrial content as evidenced by decreased mRNA and protein 
expression of LPL in muscle biopsies (Morino et al., 2012). Normally free fatty acid delivery into 
skeletal muscle results in mitochondrial biogenesis through activation of peroxisome proliferator–
activated receptor (PPAR)-δ. The primary role of LPL here is to hydrolyse the serum triglycerides and 
deliver free fatty acids to the muscle cells as described above. 
Moreover, this  study also confirmed this association when LPL was knocked down in muscle cells 
resulting in decreased fatty acid influx and reduced biogenesis of mitochondria by decreased activation 
of PPAR-δ (Morino et al., 2012). 
 
4.1.4.3 Role of lipoprotein lipase in adipose tissue distribution   
In many disorders such as diabetes, atherosclerosis and obesity, hypertriglyceridaemia is a 
characteristic feature. A well-known cause of genetic hypertriglyceridaemia is the deficiency of 
lipoprotein lipase. In humans, type I hyperlipoproteinaemia, resulting from LPL deficiency, is a rare 
autosomal recessive disease. It is characterized by low or no LPL activity resulting in 
hypertriglyceridaemia, decreased levels of HDL cholesterol, lipaemia retinalis and pancreatitis. There 
are three naturally occurring mutations in LPL that affect lipid transport and metabolism and result in 
hypertriglyceridaemia and obesity in mice (Peterfy et al., 2007; Ullrich, Purnell, & Brunzell, 2001). 
Disturbances in body fat distribution, dyslipidaemia and insulin resistance, diabetes and atherosclerosis 
in HIV patients are associated with ARV.  However, the exact mechanisms of these changes have not 
been fully elucidated. HIV infection with acute and chronic effects of some antiretroviral drugs on 




1989; Vigouroux et al., 1999). It has already been reported that HIV infection itself has an effect on 
triglyceride metabolism and lipoprotein lipase activity (Grunfeld et al., 1992).    
Hypertriglyceridaemia and impaired insulin sensitivity can be observed even in HIV-negative subjects 
treated for short periods of time using protease inhibitors but fat redistribution, on the other hand 
becomes apparent only after several months of treatment and this is most often related to dyslipidaemia 
and insulin resistance (Dube et al., 2001; Purnell et al., 2000; Vigouroux et al., 1999). 
With the advent of HAART, it  has become well known that the two drug families; the NRTI and the 
PIs are often associated with lipid abnormalities and body fat distribution, yet the cellular  and 
biochemical mechanisms underlying these effects are not well understood (Noor et al., 2002; 
Vigouroux et al., 1999). The NNRTI component of HAART also contributes to the dyslipidaemia 
although the relationship to lipodystrophy is unclear (Clotet, van der Valk, Negredo, & Reiss, 2003; 
Mallal et al., 2000; Petit et al., 2003).  
A study in transgenic mice overexpressing LPL in liver and skeletal muscle shows that this led to a 3-
fold increase in muscle triglyceride and 2-fold increase in liver triglyceride. This increase in 
triglyceride resulted in insulin resistance involving defects in IRS-I and IRS-2-associated 
phosphatidylinositol-3- kinase activities in muscle and liver respectively. Contrary to these findings, in 
liver-specific LPL knockout mice expressed no change in IRS-2 associated PI-3 kinase activity in liver 
cells as compared to the control (J. K. Kim et al., 2001).  
 
4.1.5 Methods for measuring lipoprotein lipase 
A number of methods have been used to measure LPL activity in adipocytes and in serum or plasma. 
These are mostly based on the use of radioactive or fluorescently-labelled substrates, such as the 




H] oleate) and  fluorescently-




activity assay kit (Roar LPL activity assay kit, Roar Biomedical, Inc.) has been used to measure the 
activity of the enzyme (Yokota, Nagashima, Ghazizadeh, & Kawanami, 2009). This method uses a 
ready-made non-fluorescent substrate emulsion (proprietary substrate) which becomes intensely 
fluorescent when it is hydrolysed by LPL. 
However, these methods are either expensive or laborious and cumbersome. By contrast, an earlier 
method for assaying LPL in milk established that LPL-catalysed hydrolysis of p-nitrophenyl butyrate 
(pNPB) could be measured relatively easily and cheaply using the appearance of p-nitrophenyl 
phosphate as an end product (Shirai & Jackson, 1982). 
4.1.6 Rationale for measuring lipoprotein lipse in CHO cells 
Many studies carried out with different cell lines and with primary cultures of cells, indicated that the 
expression of lipoprotein lipase is usually dependent on the growth conditions  (Cupp, Bensadoun, & 
Melford, 1987; Semb & Olivecrona, 1987, 1989; Severson, Lee, & Carroll, 1988). In Chinese-hamster 
ovary (CHO) cells LPL is expressed both in growing and in confluent cells (Cisar et al., 1989).  In 
CHO cells, LPL is consistently produced independent of cell differentiation stage (Rojas et al., 1990).  
The increased level of expression of insulin receptors also makes it easy to modulate the insulin 
response. Moreover, since the model system for much of the work described in this thesis to study 
insulin signalling makes use of a CHO cell line, it appeared prudent to use this cell line to quantify the 
regulation of LPL activity by insulin and ARVs. We therefore analysed the effect of HPIs and NRTIs 
on LPL activity in CHO cells, transfected with insulin receptors to understand whether ARVs could 









4.2.1 Preparation of CHO-IR cells for the assay of released lipoprotein lipase 
CHO-IR cells were cultured and serum-starved as described in sections 2.2.1 and 2.2.2. The cells were 
washed with PBS (2 ml) twice and left in an additional fresh PBS (500 μl) containing insulin 
(100ng/ml) (17nM) for 1 h at 37 °C in an incubator, to stimulate LPL activity. After 1 h, heparin 
sodium-fresenius (final concentration 100 U/ml) was added for a further 2 h to release the enzyme from 
the cell surface (Knutson, 2000; Ong, Kirchgessner, Schotz, & Kern, 1988; Ranganathan & Kern, 
2002; Stewart & Schotz, 1974). The cell culture supernatants were then collected in order to assay for 
LPL activity. The remaining cells in the well were lysed using lysis buffer and measured for total 
protein concentration, as described in section 2.2.3.  
The purified LPL standard was derived from Pseudomonas sp (Fluka, Buschs, Switzerland) in a range 
of concentrations from 2.13 U/mg to 213 U/mg. Enzyme activity was also measured after the addition 
of phenylmethylsulphonyl fluoride (PMSF) (1 mM), to confirm that the assessed enzyme activity was 
attributed  to the LPL, as PMSF is known to inhibit LPL activity (D. Quinn, Shirai, & Jackson, 1983). 
PMSF (10 mM) was prepared in ethanol.  
 
4.2.2 Assay of lipoprotein lipase activity  
LPL activity in supernatants from CHO-IR cells was determined as follows (Shirai & Jackson, 1982):  
 
900 μl buffer + 100 μl supernatants from CHO-IR cells + 10 μl pNPB in acetonitrile 





Cell culture supernatants (100 μl) were mixed with 900 μl buffer (0.1 M sodium phosphate, monobasic, 
anhydrous, pH 7.2; 0.9 % sodium chloride; 0.5 % (v/v) Triton X-100 (900 μl)) (D. M. Quinn, Shirai, 
Jackson, & Harmony, 1982; Shirai & Jackson, 1982). pNPB (10 μl of 50 mM in acetonitrile at 1 % 
(v/v) final concentration) was then added. The reactions were incubated in cuvettes at 37 °C in a water 
bath (Shirai & Jackson, 1982) for specific periods of time. Absorbance was then measured using a 
visible light spectrophotometer at 400 nm.  
Enzyme activity was calculated using the following formula (D. Quinn et al., 1983) :  
 
Units/ml enzyme = (ΔA400nm/min test - (ΔA400nm/min substrate blank)) (1.01) (df) 
(0.0148)(0.1) 
1.01 = volume (in ml) of incubation mixture  
df = dilution factor (0.1)  
0.0148 = μM extinction coefficient of p-nitrophenol at 400 nm  
0.1 = volume (in ml) of enzyme used  
 
 Units/mg protein = (units/ml supernatant) ÷ (mg protein/ml supernatant) 
 
Unit definition:  
One unit will release 1.0 nmole of p-nitrophenol phosphate per minute at pH 7.2 and 37° C, when using 
p-nitrophenyl butyrate as the substrate. 
For these experiment six NRTIs and four PIs that are commonly used in the treatment regimes in South 
Africa, were examined for their effects on lipoprotein lipase secretion. CHO-IR cells were serum-
starved and treated with HIV protease inhibitors and NRTIs for 16 h. The drugs were used at 




efavirenz 20µM, entricitubine 20µM, atazanavir sulphate 20µM (Minami et al., 2011), stavudine 10µM 
(Dudley et al., 1992), lamivudine 10µM  (Heald et al., 1996), tenofovir 1 µM (Cihlar et al., 2002). 
The cells were then stimulated with insulin to increase LPL activity and treated with heparin to release 
LPL. The LPL activity in 100µl of the cell culture supernatants was measured, after 30 min of 
incubation in a water bath at 37 °C.  
In addition to measuring whether these drugs influence LPL activity in cells, the same concentration of 
the drugs was added directly to the assay reaction after recovering the untreated (no drug) cell culture 
supernatants from cells stimulated with both insulin and heparin. This was done to determine if the 







































Figure 4.2(a) Time course of LPL activity in supernatants of CHO-IR cells 
stimulated with insulin and heparin. CHO-IR cells were stimulated with insulin 
(100ng) for 1 h followed by the addition of heparin (100U/ml). Cell culture supernatants 
were harvested to measure LPL activity at indicated incubation periods using 
spectrophotometry (400 nm). Fig 4.2(b) show differences in LPL activity after incubation 
of 30 min with10 ng/ml and with 100ng/ml after 30 and 45 min .LPL activity was 
measured in three independent experiments. PBS = phosphate buffered saline, H = 
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The LPL-catalysed hydrolysis of pNPB was successfully measured in supernatants of CHO-IR cells 
stimulated with both insulin and heparin (Figure 4.2.a). Cells which were stimulated with both 100 
ng/ml insulin and heparin sodium-fresenius (final concentration 100U/ml) had significantly increased 
LPL activity almost 4 fold , with detectable enzyme release from the cell surface from 5 min (p = 
0.0009) up to 30 min (p = 0.0129) incubation and then at 45 min (p=0.0127). The cells which were 
stimulated with insulin only also showed increased LPL after 30 min (p = 0.0361) up to 45 min (p = 
0.0197) incubation as shown in figure 4.2(b). In order to observe the effect of insulin concentration on 
LPL activity a low dose of insulin 10 ng (1.7nM) were used to stimulate the cells .A statistically 
insignificant (p=0.0625) low activity of LPL was measured in the supernatants as shown in Figure 
4.2(b).   
 
4.3.2 Effect of nucleoside/nucleotide reverse transcriptase inhibitors on  lipoprotein lipase 
activity in supernatant from the CHO-IR cells 
 
LPL activity was measured in CHOIR treated with Zidovudine (AZT) Efavirenz (EFV), Emtricitabine 
(FTC), Atazanavir sulfate (ATV), Stavudine(d4T), Lamivudine(3TC) and, Tenofovir (TDF) for 16 h 
using the optimized assay conditions. LPL activity increased threefold (p=0.0009) when cells were 
exposed to both 100 ng/ml of insulin and heparin, compared to that of the unstimulated cell culture 
supernatants with heparin or insulin. The effect showed by NRTIs on LPL activity compared to the 
enzyme activity in the untreated cells exposed to both insulin and heparin in two different experiments 





















































In the first experiment the NRTIs were added directly to supernatant of the untreated cell, those treated 
with insulin and heparin to observe the effects of the drugs on the lipoprotein lipase activity directly 
after secretion. NRTIs did not alter LPL activity significantly in the supernatants. A small decrease 
(3TC* p=0.130, d4T*p=0.141, AZT* p=0.394, FTC* p=0.127, EFV* p=0.378, TDF* p=0.126) in the 
LPL activity was observed, although these differences were not statistically significant as shown in 
Figure 4.3.  
Figure 4.3: Effect of NRTIs on LPL activity after adding directly in supernatants of 
CHO-IR cells. 
 CHO-IR cells were grown in 6-well plates and upon 70-80% confluency the cells were 
serum starved for 16 h, followed by exposure to both insulin (100)ng/ml) and heparin. 
LPL activity was measured in duplicate in two independent experiments. Data are shown 
as the mean and S.E.M. (n=2). C= control, H= Heparin, I = insulin, AZT* = zidovudine, 
EFV*= efavirenz, FTC* = emtricitabine, d4T* = stavudine, 3TC*= lamivudine and, 
TDF*= tenofovir. p*< 0.05 using unpaired t test (*) indicate the drugs that were added 

























































In order to examine the effect of the NRTIs on the synthesis and secretion of LPL, CHO-IR cells were 
treated for 16 hours with the NRTIs in the serum free medium. After treatment two drugs stavudine 
(p=0.0191) and emtricitabine (p=0.0173) resulted in significant decreases in the measured LPL activity 
from the cells. The remaining NRTIs; zidovudine (10µM), lamivudine, tenofovir (1µM) and efavirenz 




Figure 4.4: LPL activity in supernatants of CHO-IR cells treated for 16 hours with 
NRTIs. 
CHO-IR Cells were grown to 70-80 % confluency, usually taking 24 to 48 hours in 6-well 
plates .The cells were then serum starved for 16 h in the absence or presence of the 
nucleoside reverse transcriptase inhibitors, followed by exposure to both 100ng/ml insulin 
(17nM) and heparin. LPL activity was measured in duplicate as two independent 
experiments. Data are shown as the mean and S.E.M. (n=2). C= control, H= Heparin, I = 
insulin, AZT = zidovudine, FTC = emtricitabine, EFV= efavirenz, d4T = stavudine, 3TC= 




4.3.3 Effect of protease inhibitors on lipoprotein lipase activity in supernatant from the CHO-IR 
cells 
CHO-IR cells were serum starved for 16 h (without drugs) and supernatants were collected after 
exposure with insulin (100ng/ml) and heparin. LPL activity in these supernatants was measured after 
adding the HPIs directly to the assays reaction before the incubation. Four HPIs indinavir (50µM), 
nelfinavir (30µM), atazanavir (20µm) and ritonavir (30µM) were used in this experiment and the 
resulting differences in LPL activity were compared against heparin and insulin-induced cell 
supernatants without any addition of drugs, as shown in Figure 4.5 below. A significant decrease in 
LPL activity was observed in the presence of nelfinavir (p=.0115) and indinavir (p=.0221), while a 





































Figure 4.5: Effect of HPIs on LPL activity after adding HPIs directly in supernatants of 
CHO-IR cells. 
 CHO-IR cells were grown in 6-well plates and upon 70-80% confluency the cells were 
serum starved for 16 h, followed by exposure to both100ng/ml (17nM) insulin and heparin. 
LPL activity was measured in duplicate in two independent experiments. Data are shown as 
the mean and S.E.M. (n=2). C= control, H= Heparin, I = insulin, IND* = indinavir, NFV*= 
nelfinavir ATV* = atazanavir sulfate, RTV* = ritonavir. p*< 0.05 using unpaired t-test .(*) 












































In order to evaluate the effect of PIs on the intracellular synthesis and secretion of the LPL, CHO-IR 
cells were treated with the drugs for 16 h then supernatant were collected followed by exposure to the 
insulin and heparin. A high concentration of insulin (100ng /ml) was used in this experiment to 
exercise the maximum capacity of the cells to secret enzyme. LPL activity was measured and then 
compared with the untreated cell supernatant (only heparin and insulin exposed). A significant decrease 
in LPL activity of nelfinavir (p=.0193) and atazanavir sulphate (p=0069) was observed while smaller 






Figure 4.6: LPL activity in supernatants of CHO-IR cells treated for 16 hours with 
HPIs. 
 CHO-IR cells were grown in 6-well plates and upon 70-80 % confluency the cells were 
treated with HPIs indicated in serum starvation medium for 16 h, followed by exposure to 
both insulin (100ng/ml) and heparin. LPL activity was measured in duplicate in two 
independent experiments. Data are shown as the mean and S.E.M. (n=2). C= control, H= 
Heparin, I = insulin, IND = indinavir, NFV= nelfinavir ATV = atazanavir sulfate, RTV = 




4.4 Discussion  
 
In this study, for the first time CHO-IR cells were used to measure LPL activity using a colorimetric 
method employing pNPB as substrate. LPL has been shown to catalyse the hydrolysis of short-chain 
fatty acyl esters such as tributyrin, p-nitrophenylacetate and pNPB in vivo (Shirai & Jackson, 1982). 
This substrate is more convenient to use than lipid-soluble substrates, as the product of LPL-catalysed 
hydrolysis of pNPB, p-nitrophenol, absorbs light strongly at 400 nm.(D. M. Quinn et al., 1982).  
CHO cells provide a convenient model to study intracellular synthesis and translocation of lipoprotein 
lipase. A major advantage of CHO cells is that the synthesis of LPL is constant in these cells and is not 
associated with the differentiation processes of the cells. Another advantage compared with adipocyte 
cell lines which have been used in previous studies is that the CHO cells make the cell fractionation 
process easy because they do not contain large fat-droplets. (Rojas et al., 1990). Moreover, since the 
cell expresses large number of receptors, it is very easy to modulate the insulin dose response. 
CHO-IR cells treated with heparin and insulin showed measurable 3-fold increase in LPL activity. 
Insulin plays an important dose-dependent role in LPL synthesis and significantly affects the 
posttranscriptional and posttranslational levels with minimal effects at mRNA level during 
differentiation of adipocytes (Pradines-Figueres, Vannier, & Ailhaud, 1988; Semenkovich et al., 1989; 
Spooner, Chernick, Garrison, & Scow, 1979). These results indicate that the insulin-induced synthesis 
of LPL is dose-dependent and there is significant (p=0.0135) increases in the LPL activity in the 
presence of high concentration (17nM) of insulin while no significant (p=0.0628) increase is observed 
with   low insulin concentrations 10ng/ml (1.7nM). Insulin does not cause the release of LPL from the 
cell surface however, cells stimulated with insulin did  show significant increases in LPL activity in 
CHO-IR cells, even in the absence of heparin.  
The results also show that NRTIs did not change LPL activity in the supernatant. Stavudine and 




,saquinavir, indinavir, efavirenz and tenofovir  are the ARVs most likely to cause lipodystrophy 
(Buffalo hump), and for this reason stavudine is no longer considered an appropriate treatment for most 
patients in developed countries and is no longer recommended by the WHO. However, due to its low 
price, it is still widely used in the developing world. Moreover, fat loss on long term exposure, one of 
the major side-effects of stavudine, is associated with buffalo hump (Palacios et al., 2007). 
Major PIs such as  indinavir, nelfinavir, atazanavir sulphate and ritonavir are still being  used in South 
Africa and these were used in this study as well (Meintjes G et al., 2012). Indinavir and nelfinavir were 
also found to decrease LPL activity when added to the assay reaction in  vitro. This indicates that the 
drugs also inhibit LPL activity extracellularly. Similarly nelfinavir and atazanavir sulphate inhibited the 
activity of the LPL from the CHO-IR cells after 16 h treatment. This suggests that these drugs may 
interfere with the enzyme activity intracellularly either at the level of its synthesis or its transportation 
from cytoplasm to the cell surface. Nelfinavir was found to be the only drug that inhibited LPL activity 
intracellularly as well as extracellularly. These finding suggests that protease inhibitors may play a role 
in inhibiting LPL activity in vivo, and may thereby induce metabolic disorders in HIV-positive patients 
being treated with PIs.  
A previous study elucidating the possible mechanism of severe hypertriglyceridaemia caused by 
ritonavir described the decreased LPL activity responsible for the decrease in TG clearance and 
decreased fatty acid uptake from VLDL and albumin in adipocyte tissue. In addition ritonavir also 
decreased the total LPL activity in the plasma (den Boer et al., 2006). 
Similarly few other studies describe a relationship between the intracellular lipid content and insulin 
resistance in muscle cells (Krssak et al., 1999; Perseghin et al., 1999). A recent study revealed that  
decreased expression of LPL in insulin-resistant  muscle cells results in decreased free fatty acid influx 
in the cells which is a potent stimulator of mitochondrial biogenesis through activation of PPAR-δ 




tissue specific insulin resistance like in skeletal muscle and liver. Increased intracellular lipid 
(diacylglycerol and ceramides) which activate the novel and conventional PKC,s (PKCθ, PKCδ, and 
PKCβ) responsible of insulin resistance by effecting the insulin signalling pathway in to the cells  
(Morino et al., 2005; Morino, Petersen, & Shulman, 2006; Savage, Petersen, & Shulman, 2007; 
Shulman, 2000; Yu et al., 2002).  
LPL deficiency or overexpression is critical in the regulation of lipid metabolism and changes may 
induce metabolic disorders such as hypertriglyceridaemia, chylomicronaemia, pancreatitis, 
atherosclerosis, coronary artery disease and lipodystrophy associated with insulin resistance and 
diabetes mellitus. The hydrolysis and release of lipids for storage from triglyceride-rich lipoproteins 
such as chylomicrons and VLDLs, and their subsequent storage in adipose tissue, cannot take place 
without lipoprotein lipase. Therefore regulation of LPL expression is critically important for normal 




This study indicates that LPL activity can be readily assayed in CHO-IR cells using pNPB as a 
substrate. Furthermore, this assay and CHO-IR cells can be used to analyse the effects of PIs and 
NRTIs on LPL activity. This is the first study to report that stavudine, emtricitabine, indinavir 







CHAPTER 5: METABOLOMIC ANALYSIS OF CELL CULTURE 
SUPERNATANTS TREATED WITH PROTEASE INHIBITORS AND 
NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS 
 
5.1 Introduction  
5.1.1 Highly active antiretroviral therapy and HIV associated metabolic complication 
The introduction of HAART (a combination of the different drug groups of ARV) has completely 
changed the status of HIV/AIDS from a fatal disease to a chronic infection by decreasing the mortality 
and morbidity in the infected patients and improving the quality of the life (Gurunathan et al., 2009; 
Pendyala, Want, Webb, Siuzdak, & Fox, 2007). The use of HAART for long periods of time results in 
a number of different metabolic complications such as insulin resistance lipodystrophy, atherosclerosis 
and cardiovascular diseases.  
Currently there are only  two clinical markers, CD4 counts and viral loads that are available for the 
prognostication of HIV infection (Friis-Moller, Weber, et al., 2003; Jain, Furfine, Pedneault, White, & 
Lenhard, 2001; Schuster et al., 2008; Williams. A 2012). There are no useful biochemical markers 
available. Routine biochemical assays are not useful in understanding the detailed metabolic 
complications owing to their limited ability to analyse single metabolites at a time, along with low 
sensitivity and specificity make their application restricted in this area. 
The requirement of an advanced sophisticated, sensitive multitask analytical instrumentation to analyse 
the metabolic changes induced by HIV/HAART was fulfilled by the mass spectrometry (MS) and 
nuclear magnetic resonance (NMR). These advanced technology-based instruments are capable of 
analysing very low molecular weight metabolites in very low concentrations in a broad range of 
samples and body fluids (Lungile J. Sitole, 2012). The failure of genomic and proteomic methods to 




interactions with the environment (Pendyala & Fox, 2010). Two interchangeable terms metabolomics 
and metabonomics are used which differ in application rather than definition. Metabolomics is the 
quantitative and qualitative analysis of low molecular weight metabolites from different cells, tissues or 
any biological sample under certain circumstances while metabonomics measures the overall variations 
in the metabolic profiles of living system under the effect of any external stimuli  such as drug or 
disease (Pendyala et al., 2007; Wishart et al., 2007). 
In HIV-infected patients, metabolic complications are the result of the combined contribution of the 
virus, immune response against the virus and side effects induced by the ARVs used against the virus 
and these are often quite obvious (Alberti, Zimmet, & Shaw, 2006; Powderly, 2004; Slama et al., 
2009).  
 A number  of metabolic alterations are  detected in the  early asymptomatic stage of   HIV infection 
before the initiation of  HAART in HIV-infected subjects with normal phenotypes (Gurunathan et al., 
2009; Hommes et al., 1990; Martin & Emery, 2009; Slama et al., 2009). A group of studies in the  
normal asymptomatic  HIV-infected patients showed increased energy utilization at the resting stage 
which is proposed to be linked to the high energy requirement of the infected cells, having increased 
beta oxidation rate, higher viral load and resulting in increased catabolism in the body (Hommes et al., 
1990; Lane & Provost-Craig, 2000; Slama et al., 2009). Another study, looking at clinically stable 
HIV-infected patients using magnetic resonance imaging (MRI) and positron emission tomography, 
indicated high glucose utilization rates by the brain and other metabolic changes before any structural 
changes were observed (Pascal et al., 1991; Salas-Salvado & Garcia-Lorda, 2001). 
Metabolic profiling could be very useful in prognostication of the progress of the infection and for the 
development of corrective therapy to prevent further development of clinical complications. The 
metabolic defects induced by HIV involve almost all the main metabolic pathways of lipid, 




lipodystrophy (Garrabou et al., 2011; Lane & Provost-Craig, 2000; Martin & Emery, 2009; Polo, 
Martinez, Madrigal, & Gonzalez-Munoz, 2003). Other metabolic complications caused by HIV 
infection include effects on calcium metabolism, hypercatabolism, bone disease and liver disease 
(Pascal et al., 1991; Safrin & Grunfeld, 1999; Slama et al., 2009). Lipodystrophy induced by the NRTIs 
is the combination of lipoatrophy and lipohypertrophy associated with hyperlipidaemia, 
hypertriglyceridaemia and hypercholesterolaemia, all of which suggest dysregulation of lipid 
metabolism. With the involvement of two main NRTIs, stavudine and azidothymidine in apoptosis and 
mitochondrial toxicity at DNA level and resultant lipodystrophy, led to the removal of stavudine from 
the first line of therapy in developed countries (Caron-Debarle, Lagathu, Boccara, Vigouroux, & 
Capeau, 2010; Falutz, 2011; Haubrich et al., 2009).  Insulin resistance is among the first metabolic 
complications reported in HIV/HAART patients and is associated with inflammation and the 
development of type-2 diabetes mellitus (Feeney ER, 2011; Hofstede, Burger, & Koopmans, 2003). A 
number of studies indicate the involvement of many PIs in the development of insulin resistance, 
lipoatrophy and fat deposition which eventually after long term use results in the development of the 
metabolic syndrome (Silva et al., 1998; Wu et al., 2012). Metabolic syndrome is the term used to 
describe a cluster of conditions origination from insulin resistance, dyslipidaemia, central obesity and 
hypertension (Alberti et al., 2006). The relationship between exact drug regimens and specific 
metabolic problems has been shown using conventional biochemical assays and has yet to be 
investigated and confirmed using metabolomic approaches. 
 
5.1.2 The role of metabolomics in the investigation of HIV infection and highly active 
antiretroviral therapy 
In the last ten years, great improvements in the field of metabolomics have provided new 




Metabolomics, in common with other “omics” techniques, such as genomics, transcriptomics or 
proteomics, is a systems approach and metabolomics was first introduced by Nicholson and colleagues 
(Nicholson, Lindon, & Holmes, 1999).  
Metabolomics measures the metabolome, which constitutes the total collection of all small-molecule 
metabolites present in any biological organism (Oliver, Winson, Kell, & Baganz, 1998; Tweeddale, 
Notley-McRobb, & Ferenci, 1998). The advantages of metabolomics over other “omics” technologies 
include its high level of sensitivity and its ability to enable the analysis of relatively few metabolites 
compared with the complex and large number of corresponding genes or mRNA molecules. 
Metabolites represent the final products of the complex interaction between genes and other factors 
such as environmental, health condition or pharmaceutical interventions, which gives metabolomics yet 
another advantage over the other “omic” fields. Similarly, levels of metabolites represent the activity of 
metabolic pathways therefore, allowing the detection of temporary as well permanent physiological or 
pathological changes in cells, tissues or body fluids and offer a convenient tool for biomarker detection 
(Friedrich, 2012).  
 
5.1.3 Insulin resistance and amino acid metabolism.  
The levels of branched-chain amino acids (BCAA) leucine, isoleucine and valine in the circulation are 
regulated by insulin. In many studies, the levels of BCAA were found to be at abnormal levels related 
to conditions such as insulin deficiency or insulin resistance. Abnormal BCAA metabolism has also 
been observed in obesity, type 2 diabetes as well as conditions associated with kidney and liver failure 
(Adeva, Calvino, Souto, & Donapetry, 2012). 
Normally high protein diets or high leucine oral administration act as a positive modulator for insulin 
release and result in lower glucose and amino acid levels in circulation by enhancing their entry into 




methionine decrease significantly in plasma after insulin release (Aoki, Brennan, Fitzpatrick, & Knight, 
1981; Aoki et al., 1976; Elia & Livesey, 1983; Felig, 1975). 
Insulin release also negatively affects protein degradation and the rate of proteolysis. BCAA are highly 
responsive to these inhibitory actions of insulin on cells (Louard, Fryburg, Gelfand, & Barrett, 1992; 
Pozefsky, Felig, Tobin, Soeldner, & Cahill, 1969) resulting in a decrease of BCAA released from 
muscle tissue (Felig, 1975). Similar effects have also been seen after insulin infusion particularly on 
BCAAs, tyrosine, phenylalanine, threonine, and glycine, while alanine release is not significantly 
affected (Aoki et al., 1976; Elia & Livesey, 1983; Felig, 1975; Pozefsky et al., 1969) . Insulin infusion 
also decreases branched chain keto acids (BCKAs)  in plasma (Schauder, Schroder, Matthaei, Henning, 
& Langenbeck, 1983). 
 
5.1.4 Metabolomics technologies  
There are two main techniques for metabolomics; these are nuclear magnetic resonance (NMR) 
spectroscopy and mass spectrometry (MS). Both methods enable the comprehensive exploration of 
metabolic profiles (Dunn, Bailey, & Johnson, 2005; Hollywood, Brison, & Goodacre, 2006; Lenz & 
Wilson, 2007) and provide useful information of the metabolome of body fluids such as plasma, urine 
or cerebrospinal fluid (Bictash et al., 2010). 
 
5.1.4.1 Nuclear magnetic resonance spectroscopy 
 NMR is a generally used spectroscopic technique for metabolomics. It is based on the magnetic 






P). This method was introduced in 1980’s for the 
analysis of body fluids (Bell, Brown, & Sadler, 1989; Iles, Hind, & Chalmers, 1985; Nicholson et al., 
1984). The characteristic behaviour of NMR active nuclei in a strong magnetic field provides 
information about the structural and chemical properties of a molecule. 
1




numbers in biological fluids thus makings 
1
H-NMR spectroscopy the first choice for the body fluid 
analysis. Each separate signal in a 
1
H-NMR spectrum corresponds to a certain compound. Based on 
measurements the identification and quantification of single metabolite is possible.  Advantages of 
NMR spectroscopy over MS include the non-destructive nature of the analysis, robust and reproducible 
measurements with minimal sample preparation requirements, as no separation or ionization steps are 
necessary. However, in comparison to MS, the analytical sensitivity of NMR is relatively low, even if 
stronger magnetic fields are used to increase the analytical sensitivity. 
 
5.2 Methodology 
For NMR analyses of cell supernatants, the lyophilised supernatant was resuspended in 540 L of sodium 
phosphate buffer in D2O (0.1M, pH 7.4) containing 0.1mM of deuterated 3-trimethylsilypropionic acid 
(TSP) as the internal chemical shift standard. Samples were vortexed, centrifuged at13 000xg, 8
o
C for 10 
min, after which, 520 L of the sample  was added to a 5 mm NMR tube and analysed on the same day. 
1
H- NMR measurements were performed on a Bruker Avance III (Bruker Biospin, Karlsruhe, Germany) 
spectrometer operating at 600.10 MHz, equipped with a TXI-probe and a BCU Xtreme for maintaining 
the probehead temperature at 300K. 1H NMR data were acquired using a pulse sequence to the first 
increment of a nuclear overhauser effect spectroscopy (NOESY) pulse sequence , using a 90°-3µs-90°-
100ms-90° pulse sequence with irradiation during a 2s relaxation delay and also during the 100ms mixing 
time. A pulse width was automatically determined for each sample. A low frequency irradiation applied 
at the frequency of the water resonance during the relaxation delay and mixing time. Sixty four free 
induction decays (FIDS) were collected at a spectral resolution of 64K data points. The total acquisition 
time was ~7min per sample. An exponential line-broadening factor of 0.3Hz was applied to each FID, 
after which the resulting spectra were fourier transformed, phase and baseline corrected. Spectra were 




spectra were acquired for each sample, using 4 transients per increment for 1 increments that were 
collected into 8K data points, using spectral widths of 10KHz in F2 (chemical shift axis) and 0.1 Hz in F1 
(spin-spin coupling constant axis). A 1s relaxation delay was employed. Data sets were zero filled to 128 
points in F1, and both dimensions multiplied by sine-bell window functions prior to double complex FT. 









(Heteronuclear single quantum coherence spectroscopy) NMR experiments were performed on a single 
sample to aid in the assignment of metabolites. 
 
5.2.1 Data processing 
An in-house database of reference metabolites was created using the AMIX program, version 3.9 
(Bruker Biospin, Rheinstetten, Germany). This was done by obtaining 1D, 2D NMR spectra of 
reference compounds from the human metabolome database 
(http://www.hmdb.ca/scripts/Biofluid_browse.cgi), the Madison metabolomics consortium database 
(http://mmcd.nmrfam.wisc.edu/) and the NMR metabolomics database 
(http://www.liu.se/hu/mdl/main/). Prior to importing the spectra into the in-house database, in AMIX, 
the spectra were cleaned; by removing background noise and artefacts, and spectral peaks were 
annotated.  
For analyses of the CHO cell supernatant metabolites, integral regions were defined around selected 
peaks of interest in an interactive manner while observing all spectra superimposed or stacked vertically 
to ensure proper inclusion of the peaks of interest and exclusion of extraneous peaks across the entire 
dataset. The assigned regions contain to the most part combinations of metabolites, and this taken 




Prior to integration, all spectra were treated with a background removal tool in AMIX, using a 40 MHz 
frequency filter. A total of 53 spectral regions were assigned for integration using the statistical binning 
option for integration in AMIX. The integral regions were normalised to total integral region and results 
exported for further analyses in MatLAB (2011b).  
 
5.2.2 Statistical analyses 
Paired t-tests were performed in MatLab for each integral region. Each experiment was considered 
paired, having no treatment, treatment of the drug, treatment with insulin and finally treatment with 
insulin and drug. For each drug treatment 3 separate (6) repeats were done. The first t-test was performed 
to determine the effects of drug treatment, thus the control sample were paired with drug treated samples. 
A second test was done to compare the effects of insulin treatment in the presence of drug, thus drug 
treated cells were paired with dug and insulin treated cells. The final test was to observe changes due to 
insulin treatment alone and was used to also validate the degree of distribution of metabolites here control 
samples were paired with treatment of insulin. 
 
5.3 Results  
Initially, the concentrations of amino acids and organic acids in untreated and ARV-treated cell culture 
supernatants (followed by insulin stimulation) were compared to those in the basal culture medium 
(control). Changes in the amino acid and organic acid levels were analysed using the Student’s t-test.  
A total of 28 amino acids and organic acids derivatives were detected in untreated and ARVs (PI and 
NNRTI) treated cell culture supernatants before and after insulin stimulation, as mentioned in table 5.1. 
In two different sets of experiments the cells were treated with two PIs (indinavir and nelfinavir) and two 




Table 5.1: Amino acids and organic acids identified in the drug-treated or untreated cell culture 
supernatants using 
1
H-NMR. (CHO-IR cells were left untreated or treated with PI and NRTIs for 16 h, 




H chemical shifts of  metabolites 
Metabolite  Abbr 
1
H (ppm) 
Acetate  Ace  1.91 
Acetoacetate AcAc 2.27, 3.42 
Alanine  Ala  1.48, 3.78 
Arginine  Arg  1.65, 1.71, 1.90, 3.25, 3.76 
Asparagine  Asp  2.85, 2.94, 3.99 
Butyrate-n Byt 0.88 
Formate  For  8.45 
Glucose Glcs 3.24, 3.41, 3.47, 3.53, 3.74, 3.84, 3.89, 4.65, 5.23 
Glutamate  Glu  2.06, 2.13, 2.35, 3.76 
Glutamine Gln  2.13, 2.45, 3.77 
Histidine  His  3.14, 3.25, 3.98, 7.05, 7.80 
Isoleucine  Ile  0.95, 1.01, 1.26, 1.45, 1.98, 2.06, 3.67 
Lactate  Lac  1.33, 4.11 
Leucine  Leu  0.96,1.71, 3.74 
Lysine  Lys  1.46, 1.71, 1.89, 3.02, 3.74 
Methionine  Met  2.14, 2.18, 2.64, 3.86 
N-Acetyl-aspartate NAc-asp  2.01 
N-Acetyl-amino acid  NAc-aa 2.07 
2-oxoisovalerate Oxv 1.09, 3.00 
Phenylalanine  Phe  3.13, 3.29, 4.03, 7.33, 7.37, 7.43 
Pyruvate Pyr  2.37 
Threonine  Thr  1.32, 3.57, 4.24 
Tryptophan  Trp  3.03, 3.49, 4.06, 7.19, 7.28, 7.31, 7.54, 7.74 
Tyrosine  Tyr  3.05, 3.20, 3.94, 6.89, 7.19 




Figure 5.1: A typical representation of spectra generated from 600-MHz 1H NMR spectra of cell supernatants obtained from the CHO-





5.3.1 Amino acid  and organic acid analysis after protease inhibitors treatment in CHO-IR cells 
supernatant 
The quantities of different metabolites (amino acids and organic acids) were determined in CHO-IR cells 
supernatants after treatment for 16 hours with PIs (nelfinavir and indinavir) (table 5.2). In the first 
analysis, statistical differences in amino acids in untreated and indinavir-treated supernatants of CHO-IR 
cells with and without insulin were analysed. A significant difference in two metabolites formate (p = 
0.034) and glutamate (p = 0.017) were found. Formate was significantly reduced in indinavir treated cells 
as compared to the untreated cell supernatants. While glutamine was found in increase concentration in 
indinavir treated cells followed by insulin as compared to insulin-stimulated cell supernatants alone (see 
Figure 5.2). 
In the other experiment, when nelfinavir-treated cell supernatants were compared with basal level cell 
supernatant (control), two metabolites were significantly reduced histidine (p=0.038) and 2-oxo-
isovalerate (p=0.020) similarly when nelfinavir treated cell supernatants (with insulin) were compared 
with insulin stimulated (alone) cell supernatants, metabolites glutamate (p=0.044), glutamine (p=0.0205) 
and butyrate (p=0.008) were significantly decreased in the nelfinavir treated cell supernatants with insulin 
as compared to the inulin alone. Only two metabolites lactate (p=0.039) and tyrosine (p=0.009) increased 
significantly in supernatants with nelfinavir treated cell supernatants with inulin as compared to insulin 
alone. Similar increasing trend in lactate was also observed in the nelfinavir treated cell supernatants 
without insulin as compared to control (basal level) was (see in figure 5.3). A few other metabolites also 
showed some trends in either increasing or decreasing in levels which are shown in Table 5.2. The levels 
of amino acids and organic acids are reported as fold change after comparing  drug treated with untreated 
supernatants (without insulin) and then followed by insulin stimulation in the supernatants (with and 




Table 5.2: List of the metabolites showing significant changes and trends in their concentration 





 Metabolite  
Nelfinavir 
 Fold change  
Indinavir 
Fold change  
Control/Nelfianvir 
Insulin / 
Nelfinavir + Insulin 
Control / Indinavir 
Insulin /Indinavir + 
Insulin 
Acetate 1.3 1.00     
Acetoacetate   0.95     
Alanine 0.74 0.62     
Butyrate   0.34*     
Formate 0.72 0.33 0.89*   
Glucose 0.93 0.93 0.91   
Glutamate-l 0.68 0.33* 0.62 1.10* 
Glutamine-l   1.08*     
Histidine 0.83* 0.91     
Isoleucine       0.83 
Ketones 0.79 1.18     
Lactate 2.02 2.11*     
Lysine + Arginine     0.79 0.87 
Oxoisovalerate 0.28 0.24 0.76 0.97 
2-Oxo-isovalerate 0.47* 0.47 0.84   
Phenylalanine     0.79   
Threonine   0.75 0.67   
Tryptophan 1.14       
Tyrosine   1.01*     










Figure 5.2.Fold change in amino acid and organic acid levels of untreated and drug-treated cell culture supernatants, before 
and after insulin stimulation. Blue: Indinavir treated and untreated without insulin .Red: insulin stimulated (alone) 
compared with insulin stimulated + indinavir treated 
 CHO-IR cells were treated with indinavir (50 μM) for 16 h followed by insulin stimulation. Cell culture supernatants were 
harvested for amino acid and organic acid analysis using 
1
H NMR. Peak areas of organic acids and derivatives in the untreated and 
treated cell culture supernatants were subtracted from those in the basal culture medium. Amino acid and organic acid analysis is 
from three independent experiments. Data are shown as the mean fold change (n=3). *p < 0.05, using paired t-test, untreated or 
treated cell culture supernatants versus basal culture medium and insulin treated culture medium. For details of amino acids organic 





 Figure 5.3.Fold change in amino acid and organic acid levels of untreated and drug-treated cell culture supernatants with and 
without insulin stimulation cell culture supernatants .Blue: Nelfinavir treated and untreated without insulin .Red: Insulin 
stimulated (alone) compared with insulin stimulated + nelfinavir treated. CHO-IR cells were treated with nelfinavir (30μM) for 
16 h followed by insulin stimulation. Cell culture supernatants were harvested for amino acid and organic acid analysis using 
1
H 
NMR. Peak areas of organic acids and derivatives in the untreated and treated cell culture supernatants were subtracted from those in 
the basal culture medium. Amino acid and organic acid analysis is from three independent experiments. Data are shown as the mean 
fold change (n=3). *p < 0.05, using paired t-test, untreated or treated cell culture supernatants versus basal culture medium and insulin 




5.3.2 Amino acid and organic acid analysis in CHO-IR cells supernatant after treatment with 
NRTIs with and without insulin 
The quantities of different metabolites (amino acids and organic acids) were determined in CHO-IR cells 
supernatants after treatment for 16 h with NRTIs (stavudine and tenofovir). Following treatment with 
stavudine (without insulin), the levels of methionine (p=0.006) phenylalanine (p=0.058) and tryptophan 
(p=0.0357) were significantly reduced in the supernatants of the treated cells, whilst only one metabolite 
acetone (p=0.014 was significantly increased in the supernatant. Similarly when metabolite levels were 
determined in stavudine treated and untreated supernatants followed by insulin stimulation, the levels of 
acetate (p=0.019), glucose (p=0.021) and histidine (p=0.017) were significantly reduced in the stavudine 
treated supernatants as shown in table 5.3. Few other metabolites also showed some trend in the levels 
(non-significant) also mentioned in the Table 5.3 and presented in Figure 5.4. The significant decrease in 
acetoacetate (p=0.0349) was found in tenofovir treated cell supernatants followed by insulin stimulation 
(see in Figure 5.5) .The  levels of amino acids and organic acid are presented in fold change and parts per 
million (ppm) in the drug treated and untreated supernatants (without insulin)  and then followed by 












Table 5.3: List of the metabolites altered significantly or expressed trends in CHO-IR cells 
supernatants after NRTIs treatment with and without insulin (Fold change in chemical shift of in 
major metabolites).  
 Metabolite  
Fold change in Stavudine  Fold change in Tenofovir 
Control/Stavudine 
Insulin / Stavudine + 
Insulin 
Control / Tenofovir 
Insulin / Tenofovir +  
Insulin 
Acetate 0.89 0.61*     
Acetoacetate     1.0 0.91* 
Acetone 2.06*       
Alanine       1.0 
Butyrate   0.90     
Formate   1.04     
Glucose   0.93*     
Glutamate-l   1.2   1.11 
Glutamine-l 0.81 1.0     
Histidine   0.80*     
Isoleucine + 
Leucine   0.52     
Isoleucine   0.98     
Lactate   1.0     
Leucine-d 0.97       
Lysine + Arginine 0.77 1.20     
Methionine 0.18*       
2-oxoisovalerate 0.88   1.0 1.4 
Phenylalanine 0.73* 0.87     
Tryptophan 0.86* 0.81 0.762 0.79 













Figure 5.4.Fold change in amino acid and organic acid levels of untreated and drug-treated cell culture supernatants with and 
without insulin stimulation. Blue: Stavudine treated and untreated without insulin .Red: Insulin stimulated compared with 
insulin stimulated + Stavudine treated. CHO-IR cells were treated with nelfinavir (5μM) for 16 h followed by insulin stimulation. 
Cell culture supernatants were harvested for amino acid and organic acid analysis using 
1
H NMR. Peak areas of organic acids and 
derivatives in the untreated and treated cell culture supernatants were subtracted from those in the basal culture medium. Amino acid 
and organic acid analysis is from three independent experiments. Data are shown as the mean fold change (n=3). *p < 0.05, using 
paired t-test, untreated or treated cell culture supernatants versus basal culture medium and insulin treated culture medium. For details 











Figure 5.5.Fold change in amino acid and organic acid levels of untreated and drug-treated cell culture supernatants with and without 
insulin stimulation. Blue: Tenofovir treated and untreated without insulin .Red insulin stimulated compared with insulin stimulated + 
Tenofovir treated. CHO-IR cells were treated with nelfinavir (5μM) for 16 h followed by insulin stimulation. Cell culture supernatants were 
harvested for amino acid and organic acid analysis using 
1
H NMR. Peak areas of organic acids and derivatives in the untreated and treated cell 
culture supernatants were subtracted from those in the basal culture medium. Amino acid and organic acid analysis is from three independent 
experiments. Data are shown as the mean fold change (n=3). *p < 0.05, using paired t-test, untreated or treated cell culture supernatants versus 






Cellular metabolism is crucial for the biological functions of higher animals. Any change in the cellular 
metabolism induced by protease inhibitors is likely to affect insulin action. For the first time CHO-IR 
cells were used in this study to evaluate the effects of protease inhibitors and NRTIs on amino acid and 
organic acid metabolism, using metabolomic analysis by 
1
H-NMR. It is convenient to analyse 
metabolites in the supernatants secreted by the cells, as they require minimal sample preparation and 
require less cells compared to that of cell extracts. Any alteration in various cellular metabolisms under 
the influence of ARVs which result in change of released metabolites can be detected by analysing cell 
supernatant. Importantly, the number of comprehensive studies are limited that investigate cellular 
metabolites after treating with HIV protease inhibitors and NRTIs using sensitive techniques such as 
1
H-NMR and GC-MS. 
The reason for using CHO cells for this metabolic analysis was based on a recent study on metabolic 
flux estimation using NMR where metabolite balancing was used for flux estimation. Two methods 




C) NMR correlation spectroscopy (COSY)) 
were used to determine the metabolic flux and showed good agreement. This study validated CHO 
cells as a simplified model and suggested CHO cells can routinely be used in bioprocess development 
experiments to estimate metabolic fluxes with much reduced analytical investment(Goudar et al., 
2010). 
Normally the synthesis of amino acids and organic acids with and without insulin stimulation was 
found to be higher in cell culture supernatants as compared to the drug treated supernatants. However, 
significant decrease and trends were observed in the amino acids and organic acids synthesis after the 
drug-treated cell supernatants.  
In amino acid analysis, glutamate increased the most significantly among the amino acids, when 




stimulation. An opposite trend was observed between untreated and indinavir-treated cells without 
insulin. Glutamate is the central amino acid in nitrogen metabolism and is involved in many cellular 
pathways.  
Glutamate metabolism is also linked with other biochemical pathways such as aminotransferase 
reactions, ureagenesis, the tricarboxylic acid (TCA) cycle, γ-Amino butyric acid (GABA) synthesis, 
and glutathione synthesis. Two enzymes are very important in glutamate metabolism: one is glutamate 
dehydrogenase (GDH) (mitochondrial matrix enzyme responsible for conversion of glutmate to the α-
ketoglutarate); the other one is glutaminase (catalyzes the hydrolysis of glutamine to glutamate and 
ammonia). A regulation link also exists between GDH and insulin secretion from the pancreatic β cells 
(Stanley, 2009). Glutaminase is the major enzyme of glutamine catabolism in liver cells and is also 
located within the mitochondria (Kalra & Brosnan, 1973) .  
Oxidative deamination of glutamate by GDH supplies α-ketoglutarate (α-KG) to the TCA cycle and 
generates ATP. This increase in the ATP/ADP ratio triggers insulin release through the sulfonylurea 
receptor/potassium channel complex (Matschinsky FM, 1996). This step in cellular metabolism 
connects amino acid metabolism with carbohydrate metabolism (TCA) for energy production. (Karaca, 
Frigerio, & Maechler, 2011). 
 Hyperinsulinism/hyperammonemia syndrome (HI/HA) is a rare congenital disorder associated with 
hyperinsulinism (HI) due to mutations of GDH (Stanley et al., 2000; Weinzimer et al., 1997; 
Zammarchi, Filippi, Novembre, & Donati, 1996). The children suffering from HI/HA express recurrent 
hypoglycemia due to inappropriate secretion of insulin. It is possible that the inhibition of these 
enzymes affecting glutamate levels induced by indinavir suggests possible links between protein and 
carbohydrate metabolism, which is often the case among those receiving ART. 
Synthesis of lactate and tyrosine was significantly increased in cell culture supernatants treated with 




also noticed in the nelfinavir treated cell supernatants as compared to the untreated without insulin 
stimulation. 
Lactate is continuously produced by the cells converting  pyruvate to lactate through reaction catalysed 
by the enzyme lactate dehydrogenase  (LDH) during normal  metabolism  and exercise. In cellular 
metabolism, lactate is known to decrease insulin-stimulated glycolysis and this effect precedes the 
effect of lactate to decrease insulin-stimulated glucose uptake in the skeletal muscle  (Choi et al., 
2002). The other enzyme pyruvate dehydrogenase complex (PDC) in several mammalian tissues is 
responsible for the conversion of pyruvate to acetyl Co-A. This enzyme complex exists both in an 
inactive phosphorylated form (pyruvate dehydrogenase phosphate) and an active unphosphorylated 
form (pyruvate dehydrogenase) (Harris et al., 1995; Patel & Korotchkina, 2006)  However the 
regulation of this critical enzyme is controlled by insulin (S. I. Taylor & Jungas, 1974) . 
Overproduction of lactate and ketones in the nelfinavir treated cell supernatants may be as a result of 
the alteration in the activity of these enzymes. 
The amino acid analysis of cells treated with nelfinavir with and without insulin showed high levels of 
glutamine and significantly reduced levels of glutamate in the cell supernatants. Glutamine is the most 
abundant non-essential amino acid in human plasma. It makes up almost 6% of all bound amino acids 
(Newsholme, Procopio, Lima, Pithon-Curi, & Curi, 2003). It functions as a precursor in the synthesis 
of purines, pyrimidines, glucosamine, and NAD. Glutamine is synthesized in the cell cytoplasm 
predominantly from glutamate and branched-chain amino acids. Glutamine increases glucose-
stimulated insulin secretion via the metabolism of the gamma-glutamyl cycle, glutathione synthesis and 
mitochondrial function (Brennan et al., 2003). Moreover a unique metabolic pathway also exists in 
adipocytes responsible for insulin desensitization of the insulin-responsive GTS (glucose transport 




6-phosphate via glutamine:fructose-6-phosphate amidotransferase (first rate-limiting enzyme of the 
hexosamine pathway) (Marshall, Bacote, & Traxinger, 1991). 
A trend in decreasing concentrations of 2-oxo-isovalerate was also identified in cell culture 
supernatants treated with nelfinavir, indinavir and stavudine. However, this was not seen with 
tenofovir. This organic acid is derived from leucine catabolism,2-oxoisovalerate is a branched chain 
organic acid which is a precursor to leucine and valine synthesis. It is also a degradation product of 
valine. The enzyme dihydroxy-acid dehydratase catalyzes the fourth step in the biosynthesis of 
isoleucine and valine, through the dehydration of 2, 3-dihydroxy-isovaleic acid into oxo-isovalerate 
(http://www.hmdb.ca/). An underutilization of branched chain amino acids suggests a decrease in 
synthesis of 2-oxoisovalerate in the treated cell culture supernatants. However, the function of 2-
oxoisovalerate is unclear but increased 2-oxoisovalerate has been found to be associated with certain 
diseases such as Reye’s syndrome (A potential fatal disease mainly caused by liver dysfunction and 
which can cause hypoglycaemia and which is associated with aspirin use in children) (Trauner, Nyhan, 
& Sweetman, 1975). 
Stavudine resulted in a significant decrease in the levels of acetate.  Similar affect were also seen with 
the neutral amino acids levels such as methionine tryptophan and phenylalanine and basic amino acid 
histidine. Acetone was the only organic acid that significantly increased in the supernatants. 
Overproduction of acetone and ketone (in case on nelfinavir) may produce ketone bodies and is likely 
an indication of induced ketosis and ketoacidosis. Overproduction of ketone bodies is associated with 
insulin deficiency in type 1 diabetes mellitus (Laffel, 1999).   
A trend of increasing acetate levels was observed in supernatants of nelfinavir-treated cells, whereas a 
decrease in acetate was observed with stavudine treatment. Plasma concentrations of acetate depends 





The high plasma concentration of acetate is associated with type 2 diabetes (Akanji, Ng, & Humphreys, 
1988; Smith, Humphreys, & Hockaday, 1986; Todesco et al., 1993).Acetate and glucose concentration 
in the blood, are associated by a key enzyme [acetyl-coenzyme A (CoA) synthetase (ACAS)] of acetate 
metabolism that is regulated by insulin, which has been shown with in vitro models (Sone et al., 2002). 
Increase of acetate in the nelfinavir treated cells supernatants may be as a result of the alteration in the 
activity of this enzyme. 
Both insulin and amino acids play a role in the activation of the mTOR/p70S6k pathway (Hara et al., 
1998; Patti, Brambilla, Luzi, Landaker, & Kahn, 1998) but long term activation of the mTOR and 
70S6k pathway by amino acid exposure decrease the IRS-1 dependent PI3 kinase activity. 
Furthermore, the  same study also revealed that high concentration of tyrosine amino acid decreased in 
insulin-dependent glucose uptake in L6 skeletal muscle cells (Tremblay & Marette, 2001). In our study, 
a significant increase was observed in tyrosine levels in nelfinavir- treated cell supernatants followed 
by insulin stimulation. This increase in tyrosine may mediate the inhibition of insulin receptor 
signalling pathways in cells treated with antiretroviral protease inhibitors. 
Specifically no significant changes were observed in the metabolite concentration after treatment with 
insulin as compared to the basal level(data not here ). It may be due to fact that change in metabolite 
concentration require time. So it is suggested for the future work to use high concentration insulin 
(100ng) for long time exposure (possibly one hour) .These alterations in the metabolism as a result of 
protease inhibitors and NRTIs provide very basic information about the metabolite synthesis and 
utilization at the cellular level. As CHO cell are very rapidly growing cells compared to the 
differentiated adipocytes and it is difficult to treat these cells for longer periods of time. Moreover these 
cells are transfected with high levels of insulin receptors, which may result in the cells having 
abnormally high glucose related metabolic pathways that could mask the effects of possible more slow 




required that will include prolonged treatment of cells with drugs, with more than three replicates, and 
multiple drug combinations. 
   
5.5 Conclusion  
The application of metabolite analysis (Metabolite profiling with GC-MS and LC-MS) is expanding 
and it is developing into a very powerful analytical tool for analysing different health conditions. The 
results from this study suggest that HIV protease inhibitors and NRTIs affect different cellular 
metabolic pathways and induce alterations. Protease inhibitors are more potent and diverse in affecting 
metabolitic pathways as compared to NRTIs. Changes in metabolite such as lactate, glutamate, 
glutamine, acetone tyrosine and acetate strongly correlate with insulin resistance. However to confirm 
and develop a more detailed understanding, analyses of intracellular metabolites is needed. A 
comprehensive analysis of these affects of protease inhibitors and NRTIs on cellular metabolism may 
open new doors for drug improvement.  
One drawback of NMR during quantitative analyses is that in some instances, an integration-of-defined 
region has to be applied where spectral peaks of more than one metabolite are being reported. Here even 
for well pronounced peaks, the information regarding the defined region is cannot be used to report 
metabolites in isolations because of underlying overlapping peaks of sometimes other less-well 
pronounced metabolites. However, in these cases this approach still allows for non-targeted analyses of 













CHAPTER 6: GENERAL DISCUSSION AND CONCLUSION 
 
 
6.1 Major finding about the effects of protease inhibitors and nucleoside/nucleotide reverse 
transcriptase inhibitors on insulin signaling pathway 
 
In the treatment of HIV/AIDS, protease inhibitor and nucleoside/ nucleotide analogue reverse 
transcriptase inhibitor drugs, are the major components of HAART, and cause various metabolic 
disorders in HIV patients. The primary side-effects induced by the drugs in HAART are insulin 
resistance and lipodystrophy. The precise mechanistic basis of insulin resistance and lipodystrophy 
remain largely unknown although there has been some progress in recent years. 
A wide range of published data from the last decade suggests an increase in the development of 
metabolic side effects associated with HIV infection and anti-retroviral therapy (ART) (Hruz, 2011). 
Insulin resistance is the primary metabolic disorder in type 2 diabetes, obesity, metabolic syndrome and 
atherosclerotic cardiovascular disease (Meyer et al., 2002; Nolan et al., 1994; Savage et al., 
2005).Previous studies have shown the involvement  of PIs in inhibition of  insulin-stimulated glucose 
uptake in the insulin signaling pathway (Murata et al., 2002; Rudich, Ben-Romano, Etzion, & Bashan, 
2005). In these studies, the major focal points were PIs and their effect on the selected steps (proximal 
or distal) in the insulin signaling pathway. The inhibition of glucose uptake may occur at a proximal 
step, which has been observed in cases of insulin resistance in type 2 diabetes and obesity (Arner, 
Pollare, Lithell, & Livingston, 1987; Caro et al., 1987; Meyer et al., 2002; Nolan et al., 1994).  
Furthermore, it has been also observed that many inducers of insulin resistance (ceramide  oxidative 
stress and GH) also affect the downstream steps without altering insulin receptor activation (Rudich et 




that rate limiting steps in insulin signaling pathway exist more distal to the insulin receptor and its 
immediate substrates. 
The effect of PIs and NRTIs on the insulin dependent tyrosine phosphorylation of proximal end (IR-β 
and IRS-1) and distal end (Akt, MAPK and GSK-3α\β) were investigated using CHO-IR cells 
(transfected with high numbers of insulin receptor). This is the first time CHO-IR cells were used to 
study the effects of NRTIs on the insulin signaling pathways. CHO-IR cells have a high level of insulin 
receptor expression, which expedites sensitive detection of any alteration in the expression of signaling 
proteins as compared to 3T3-L1 adipocytes. This may have facilitated easier analysis of changes in the 
insulin receptor β-subunit than has been possible previously.  
Three PIs, indinavir, nelfinavir and ritonavir were used in this study. Indinavir and nelfinavir treatment 
significantly reduced the insulin-stimulated phosphorylation of the IRβ, IRS-1, Akt and MAPK in 
CHO-IR cells. However phosphorylation of GSK-3α\β was not affected by the PIs. Ritonavir also 
decreased (not statistically significant) the phosphorylation of IR-β and IRS-1 but its effect to decrease 
MAPK was the same as by the other PIs. 
Similarly two NRTIs, tenofovir and stavudine, were studied for the first time to investigate their role in 
inducing insulin resistance. No effect was observed on the insulin stimulated tyrosine phosphorylation 
of IRβ and IRS-1 but phosphorylation at MAPK and Akt was decreased by the both NRTIs. In order to 
understand the role of NFκ-B pathway in blocking phosphorylation of insulin receptor-β, IKK-16, 
selective inhibitor of IkB kinase (IKK) was used. Similarly two therapeutic compounds sodium 
salicylate and berberine chloride were used to reverse the side effects induced by protease inhibitors 
and NRTIs in CHO-IR cells. 
The inhibition of NFκB activated IKK did not alter the impact of PIs on the inhibition of tyrosine 
phosphorylation of IR-β and IRS-1. It had a very limited effect on NFκB pathway induction of insulin 




Similarly sodium salicylate and berberine reduced (but not significantly) the effects of PIs (indinavir 
and nelfinavir) on IR-β and IRS-1. In order to block the affects of PIs and NRTIs on the latter steps of 
insulin signaling, cells pre-treated with sodium salicylate and berberine chloride were used but no 
significant change was observed. These findings suggest that PIs induce insulin resistance by affecting 
multiple steps in the signaling pathway. At the proximal end of the insulin signalling pathway, protease 
inhibitors affect IR-β and IRS-1 while at the distal end they affect phosphorylation of Akt and MAPK 
while NRTIs only affect distal end, Akt and MAPK of insulin signaling.   
 
6.2 Metabolomic changes induced by antiretroviral drugs 
For the first time CHO-IR cells were used to analyse changes in metabolic profiles after treatment with 
protease inhibitors and NRTIs. 
1
H-NMR was used to quantify the changes in amino acids and organic 
acids in the cell culture supernatants after treatment with PIs (indinavir and nelfinavir) and NRTIs 
(tenofovir and stavudine) in the presence and absence of insulin stimulation. In the amino acid analysis, 
it was found that indinavir significantly increased glutamate levels. Glutamate is the central amino acid 
in nitrogen metabolism and is involved in many cellular pathways. Similarly, indinavir also decreased 
amino acid such as threonine, 2-oxo-isovalerate, phenylalanine lysine arginine and isoleucine in cell 
supernatants. It is  well established that branched chain amino acids (BCAA) particularly leucine are 
associated with insulin resistance via activating mTOR and S6K1 and serine phosphorylation of IRS-
1(Krebs et al., 2007; Tremblay, Brule, et al., 2007; Tremblay, Lavigne, Jacques, & Marette, 2007; Um, 
D'Alessio, & Thomas, 2006).However in this study increase synthesis of glutamate maybe associated 
with increased BCAA catabolism. Furthermore glutamate accumulation may increase transamination of 
pyruvate to alanine (Newgard et al., 2009). The increasing trend in synthesis of alanine with glutamate 




alanine (gluconeogenic amino acid) may contribute in glucose intolerance in insulin resistance 
(Newgard et al., 2009).  
Nelfinavir also caused many significant changes and trend in the metabolite concentrations. It appeared 
that nelfinavir caused more extensively effects on cellular metabolism when compared to indinavir. 
Lactate and tyrosine synthesis was significantly increased in cell culture supernatants treated with 
nelfinavir versus untreated supernatants, followed by insulin stimulation. Similar trend was also 
noticed in the lactate level in the nelfinavir treated without insulin. Also significant decrease in the 
synthesis of butyrate, glutamate, histidine and 2-oxo-isovalerate were observed in the nelfinavir treated 
supernatants. In the cell metabolism lactate is known to decrease insulin-stimulated glycolysis and this 
effect precedes the effect of lactate to decrease insulin-stimulated glucose uptake in the skeletal muscle 
with affecting the GLUT4 content of the cell (Choi et al., 2002). The other enzyme pyruvate 
dehydrogenase Complex (PDC) in several mammalian tissues exists responsible for conversion of 
pyruvate to acetyl Co-A. This enzyme complex exist both in an inactive phosphorylated form (pyruvate 
dehydrogenase phosphate) and an active un-phosphorylated form (pyruvate dehydrogenase) (Harris et 
al., 1995; Patel & Korotchkina, 2006) however the regulation of this critical enzyme is controlled by 
insulin (S. I. Taylor & Jungas, 1974) . Overproduction of in lactate levels and ketone in the nelfinavir 
treated cells supernatants may associate with alteration in the activity of these enzymes. 
The activation of the mTOR/p70S6K pathway by insulin and amino acids is very important (Hara et 
al., 1998; Patti et al., 1998) but long term activation of the mTOR and 70S6k pathway by amino acid 
exposure decrease the IRS-1 dependent PI3 kinase activity. Furthermore, the  same study also revealed 
that high concentration of tyrosine amino acid decreased in insulin-dependent glucose uptake in L6 
skeletal muscle cells (Tremblay & Marette, 2001) .In our study, a significant increase was observed in 




tyrosine may mediate the inhibition of insulin receptor signalling pathways in cells treated with 
antiretroviral protease inhibitors. 
Stavudine treatment produced pronounced effects on many amino acids and organic acid .It caused 
significant decrease the synthesis of acetate, histidine, methionine, phenylalanine and tryptophan while 
significant increase in the acetone was observed in stavudine treated cell supernatants without insulin. 
The other NRTI, tenofovir induced a significant decrease in the acetoacetate followed by the insulin 
treatment but opposite trend were analysed without insulin.  Similar patterns in gluconeogenic amino 
acid (aspartate, glutamine glycine histidine) were observed in the serum of zucker diabetic fatty (ZDF) 
rats (Wijekoon, Skinner, Brosnan, & Brosnan, 2004) which  may correlate these alterations with insulin 
resistance. 
6.3 Findings about lipoprotein lipase activity in CHO-IR cells supernatants. 
CHO-IR cells were also used to measure LPL activity using a colorimetric method employing pNPB as 
substrate. LPL has been shown to catalyse the hydrolysis of short-chain fatty acyl esters such as 
tributyrin, p-nitrophenylacetate and pNPB in vivo (Shirai & Jackson, 1982). A previous study 
elucidating the possible mechanism of severe hypertriglyceridaemia caused by ritonavir described the 
decreased LPL activity responsible for the decrease in TG clearance and decreased fatty acid uptake 
from VLDL and albumin in adipocyte tissue. In addition ritonavir also decreased the total LPL activity 
in the plasma (den Boer et al., 2006). 
The results indicate that NRTIs did induce changes in LPL activity in the supernatant. Stavudine and 
emtricitabine significantly inhibited the LPL activity from the CHO-IR cells. Indinavir and nelfinavir 
were also found to decrease LPL activity when added to the assay reaction in vitro. This indicates that 
the drugs also inhibit LPL activity extracellularly. Similarly nelfinavir and atazanavir sulphate inhibited 
the activity of the LPL from the CHO-IR cells after 16 h treatment. This suggests that these drugs may 




from cytoplasm to the cell surface. Nelfinavir was found to be the only drug that inhibits LPL activity 
intracellularly as well as extracellularly. These finding suggests that protease inhibitors may play a role 
in inhibiting lipoprotein lipase activity in vivo, and may thereby induce metabolic disorders in HIV-
positive patients being treated with protease inhibitors. 
Any alteration in the LPL activity is critical in the regulation lipid metabolism and may induce 
metabolic disorders such as hypertriglyceridaemia, chylomicronaemia, pancreatitis, atherosclerosis, 
coronary artery disease and lipodystrophy associated with insulin resistance and diabetes mellitus.  
A previous study elucidating the possible mechanism of severe hypertriglyceridaemia caused by 
ritonavir described the decreased LPL activity responsible for the decrease in TG clearance and 
decreased fatty acid uptake from VLDL and albumin in adipocyte tissue. In addition ritonavir also 
decreased the total LPL activity in the plasma as described above (den Boer et al., 2006).The 
hydrolysis and release of lipids for storage from triglyceride-rich lipoproteins such as chylomicrons and 
very low density lipoproteins, and their subsequent storage in adipose tissue, cannot take place without 
lipoprotein lipase. Therefore regulation of LPL expression is crucial for normal lipid-lipoprotein 
homeostasis (Bijvoet et al., 1996; Brunzell, 1995; Mead & Ramji, 2002). 
 
6.4 Conclusion  
It is first basic study in which role of two groups of ARVs (PIs and NRTIs)  were evaluated at 
molecular level to understand the cellular basis of different side effects in HIV infected patients as 
compared to previous studies which were only focusing the PIs only. Furthermore CHO-IR cells were 
used previously only for one drug (described in section 1.5.1 page 34) side effects evaluation but in this 
study cells were used for multiple drugs .Similarly in this study not only signalling pathway of insulin 




also analysed. Both methods (NMR and p-NPB) which were used in this study also never been used 
before for such kind of studies.  
Taken together, the data from this study suggests that PIs and NRTIs treatment inhibit insulin signaling 
pathways at several steps in CHO-IR cells. The NFkB pathway has a very limited involvement in the 
induction of insulin resistance. The effects of PIs and NRTIs in CHO-IR cells report that stavudine, 
emtricitabine, indinavir atazanavir sulphate and nelfinavir significantly decrease LPL activity. High 
level of glutamate, lactate, acetone and ketone and low levels glutamine, 2-oxo-isovalerate and 
histidine may be secondary effects of insulin resistance by PIs and NRTIs. 
 
6.5 Future work 
This study  give a new cellular mode CHO-IR cells to evaluate different therapeutic compounds which 
can be used as possible reversing agents for the side effects induced by ARVs , insulin resistance and 
lipodystrophy. It’s fast, consistent and specific in nature as compared to the other available cellular 
models such as adipocyte. Due to competent role in evaluating the side effects of ARVs, in future 
CHO-IR cells can also be used to evaluate the side effects of newly designed or developed  ARV . 
The present study suggests very limited involvement of NFκB pathway in induction of insulin 
resistance by protease inhibitors. Activation of mTOR, S6K1 and JNK need to be evaluated in the 
possible involvement in causing insulin resistance by protease inhibitor (Dann, Selvaraj, & Thomas, 
2007; Hirosumi et al., 2002). In order to confirm this finding, the effects of protease inhibitors should 
be investigated in NFκB-knockout cells.  
In addition, as the present study showed, it would be useful to perform metabolomic analysis with 
protease inhibitors and NRTIs for longer exposure and multiple repeat (more than 3) to confirm and 




metabolism cellular metabolites need to be analysed and compared with the current supernatant 
metabolite data.   
Similarly in HIV patients protease inhibitors and NRTIs are used in fixed dose combinations (Meintjes 
G et al., 2012)(according to the guidelines for the antiviral therapy by southern African society of 
clinicians) so for the future work it would be excellent approach to use different protease inhibitors and 
NRTIs in combinations to get more detailed picture of the side effects induced by the ARVs . The 
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(A) Cell Culture Reagents 
1.              f  M’  F 2 
 
Reagents Volume Final Concentration 
Ham’s F12 medium 500  
Fetal calf serum (FCS) 50 10% 
200 mM Glutamine 5 2mM 
100 x Antibiotic/antimycotic 
solution 
5 1% 
Gentamicin 2.5 0.5 
G418 .5 400 ug/ml 
Total volume 563  
 
G418-sulphate 
0.4 g was dissolved in 1 ml dH2O and filtered using a 0.2 μM syringe filter. 
2. Serum Free Medium  
 
Reagents Volume (ml) Final concentration 
DEMEM 500  
200 mM Glutamine 5 2mM 
100 x Antibiotic/antimycotic solution 5 1% 
Gentamicin 2.5 0.5 
Total volume 5.12  
 






r was prepared with 1 tablet of protease inhibitor and 1 tablet of phosphatase inhibitor in 10 ml of 10 x 
lysis buffer stock solution 
Reagents Volume Final concentration  
4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), pH 7.5 
445 ml 50mM 
Trintron X-100 5 ml 1% 
Glycerol  50ml 10% 
Sodium Chloride  1.461 g 50mM 





4. 5 x Laemmli buffer 
 
5. Freezing medium  for CHO-IR cells 
 
Reagents Volume (ml) Final concentration 
Dimethyl sulphoxide (DMSO) 10 10% 
FCS 40  
Total Volume 50  
 
6. Phosphate buffered saline (PBS) 
1 tablet of PBS was dissolved in 200 ml dH2O and the mixture was sterile by autoclave.  
7. 1mg /ml Insulin stock 
Insulin was prepared in 100 mM acetic acid + 0.1% bovine serum albumin (BSA)  
(1) 100 mM acetic acid  
a. 0.294 ml 17 M acetic acid + 49.706 ml dH2O  
(2) 0.1% BSA  
a. Add 0.05 g BSA into 50 ml acetic acid to become 0.1% BSA  
(3) 5 mg insulin was dissolved in 5 ml of 100 mM acetic acid + 0.1% BSA = 1 mg/ml  
9. Working Insulin solution 
100 ng/ml (17 nM) insulin = 10 μl of 1 mg + 990 μl PBS   
Reagents Volume Final concentration 
1 M Tris, pH 6.8 1.25 ml 25 nM 
Sodium dodecyl sulphate (SDS) 1 g 2 % 
1 % Bromophenol blue 0.33 ml 0.002 % 
Glycerol 5 m 10 % 
2-Mercaptoethanol 2.5 ml 5 % 
H2O 1.25 ml  




10 ng/ml (1.7 nM) insulin = 100 μl of 100 ng/ml (17 nM) insulin + 900 μl PBS 
 
 
10. Drugs stock solutions  
Drugs were prepared using a standard formula:  
Mass drug (g) = concentration (M) x molecular weight (MW) x volume (L)  
a)  Indinavir, MW = 711.88  
b)  Nelfinavir, MW = 663.89 
c)  Ritonavir, MW = 720.95 
d) Tenofovir, MW = 287.21 
e) Stavudine, MW = 224.21 
f) Sodium salicylate, MW = 160.10  
g) Berberine chloride, MW = 371.82 
h) IKK-16,MW = 520.09 
 
11. Calculation of cell number  
CHO-IR cells were counted using a haemocytometer to determine the total number of cells in the 
original flask. Then, 10 μl cells suspension was loaded into the haemocytometer. The number of cells 
in 5 of 10 of the 0.1 mm3 blocks was counted as follows:  
Cells cm-3 = Number of cells counted x conversion factor (1000)  
Number of squares counted  
100 000 cells per well of each 6-well plate was required to achieve 70-85 % confluence on day 2/3.  
 







a)1.5M Tris pH 8.8 
Prepared by 54.46 g of Tris dissolve in 300ml dH2O 
b)0.5M Tris pH 6.8 
12 g Tris dissolved in 200ml dH2O  
c)10 % Ammonium persulphate (APS)  
0.1 g APS was dissolved in 1 ml dH2O  
d)10 % SDS  
5 g SDS was dissolved in 50 ml dH2O  
e)0.1 % Ponceau S solution  
0.1 g Ponceau was dissolved in 100 ml of 5 % acetic acid.  
 f) 5 % BSA  
2.5 g BSA was dissolved in 50 ml TBST 
 g) 5 % Milk solution  
2.5 g skimmed milk powder was dissolved in 50 ml TBST. 
1. 4% Stacking Gel 
Reagents Volume (ml) Final concentration 
0.5 M Tris-HCl, pH 6.8 2.52 0.126 M 
30 % Acrylamide/bis 1.32 4 % 
dH2O 6.00  
10 % SDS .1 0.1 % 
10 % APS .05 0.05 % 
TEMED .01 0.1 % 
Total volume 11.35  
 
2. 7.5% Resolving gel 
 
Reagents Volume (ml) Final concentration 
1.5 M Tris-HCl, pH 6.8 2.5 .375 
30 % Acrylamide/bis 2.5 7.5 




10 % SDS .1 0.1 % 
10 % APS .05 0.05 % 
TEMED .01 0.05% 
Total volume 10ml  
 
 
3. 10X Running Buffer  
 
Reagents Volume (ml) Final concentration 
Tris  30.3 g .025 
Glycine 144 g .0195 
SDS 10 g 0.1% 
dH2O Make up to 1 Litter  
Total volume  1L  
 
1 x Running buffer  
100 ml of 10 x stock solution was added to 900 ml dH2O 
4 X Transfer buffer  
 
Reagents Volume (ml) Final concentration 
Tris  3.03 g .25M 
Glycine 14.4g 1.92M 
Methanol 200 ml  
H2O 800 ml  
Total Volume 1 L  
 
5 Tris bufferd saline +.05%Tween 20(TBST). PH 7.4 
 
Reagents Volume (ml) Final concentration 
Sodium chloride  8g  
Potassium chloride  .2 g  
Tris  3 g  
Tween 20 .5 ml  
dH2O 1L  









(C) Lipoprotein Lipase essay Reagent  
Reagent A 
Reagent  Volume  Final concentration  
Sodium Phosphate, 
Monobasic 
6.89 g 100mM 
Sodium Chloride 4.38 g 150mM 
Triton1 X-100, 2.5 ml .5% 
Total Volume  500 ml  
Adjusted the PH7.2 with 1M sodium hydroxide. 
Reagent B: Acetonitrile 
Reagent C: 50 mM p-Nitrophenyl Butyrate (P-NPB) 
10.2ul of 98% solution of p-Nitrophenyl Butyrate (MW209.2) in 1 ml of acetonitrile. 
Reagent D 
I mg of lipoprotein lipase dissolved in 1 ml of Reagent A. 
